THE CONCISE GUIDE TO PHARMACOLOGY 2017/18:Enzymes by Alexander, Stephen P. H. et al.
                                                              
University of Dundee
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18
Alexander, Stephen P. H.; Fabbro, Doriano; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.;
Faccenda, Elena; Harding, Simon D.; Pawson, Adam J.; Sharman, Joanna L.; Southan,
Christopher; Davies, Jamie A.; CGTP Collaborators
Published in:
British Journal of Pharmacology
DOI:
10.1111/bph.13877
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Alexander, S. P. H., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., ... CGTP Collaborators
(2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology, 174
(Suppl. 1), S272-S359. DOI: 10.1111/bph.13877
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology (2017) 174, S272–S359
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
Stephen PH Alexander1, Doriano Fabbro2, Eamonn Kelly3, Neil V Marrion3, John A Peters4, Elena Faccenda5,
Simon D Harding5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5
and CGTP Collaborators
1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
2PIQUR Therapeutics, Basel 4057, Switzerland
3School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK
Abstract
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus
links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide
represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that
will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13877/full. Enzymes are one of the eight major pharmacological targets into
which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors
and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14
Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR),
therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
Conﬂict of interest
The authors state that there are no conﬂicts of interest to declare.
© 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Overview: Enzymes are protein catalysts facilitating the conver-
sion of substrates into products. The Nomenclature Committee of
the International Union of Biochemistry and Molecular Biology
(NC-IUBMB) classiﬁes enzymes into families, using a four num-
ber code, on the basis of the reactions they catalyse. There are six
main families:
EC 1.-.-.- Oxidoreductases;
EC 2.-.-.- Transferases;
EC 3.-.-.- Hydrolases;
EC 4.-.-.- Lyases;
EC 5.-.-.- Isomerases;
EC 6.-.-.- Ligases.
Although there are many more enzymes than receptors in biol-
ogy, and many drugs that target prokaryotic enzymes are effective
medicines, overall the number of enzyme drug targets is relatively
small [392, 430], which is not to say that they are of modest im-
portance.
The majority of drugs which act on enzymes act as inhibitors;
one exception is metformin, which appears to stimulate activity
of AMP-activated protein kinase, albeit through an imprecisely-
deﬁned mechanism. Kinetic assays allow discrimination of com-
petitive, non-competitive, and un-competitive inhibitors. The
majority of inhibitors are competitive (acting at the enzyme’s lig-
and recognition site), non-competitive (acting at a distinct site;
potentially interfering with co-factor or co-enzyme binding) or of
mixed type. One rare example of an uncompetitive inhibitor is
lithium ions, which are effective inhibitors at inositol monophos-
phatase only in the presence of high substrate concentrations.
Some inhibitors are irreversible, including a group known as sui-
cide substrates, which bind to the ligand recognition site and then
couple covalently to the enzyme. It is beyond the scope of the
Guide to give mechanistic information about the inhibitors de-
scribed, although generally this information is available from the
indicated literature.
Many enzymes require additional entities for functional activity.
Some of these are used in the catalytic steps, while others pro-
Searchable database: http://www.guidetopharmacology.org/index.jsp Enzymes S272
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mote a particular conformational change. Co-factors are tightly
bound to the enzyme and include metal ions and heme groups.
Co-enzymes are typically small molecules which accept or donate
functional groups to assist in the enzymatic reaction. Examples
include ATP, NAD, NADP and S-adenosylmethionine, as well as a
number of vitamins, such as riboﬂavin (vitamin B1) and thiamine
(vitamin B2). Where co-factors/co-enzymes have been identiﬁed,
the Guide indicates their involvement.
Family structure
S275 Kinases (EC 2.7.x.x)
– AGC: Containing PKA, PKG, PKC families
– DMPK family
– GEK subfamily
– Other DMPK family kinases
S276 Rho kinase
– G protein-coupled receptor kinases (GRKs)
– Beta-adrenergic receptor kinases (βARKs)
– Opsin/rhodopsin kinases
– GRK4 subfamily
– MAST family
– NDR family
– PDK1 family
– Protein kinase A
– Akt (Protein kinase B)
S276 Protein kinase C (PKC)
S277 Alpha subfamily
S277 Delta subfamily
S277 Eta subfamily
– Iota subfamily
– Protein kinase G (PKG)
– Protein kinase N (PKN) family
– RSK family
– MSK subfamily
– p70 subfamily
– RSK subfamily
– RSKR subfamily
– RSKL family
– SGK family
– YANK family
– Atypical
– ABC1 family
– ABC1-A subfamily
– ABC1-B subfamily
– Alpha kinase family
– ChaK subfamily
– eEF2K subfamily
– Other alpha kinase family kinases
– BCR family
– Bromodomain kinase (BRDK) family
– G11 family
–
Phosphatidyl inositol 3’ kinase-related
kinases (PIKK) family
– ATR subfamily
S278 FRAP subfamily
– SMG1 subfamily
– TRRAP subfamily
– Other PIKK family kinases
– RIO family
– RIO1 subfamily
– RIO2 subfamily
– RIO3 subfamily
– PDHK family
– Pyruvate dehydrogenase kinase (PDHK) family
– TAF1 family
– TIF1 family
–
CAMK: Calcium/calmodulin-dependent
protein kinases
– CAMK1 family
– CAMK2 family
– CAMK-like (CAMKL) family
– AMPK subfamily
– BRSK subfamily
– CHK1 subfamily
– HUNK subfamily
– LKB subfamily
– MARK subfamily
– MELK subfamily
– NIM1 subfamily
– NuaK subfamily
– PASK subfamily
– QIK subfamily
– SNRK subfamily
– CAMK-unique family
– CASK family
– DCAMKL family
– Death-associated kinase (DAPK) family
– MAPK-Activated Protein Kinase (MAPKAPK) family
– MAPKAPK subfamily
– MKN subfamily
– Myosin Light Chain Kinase (MLCK) family
– Phosphorylase kinase (PHK) family
– PIM family
– Protein kinase D (PKD) family
– PSK family
– RAD53 family
– Testis speciﬁc kinase (TSSK) family
– Trbl family
– Trio family
– CK1: Casein kinase 1
– Casein kinase 1 (CK1) family
– Tau tubulin kinase (TTBK) family
– Vaccina related kinase (VRK) family
– CMGC: Containing CDK, MAPK, GSK3, CLK families
– CLK family
S279 Cyclin-dependent kinase (CDK) family
– CCRK subfamily
– CDK1 subfamily
S279 CDK4 subfamily
– CDK5 subfamily
– CDK7 subfamily
– CDK8 subfamily
– CDK9 subfamily
– CDK10 subfamily
– CRK7 subfamily
– PITSLRE subfamily
– TAIRE subfamily
– Cyclin-dependent kinase-like (CDKL) family
–
Dual-speciﬁcity tyrosine-(Y)-phosphorylation
regulated kinase (DYRK) family
– Dyrk1 subfamily
– Dyrk2 subfamily
– HIPK subfamily
– PRP4 subfamily
– Glycogen synthase kinase (GSK) family
S279 GSK subfamily
–
Mitogen-activated protein kinases
(MAP kinases)
– ERK subfamily
– Erk7 subfamily
– JNK subfamily
– p38 subfamily
– nmo subfamily
– RCK family
– SRPK family
– Other protein kinases
– CAMKK family
Searchable database: http://www.guidetopharmacology.org/index.jsp Enzymes S273
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– Meta subfamily
– Aurora kinase (Aur) family
– Bub family
– Bud32 family
– Casein kinase 2 (CK2) family
– CDC7 family
– Haspin family
– IKK family
– IRE family
– MOS family
– NAK family
–
NIMA (never in mitosis gene a)
- related kinase (NEK) family
– NKF1 family
– NKF2 family
– NKF4 family
– NKF5 family
– NRBP family
– Numb-associated kinase (NAK) family
– Other-unique family
S280 Polo-like kinase (PLK) family
– PEK family
– GCN2 subfamily
– PEK subfamily
– Other PEK family kinases
– SgK493 family
– Slob family
– TBCK family
– TOPK family
– Tousled-like kinase (TLK) family
– TTK family
– Unc-51-like kinase (ULK) family
– VPS15 family
– WEE family
– Wnk family
– Miscellaneous protein kinases
– actin-binding proteins ADF family
– Twinﬁlin subfamily
– SCY1 family
– Hexokinases
–
STE: Homologs of yeast Sterile 7,
Sterile 11, Sterile 20 kinases
S280 STE7 family
– STE11 family
– STE20 family
– FRAY subfamily
– KHS subfamily
– MSN subfamily
– MST subfamily
– NinaC subfamily
– PAKA subfamily
– PAKB subfamily
– SLK subfamily
– STLK subfamily
– TAO subfamily
– YSK subfamily
– STE20 family
– STE-unique family
– TK: Tyrosine kinase
– Non-receptor tyrosine kinases (nRTKs)
S281 Abl family
S281 Ack family
– Csk family
– Fak family
– Fer family
S281 Janus kinase (JakA) family
S282 Src family
– Syk family
S282 Tec family
– TKL: Tyrosine kinase-like
–
Interleukin-1 receptor-associated
kinase (IRAK) family
– Leucine-rich repeat kinase (LRRK) family
– LIM domain kinase (LISK) family
– LIMK subfamily
– TESK subfamily
– Mixed Lineage Kinase (MLK) family
– HH498 subfamily
– ILK subfamily
– LZK subfamily
– MLK subfamily
– TAK1 subfamily
S283 RAF family
–
Receptor interacting protein
kinase (RIPK) family
– TKL-unique family
S284 Peptidases and proteinases
– AA: Aspartic (A) Peptidases
S284 A1: Pepsin
– AD: Aspartic (A) Peptidases
S284 A22: Presenilin
– CA: Cysteine (C) Peptidases
– C1: Papain
– C2: Calpain
– C12: Ubiquitin C-terminal hydrolase
– C19: Ubiquitin-speciﬁc protease
– C54: Aut2 peptidase
– C101: OTULIN peptidase
– CD: Cysteine (C) Peptidases
– C13: Legumain
S284 C14: Caspase
– CE: Cysteine (C) Peptidases
– C48: Ulp1 endopeptidase
– M-: Metallo (M) Peptidases
– M79: Prenyl protease 2
– MA: Metallo (M) Peptidases
S285 M1: Aminopeptidase N
S285 M2: Angiotensin-converting (ACE and ACE2)
S286 M10: Matrix metallopeptidase
S286 M12: Astacin/Adamalysin
– M13: Neprilysin
– M49: Dipeptidyl-peptidase III
– MC: Metallo (M) Peptidases
– M14: Carboxypeptidase A
– ME: Metallo (M) Peptidases
– M16: Pitrilysin
– MF: Metallo (M) Peptidases
– M17: Leucyl aminopeptidase
– MG: Metallo (M) Peptidases
– M24: Methionyl aminopeptidase
– MH: Metallo (M) Peptidases
– M18: Aminopeptidase I
– M20: Carnosine dipeptidase
S286 M28: Aminopeptidase Y
– MJ: Metallo (M) Peptidases
S287 M19: Membrane dipeptidase
– MP: Metallo (M) Peptidases
– M67: PSMD14 peptidase
– PA: Serine (S) Peptidases
S287 S1: Chymotrypsin
– PB: Threonine (T) Peptidases
– C44:
Phosphoribosyl pyrophosphate
amidotransferase
S288 T1: Proteasome
– T2: Glycosylasparaginase precursor
– PC: Cysteine (C) Peptidases
– C26: Gamma-glutamyl hydrolase
– SB: Serine (S) Peptidases
S289 S8: Subtilisin
– SC: Serine (S) Peptidases
S289 S9: Prolyl oligopeptidase
– S10: Carboxypeptidase Y
– S28: Lysosomal Pro-Xaa carboxypeptidase
– S33: Prolyl aminopeptidase
– AAA ATPases
S290 Acetylcholine turnover
S291 Adenosine turnover
S292 Amino acid hydroxylases
S293 L-Arginine turnover
S294 2.1.1.- Protein arginine N-methyltransferases
Searchable database: http://www.guidetopharmacology.org/index.jsp Enzymes S274
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S294 Arginase
S294 Arginine:glycine amidinotransferase
S294 Dimethylarginine dimethylaminohydrolases
S295 Nitric oxide synthases
S296 Carboxylases and decarboxylases
S296 Carboxylases
S298 Decarboxylases
S299 Catecholamine turnover
S302 Ceramide turnover
S302 Serine palmitoyltransferase
– 3-ketodihydrosphingosine reductase
S303 Ceramide synthase
S304 Sphingolipid 4-desaturase
S304 Sphingomyelin synthase
S305 Sphingomyelin phosphodiesterase
S305 Neutral sphingomyelinase coupling factors
S305 Ceramide glucosyltransferase
S306 Acid ceramidase
S306 Neutral ceramidases
S307 Alkaline ceramidases
S307 Ceramide kinase
S308 Chromatin modifying enzymes
– Enzymatic bromodomain-containing proteins
– Bromodomain kinase (BRDK) family
– TAF1 family
– TIF1 family
– 1.14.11.- Histone demethylases
S309 2.1.1.- Protein arginine N-methyltransferases
– 2.1.1.43 Histone methyltransferases (HMTs)
– 2.3.1.48 Histone acetyltransferases (HATs)
S309 3.5.1.- Histone deacetylases (HDACs)
– 3.6.1.3 ATPases
S310 Cyclic nucleotide turnover/signalling
S310 Adenylyl cyclases (ACs)
S311 Exchange protein activated by cyclic AMP (EPACs)
S312 Nitric oxide (NO)-sensitive (soluble)
guanylyl cyclase
S313 Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
S317 Cytochrome P450
S317 CYP1 family
S317 CYP2 family
S318 CYP3 family
S319 CYP4 family
S320 CYP5, CYP7 and CYP8 families
S320 CYP11, CYP17, CYP19, CYP20 and CYP21 families
S321 CYP24, CYP26 and CYP27 families
S321 CYP39, CYP46 and CYP51 families
S323 Endocannabinoid turnover
S323 N-Acylethanolamine turnover
S324 2-Acylglycerol ester turnover
S325 Eicosanoid turnover
S325 Cyclooxygenase
S326 Prostaglandin synthases
S327 Lipoxygenases
S328 Leukotriene and lipoxin metabolism
S329 GABA turnover
S330 Glycerophospholipid turnover
S331 Phosphoinositide-speciﬁc phospholipase C
S332 Phospholipase A2
S333 Phosphatidylcholine-speciﬁc phospholipase D
S334 Lipid phosphate phosphatases
S335 Phosphatidylinositol kinases
S336 Phosphatidylinositol phosphate kinases
S339 Haem oxygenase
S340 Hydrogen sulphide synthesis
S341 Hydrolases
S342 Inositol phosphate turnover
S342 Inositol 1,4,5-trisphosphate 3-kinases
S343 Inositol polyphosphate phosphatases
S343 Inositol monophosphatase
S344 Lanosterol biosynthesis pathway
– LPA synthesis
S346 Nucleoside synthesis and metabolism
S347 Sphingosine 1-phosphate turnover
S348 Sphingosine kinase
S348 Sphingosine 1-phosphate phosphatase
S349 Sphingosine 1-phosphate lyase
S349 Thyroid hormone turnover
– 1.-.-.- Oxidoreductases
– 1.1.1.42 Isocitrate dehydrogenases
– 1.4.3.13 Lysyl oxidases
– 1.13.11.- Dioxygenases
S350 1.14.11.29 2-oxoglutarate oxygenases
S351 1.14.13.9 kynurenine 3-monooxygenase
– 1.17.4.1 Ribonucleoside-diphosphate reductases
– 2.1.1.- Methyltransferases
– 2.1.2.- Hydroxymethyl-, formyl- and related transferases
– 2.3.-.- Acyltransferases
– 2.4.2.1 Purine-nucleoside phosphorylase
S351 2.4.2.30 poly(ADP-ribose)polymerases
S352 2.5.1.58 Protein farnesyltransferase
– 2.6.1.42 Branched-chain-amino-acid transaminase
– 3.1.-.- Ester bond enzymes
– 3.1.1.- Carboxylic Ester Hydrolases
– 3.2.1.- Glycosidases
– 3.4.21.46 Complement factor D
S353 3.5.1.- Histone deacetylases (HDACs)
– 3.5.1.2 Glutaminases
S353 3.5.3.15 Peptidyl arginine deiminases (PADI)
– 3.6.5.2 Small monomeric GTPases
S354 RAS subfamily
– RAB subfamily
S355 4.2.1.1 Carbonate dehydratases
– 5.-.-.- Isomerases
– 5.2.-.- Cis-trans-isomerases
S355 5.99.1.2 DNA Topoisomerases
– 6.3.3.- Cyclo-ligases
Kinases (EC 2.7.x.x)
Enzymes → Kinases (EC 2.7.x.x)
Overview: Protein kinases (E.C. 2.7.11.-) use the co-substrate
ATP to phosphorylate serine and/or threonine residues on target
proteins. Analysis of the human genome suggests the presence
of 518 protein kinases in man (divided into 15 subfamilies), with
over 100 protein kinase-like pseudogenes [335]. It is beyond the
scope of the Concise Guide to list all these protein kinase activi-
ties, but full listings are available on the ’Detailed page’ provided
for each enzyme.
Most inhibitors of these enzymes have been assessed in cell-free
investigations and so may appear to ’lose’ potency and selectiv-
ity in intact cell assays. In particular, ambient ATP concentrations
may be inﬂuential in responses to inhibitors, since the majority
are directed at the ATP binding site [110] .
Searchable database: http://www.guidetopharmacology.org/index.jsp Kinases (EC 2.7.x.x) S275
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Rho kinase
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → DMPK family → Rho kinase
Overview: Rho kinase (also known as P160ROCK, Rho-activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as ARHGEF1
(Q92888, p115-RhoGEF), which in turn may be activated by Gα12/13 subunits [282].
Nomenclature Rho associated coiled-coil containing protein kinase 1 Rho associated coiled-coil containing protein kinase 2
Systematic nomenclature ROCK1 ROCK2
HGNC, UniProt ROCK1, Q13464 ROCK2, O75116
EC number 2.7.11.1 2.7.11.1
Common abreviation Rho kinase 1 Rho kinase 2
Inhibitors RKI-1447 (pIC50 >9) [414], Y27632 (pIC50 5.9–7.3) [328, 575],
fasudil (pKi 7) [434], Y27632 (pKi 6.8) [540], fasudil (pIC50 5.5–5.6)
[328, 434]
RKI-1447 (pIC50 >9) [414], compound 11d [DOI: 10.1039/c0md00194e] (pIC50
>9) [90], GSK269962A (pIC50 8.4) [126], compound 32 (pIC50 8.4) [49],
compound 22 (pIC50 7.7) [575], Y27632 (pIC50 6.3–7.2) [328, 575], Y27632
(pKi 6.8–6.9) [328, 540], fasudil (pIC50 5.9–5.9) [328, 434]
Selective inhibitors GSK269962A (pIC50 8.8) [126] –
Further reading on Rho kinases
Feng, Y, PV LoGrasso, O Defert and R Li 2016 Rho Kinase (ROCK) Inhibitors and Their Therapeutic
Potential J Med Chem 59: 2269-300 [PMID:26486225]
Nishioka, T, MH Shohag, M Amano and K Kaibuchi 2015 Developing novel methods to search
for substrates of protein kinases such as Rho-kinase Biochim Biophys Acta 1854: 1663-6
[PMID:25770685]
Shimokawa, H, S Sunamura and K Satoh 2016 RhoA/Rho-Kinase in the Cardiovascular System Circ
Res 118: 352-66 [PMID:26838319]
Protein kinase C (PKC)
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC)
Overview: Protein kinase C is the target for the tumour-
promoting phorbol esters, such as tetradecanoyl-β-phorbol
acetate (TPA, also known as phorbol 12-myristate 13-acetate).
Classical protein kinase C isoforms: PKCα, PKCβ, and PKCγ
are activated by Ca2+ and diacylglycerol, and may be inhib-
ited by GF109203X, calphostin C, Gö 6983, chelerythrine and
Ro31-8220.
Novel protein kinase C isoforms: PKCδ, PKC, PKCη, PKCθ and
PKCμ are activated by diacylglycerol and may be inhibited by
calphostin C, Gö 6983 and chelerythrine.
Atypical protein kinase C isoforms:PKCι, PKCζ .
Searchable database: http://www.guidetopharmacology.org/index.jsp Protein kinase C (PKC) S276
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Alpha subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) → Alpha subfamily
Nomenclature protein kinase C beta protein kinase C gamma
HGNC, UniProt PRKCB, P05771 PRKCG, P05129
EC number 2.7.11.13 2.7.11.13
Common abreviation PKCβ PKCγ
Inhibitors sotrastaurin (pIC50 8.7) [548], Gö 6983 (pIC50 8.1) [195], GF109203X (pIC50 7.8) [533] –
Bovine, 7-hydroxystaurosporine (pIC50 7.5) [468]
Gö 6983 (pIC50 8.2) [195],
7-hydroxystaurosporine (pIC50 7.5) [469]
Selective inhibitors ruboxistaurin (pIC50 8.2) [250], enzastaurin (pIC50 7.5) [140], CGP53353 (pIC50 6.4) [75] –
Delta subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) → Delta subfamily
Nomenclature protein kinase C alpha protein kinase C delta
HGNC, UniProt PRKCA, P17252 PRKCD, Q05655
EC number 2.7.11.13 2.7.11.13
Common abreviation PKCα PKCδ
Activators – ingenol mebutate (pKi 9.4) [263]
Inhibitors sotrastaurin (pIC50 8.7) [548], Gö 6983 (pIC50 8.1) [195], 7-hydroxystaurosporine (pIC50 7.5) [468] sotrastaurin (pIC50 8.9) [548], Gö 6983 (pIC50 8) [195]
Searchable database: http://www.guidetopharmacology.org/index.jsp Delta subfamily S277
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Eta subfamily
Enzymes → Kinases (EC 2.7.x.x) → AGC: Containing PKA, PKG, PKC families → Protein kinase C (PKC) → Eta subfamily
Nomenclature protein kinase C epsilon
HGNC, UniProt PRKCE, Q02156
EC number 2.7.11.13
Common abreviation PKC
Inhibitors sotrastaurin (pIC50 8.2) [548]
Further reading on Protein kinase C
Igumenova TI. (2015) Dynamics and Membrane Interactions of Protein Kinase C. Biochemistry 54:
4953-68 [PMID:26214365]
Newton AC et al. (2017) Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends
Pharmacol Sci 38: 438-447 [PMID:28283201]
Salzer E et al. (2016) Protein Kinase C delta: a Gatekeeper of Immune Homeostasis. J Clin Immunol
36: 631-40 [PMID:27541826]
FRAP subfamily
Enzymes → Kinases (EC 2.7.x.x) → Atypical → Phosphatidyl inositol 3’ kinase-related kinases (PIKK) family → FRAP subfamily
Nomenclature mechanistic target of rapamycin
HGNC, UniProt MTOR, P42345
EC number 2.7.11.1
Common abreviation mTOR
Inhibitors ridaforolimus (pIC50 9.7) [441], torin 1 (pIC50 9.5) [310], INK-128 (pIC50 9) [231], INK-128 (pKi 8.9) [231], gedatolisib (pIC50 8.8) [544], dactolisib (pIC50 8.2)
[332], PP-242 (pIC50 8.1) [15], PP121 (pIC50 8) [15], XL388 (pIC50 8) [511], PF-04691502 (pKi 7.8) [309], apitolisib (pKi 7.8) [506]
Selective inhibitors everolimus (pIC50 8.7) [464], temsirolimus (pIC50 5.8) [278]
Further reading on FRAP subfamily
Hukelmann JL et al. (2016) The cytotoxic T cell proteome and its shaping by the kinase mTOR.
Nat. Immunol. 17: 104-12 [PMID:26551880]
Saxton RA et al. (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 169: 361-371
[PMID:28388417]
Searchable database: http://www.guidetopharmacology.org/index.jsp FRAP subfamily S278
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Cyclin-dependent kinase (CDK) family
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Cyclin-dependent kinase (CDK) family
Overview: The development of CDK inhibitors as anticancer drugs is reviewed in [508], with detailed content covering CDK4 and CDK6 inhibitors under clinical evaluation.
CDK4 subfamily
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Cyclin-dependent kinase (CDK) family → CDK4 subfamily
Nomenclature cyclin dependent kinase 4 cyclin dependent kinase 6
HGNC, UniProt CDK4, P11802 CDK6, Q00534
EC number 2.7.11.22 2.7.11.22
Common abreviation CDK4 CDK6
Inhibitors R547 (pKi 9) [117], palbociclib (pIC50 8) [160], Ro-0505124 (pIC50 7.7) [129], riviciclib (pIC50 7.2)
[258], alvocidib (pKi 7.2) [70]
palbociclib (pIC50 7.8) [160]
GSK subfamily
Enzymes → Kinases (EC 2.7.x.x) → CMGC: Containing CDK, MAPK, GSK3, CLK families → Glycogen synthase kinase (GSK) family → GSK subfamily
Nomenclature glycogen synthase kinase 3 beta
HGNC, UniProt GSK3B, P49841
EC number 2.7.11.26
Common abreviation GSK3B
Inhibitors CHIR-98014 (pIC50 9.2) [440], LY2090314 (pIC50 9) [133], CHIR-99021 (pIC50 8.2) [440], SB 216763 (pIC50 ∼8.1) [95], 1-azakenpaullone (pIC50 7.7) [285],
SB-415286 (pIC50 ∼7.4) [95], IM-12 (pIC50 7.3) [460]
Selective inhibitors AZD2858 (pKi 8.3) [31]
Comments Due to its Tau phosphorylating activity, small molecule inhibitors of GSK-3β are being investigated as potential treatments for Alzheimer’s disease (AD) [31].
GSK-3β also plays a role in canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised
that small molecule inhibitors of GSK-3β may provide effective therapeutics for the treatment of diseases characterised by low bone mass [320].
Searchable database: http://www.guidetopharmacology.org/index.jsp GSK subfamily S279
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Further reading on GSK subfamily
Beurel E et al. (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Phar-
macol Ther 148: 114-31 [PMID:25435019]
Domoto T et al. (2016) Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion
and resistance to therapy. Cancer Sci 107: 1363-1372 [PMID:27486911]
Khan I et al. (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J
Med Chem 125: 464-477 [PMID:27689729]
Maqbool M et al. (2016) Pivotal role of glycogen synthase kinase-3: A therapeutic target for
Alzheimer’s disease. Eur J Med Chem 107: 63-81 [PMID:26562543]
Polo-like kinase (PLK) family
Enzymes → Kinases (EC 2.7.x.x) → Other protein kinases → Polo-like kinase (PLK) family
Nomenclature polo like kinase 4
HGNC, UniProt PLK4, O00444
EC number 2.7.11.21
Common abreviation PLK4
Inhibitors CFI-400945 (pIC50 8.6) [343]
STE7 family
Enzymes → Kinases (EC 2.7.x.x) → STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases → STE7 family
Nomenclature mitogen-activated protein kinase kinase 1 mitogen-activated protein kinase kinase 2
HGNC, UniProt MAP2K1, Q02750 MAP2K2, P36507
EC number 2.7.12.2 2.7.12.2
Common abreviation MEK1 MEK2
Inhibitors trametinib (pIC50 9–9.1) [183, 589], PD 0325901 (pIC50 8.1) [208] trametinib (pIC50 8.7) [589]
Allosteric modulators binimetinib (Negative) (pIC50 7.9) [428], refametinib (Negative) (pIC50 7.7)
[242], CI-1040 (Negative) (pKd 6.9) [112]
binimetinib (Negative) (pIC50 7.9) [428], refametinib (Negative)
(pIC50 7.3) [242]
Selective allosteric modulators cobimetinib (Negative) (pIC50 9.1) [457] –
Searchable database: http://www.guidetopharmacology.org/index.jsp STE7 family S280
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Abl family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Abl family
Nomenclature ABL proto-oncogene 1, non-receptor tyrosine kinase
HGNC, UniProt ABL1, P00519
EC number 2.7.10.2
Common abreviation Abl
Inhibitors compound 8h (pIC50 9.7) [529], dasatinib (pIC50 9.6) [270], compound 24 (pIC50 9.3) [118], PD-173955 (pKd 9.2) [112], bosutinib (pIC50 9) [186],
PD-173955 (pIC50 ∼8.3) [362], bafetinib (pIC50 7.6–8.2) [228, 269], ponatinib (pIC50 8.1) [232], nilotinib (pIC50 7.8) [372], PP121 (pIC50 7.7) [15], imatinib
(pIC50 6.7) [228], GNF-5 (pIC50 6.7) [597]
Ack family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Ack family
Nomenclature tyrosine kinase non receptor 2
HGNC, UniProt TNK2, Q07912
EC number 2.7.10.2
Common abreviation Ack
Inhibitors compound 30 (pIC50 9) [122]
Janus kinase (JakA) family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Janus kinase (JakA) family
Nomenclature Janus kinase 1 Janus kinase 2 Janus kinase 3 tyrosine kinase 2
HGNC, UniProt JAK1, P23458 JAK2, O60674 JAK3, P52333 TYK2, P29597
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Common abreviation JAK1 JAK2 JAK3 Tyk2
Searchable database: http://www.guidetopharmacology.org/index.jsp Janus kinase (JakA) family S281
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(continued)
Nomenclature Janus kinase 1 Janus kinase 2 Janus kinase 3 tyrosine kinase 2
Inhibitors ruxolitinib (pIC50
8.5–10.1) [203,
423], ﬁlgotinib
(pIC50 8) [541]
NS-018 (pIC50 9.1) [374], BMS-911543 (pIC50 9) [420], AT-9283
(pIC50 8.9) [230], XL019 (pIC50 8.7) [152], fedratinib (pIC50 8.5)
[333, 566], gandotinib (pIC50 8.4) [330]
AT-9283 (pIC50 9) [230] –
Selective inhibitors – compound 1d (pIC50 >9) [554] – –
Comments – The JAK2V617F mutation, which causes constitutive activation,
plays an oncogenic role in the pathogenesis of the
myeloproliferative disorders, polycythemia vera, essential
thrombocythemia, and idiopathic myeloﬁbrosis [64, 115]. Small
molecule compounds which inhibit aberrant JAK2 activity are
being developed as novel anti-cancer pharmaceuticals.
– –
Src family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Src family
Nomenclature BLK proto-oncogene, Src
family tyrosine kinase
fyn related Src family
tyrosine kinase
FYN proto-oncogene, Src
family tyrosine kinase
LYN proto-oncogene, Src
family tyrosine kinase
SRC proto-oncogene,
non-receptor tyrosine
kinase
HGNC, UniProt BLK, P51451 FRK, P42685 FYN, P06241 LYN, P07948 SRC, P12931
EC number 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2 2.7.10.2
Common abreviation Blk FRK Fyn Lyn Src
Inhibitors – – PP1 (pIC50 8.2) [205] bafetinib (pIC50 8) [228] WH-4-023 (pIC50 8.2)
[340], PD166285 (pKi
8.1) [396], PP121 (pIC50
7.8) [15], ENMD-2076
(pIC50 7.7) [416]
Searchable database: http://www.guidetopharmacology.org/index.jsp Src family S282
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Tec family
Enzymes → Kinases (EC 2.7.x.x) → TK: Tyrosine kinase → Non-receptor tyrosine kinases (nRTKs) → Tec family
Nomenclature BMX non-receptor tyrosine kinase Bruton tyrosine kinase TXK tyrosine kinase
HGNC, UniProt BMX, P51813 BTK, Q06187 TXK, P42681
EC number 2.7.10.2 2.7.10.2 2.7.10.2
Common abreviation Etk Btk TXK
Inhibitors compound 38 (pIC50 9.1) [300], ibrutinib (pIC50 9.1)
[318], compound 31 (pIC50 8.7) [300]
ibrutinib (pIC50 9.3) [395], compound 31 (pIC50 8.4)
[300], compound 38 (pIC50 >8.4) [300]
–
Selective inhibitors BMX-IN-1 (pIC50 8.1) [307] CGI1746 (pIC50 8.7) [120], CHMFL-BTK-11 (Irreversible
inhibition) (pIC50 7.6) [576]
–
RAF family
Enzymes → Kinases (EC 2.7.x.x) → TKL: Tyrosine kinase-like → RAF family
Nomenclature B-Raf proto-oncogene, serine/threonine kinase Raf-1 proto-oncogene, serine/threonine kinase
HGNC, UniProt BRAF, P15056 RAF1, P04049
EC number 2.7.11.1 2.7.11.1
Common abreviation B-Raf c-Raf
Inhibitors GDC-0879 (pIC50 9.7–9.9) [112, 206], dabrafenib (pIC50 8.5) [305],
regorafenib (pIC50 7.6) [594], vemurafenib (pIC50 7) [555], PLX-4720
(pKd 6.5) [112], compound 2 (pKd 6.3) [227], CHIR-265 (pKd 5.9) [112]
–
Selective inhibitors – GW5074 (pIC50 8.1) [88]
Further reading on Kinases (EC 2.7.x.x)
Eglen R et al. (2011) Drug discovery and the human kinome: recent trends. Pharmacol. Ther. 130:
144-56 [PMID:21256157]
Graves LM et al. (2013) The dynamic nature of the kinome. Biochem. J. 450: 1-8 [PMID:23343193]
Liu Q et al. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol.
20: 146-59 [PMID:23438744]
Martin KJ et al. (2012) Selective kinase inhibitors as tools for neuroscience research. Neuropharma-
cology 63: 1227-37 [PMID:22846224]
Tarrant MK et al. (2009) The chemical biology of protein phosphorylation. Annu. Rev. Biochem.
78: 797-825 [PMID:19489734]
Wu-Zhang AX et al. (2013) Protein kinase C pharmacology: reﬁning the toolbox. Biochem. J. 452:
195-209 [PMID:23662807]
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Peptidases and proteinases
Enzymes → Peptidases and proteinases
Overview: Peptidases and proteinases hydrolyse peptide bonds,
and can be simply divided on the basis of whether terminal
peptide bonds are cleaved (exopeptidases and exoproteinases)
at the amino terminus (aminopeptidases) or carboxy terminus
(carboxypeptidases). Non-terminal peptide bonds are cleaved
by endopeptidases and endoproteinases, which are divided into
serine endopeptidases (EC 3.4.21.-), cysteine endopeptidases
(EC 3.4.22.-), aspartate endopeptidases (EC 3.4.23.-), metalloen-
dopeptidases (EC 3.4.24.-) and threonine endopeptidases (EC
3.4.25.-).
Since it is beyond the scope of the Guide to list all peptidase and
proteinase activities, this summary focuses on selected enzymes
of signiﬁcant pharmacological interest that have ligands (mostly
small-molecules) directed against them. For those interested in
detailed background we recommend the MEROPS database [450]
(with whom we collaborate) as an information resource [432].
A1: Pepsin
Enzymes → Peptidases and proteinases → AA: Aspartic (A) Peptidases → A1: Pepsin
Nomenclature renin
HGNC, UniProt REN, P00797
EC number 3.4.23.15
Inhibitors aliskiren (pIC50 9.2) [580]
A22: Presenilin
Enzymes → Peptidases and proteinases → AD: Aspartic (A) Peptidases → A22: Presenilin
Overview: Presenilin (PS)-1 or -2 act as the catalytic compo-
nent/essential co-factor of the γ-secretase complex responsible for
the ﬁnal carboxy-terminal cleavage of amyloid precursor protein
(APP) [260] in the generation of amyloid beta (Aβ) [7, 510]. Given
that the accumulation and aggregation of Aβ in the brain is piv-
otal in the development of Alzheimer’s disease (AD), inhibition
of PS activity is one mechanism being investigated as a therapeu-
tic option for AD [187]. Several small molecule inhibitors of PS-1
have been investigated, with some reaching early clinical trials,
but none have been formally approved. Dewji et al. (2015) have
reported that small peptide fragments of human PS-1 can signif-
icantly inhibit Aβ production (total Aβ, Aβ40 and Aβ42) both in
vitro and when infused in to the brains of APP transgenic mice
[119]. The most active small peptides in this report were P4 and
P8, from the amino-terminal domain of PS-1.
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp A22: Presenilin S284
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C14: Caspase
Enzymes → Peptidases and proteinases → CD: Cysteine (C) Peptidases → C14: Caspase
Overview: Caspases, (E.C. 3.4.22.-) which derive their name
from Cysteine ASPartate-speciﬁc proteASES, include at least two
families; initiator caspases (caspases 2, 8, 9 and 10), which are
able to hydrolyse and activate a second family of effector cas-
pases (caspases 3, 6 and 7), which themselves are able to hy-
drolyse further cellular proteins to bring about programmed cell
death. Caspases are heterotetrameric, being made up of two pairs
of subunits, generated by a single gene product, which is prote-
olysed to form the mature protein. Members of the mammalian
inhibitors of apoptosis proteins (IAP) are able to bind the procas-
pases, thereby preventing maturation to active proteinases.
Information on members of this family may be found in the online database.
Comments: CARD16 (Caspase recruitment domain-containing protein 16, caspase-1 inhibitor COP, CARD only domain-containing protein 1, pseudo interleukin-1β converting enzyme, pseudo-ICE,
ENSG00000204397) shares sequence similarity with some of the caspases.
M1: Aminopeptidase N
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M1: Aminopeptidase N
Overview: Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this
enzyme family may be monomeric or multi-subunit complexes, and many are zinc metalloenzymes [522].
Information on members of this family may be found in the online database.
M2: Angiotensin-converting (ACE and ACE2)
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M2: Angiotensin-converting (ACE and ACE2)
Nomenclature Angiotensin-converting enzyme
HGNC, UniProt ACE, P12821
EC number 3.4.15.1
Common abreviation ACE
Endogenous substrates angiotensin I (AGT, P01019) > angiotensin II (AGT, P01019)
Inhibitors zofenoprilat (pKi 9.4) [283] – Rabbit, captopril (pKi 8.4) [354], zofenopril
Selective inhibitors perindoprilat (pIC50 9) [73], cilazaprilat (pIC50 8.7) [559] – Rabbit, imidaprilat (pIC50 8.7) [443], lisinopril-tryptophan (C-domain assay) (pIC50 8.2) [560],
RXP-407 (N-domain selective inhibition) (pIC50 8.1) [472], fosinoprilat (pIC50 8) [113] – Rabbit, enalaprilat (pIC50 7.5) [87], benazeprilat (pIC50 6.6) [296]
Comments Reports of ACE GPI hydrolase activity [277] have been refuted [298]
Searchable database: http://www.guidetopharmacology.org/index.jsp M2: Angiotensin-converting (ACE and ACE2) S285
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M10: Matrix metallopeptidase
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M10: Matrix metallopeptidase
Overview: Matrix metalloproteinases (MMP) are calcium- and zinc-dependent proteinases regulating the extracellular matrix and are often divided (e.g. [545]) on functional and structural bases into
gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type-MMP (MT-MMP).
Nomenclature MMP2 MMP8
HGNC, UniProt MMP2, P08253 MMP8, P22894
EC number 3.4.24.24 3.4.24.34
Selective inhibitors ARP100 [537] –
Comments MMP2 is categorised as a gelatinase with substrate speciﬁcity for gelatinase A. MMP8 is categorised as a collagenase.
Comments: A number of small molecule ‘broad spectrum’ inhibitors of MMP have been described, including marimastat and batimastat.
Tissue inhibitors of metalloproteinase (TIMP) proteins are endogenous inhibitors acting to chelate MMP proteins: TIMP1 (TIMP1, P01033), TIMP2 (TIMP2, P16035), TIMP3 (TIMP3, P35625),
TIMP4 (TIMP4, Q99727)
M12: Astacin/Adamalysin
Enzymes → Peptidases and proteinases → MA: Metallo (M) Peptidases → M12: Astacin/Adamalysin
Overview: ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited
products.
ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited products.
Information on members of this family may be found in the online database.
Comments: Additional ADAM familymembers include AC123767.2 (cDNA FLJ58962, moderately similar tomouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21-like protein, ENSG00000235812),
AC136428.3-2 (ENSG00000185520) and ADAMDEC1 (decysin 1, ENSG00000134028).
Other ADAMTS family members include AC104758.12-5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3-1 (ENSG00000225577), and AC126339.6-1 (ENSG00000225734).
Searchable database: http://www.guidetopharmacology.org/index.jsp M12: Astacin/Adamalysin S286
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M28: Aminopeptidase Y
Enzymes → Peptidases and proteinases → MH: Metallo (M) Peptidases → M28: Aminopeptidase Y
Nomenclature Folate hydrolase (prostate-speciﬁc membrane antigen) 1
HGNC, UniProt FOLH1, Q04609
EC number 3.4.17.21
Antibodies capromab (Binding)
Comments Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate (L-glutamic acid). In
the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression
is up-regulated in cancerous tissue. A tagged version of the antibody capromab has been used for imaging purposes.
Comments: Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N-acetaspartylglutamate to form N-acetylaspartate and L-glutamate. In the gut, the enzyme assists in
the assimilation of folate by hydrolysing dietary poly-gamma-glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up-regulated in cancerous tissue. A tagged version of
the antibody capromab has been used for imaging purposes.
M19: Membrane dipeptidase
Enzymes → Peptidases and proteinases → MJ: Metallo (M) Peptidases → M19: Membrane dipeptidase
Nomenclature Dipeptidase 1
HGNC, UniProt DPEP1, P16444
EC number 3.4.13.19: LTD4 + H2O = LTE4 + glycine
Inhibitors cilastatin (pKi 6) [189]
Searchable database: http://www.guidetopharmacology.org/index.jsp M19: Membrane dipeptidase S287
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S1: Chymotrypsin
Enzymes → Peptidases and proteinases → PA: Serine (S) Peptidases → S1: Chymotrypsin
Nomenclature complement C1r coagulation factor II, thrombin coagulation factor X
HGNC, UniProt C1R, P00736 F2, P00734 F10, P00742
EC number 3.4.21.41 3.4.21.5 3.4.21.6
Inhibitors nafamostat (pIC50 4.9) [216] lepirudin (pKi 13) [506], desirudin (pKi 12.7) [254], AZ12971554 (pKi 9.5)
[19], melagatran (pKi 8.7) [198], bivalirudin (pKi 8.6) [573], dabigatran (pKi
8.3) [211], argatroban (pKi 7.7) [238]
rivaroxaban (pKi 9.4) [407], edoxaban
(pKi 9.2) [412], apixaban (pKi 9.1) [574]
Selective inhibitors – Dup-714 (pKi 10.4) [175], AR-H067637 (pIC50 8.4) [114] –
Nomenclature elastase, neutrophil
expressed
plasminogen plasminogen
activator, tissue type
protease, serine 1 tryptase alpha/beta 1
HGNC, UniProt ELANE, P08246 PLG, P00747 PLAT, P00750 PRSS1, P07477 TPSAB1, Q15661
EC number 3.4.21.37 3.4.21.7 3.4.21.68 3.4.21.4 3.4.21.59
Inhibitors alvelestat (pKi 8) [502],
sivelestat (pIC50 7.4) [103]
aprotinin {Bovine} (Binding)
(pIC50 6.8) [492], tranexamic acid
(Binding) (pIC50 3.6) [492]
– nafamostat (pIC50
7.8) [216]
nafamostat (pIC50
10) [365]
Selective inhibitors – 6-aminocaproic acid (Binding)
(pIC50 4.4) [86]
– – gabexate (pIC50 8.5)
[135]
T1: Proteasome
Enzymes → Peptidases and proteinases → PB: Threonine (T) Peptidases → T1: Proteasome
Overview: The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex [93]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and
Glu adjacent to the cleavage site. The β5 subunit is the principal target of the approved drug proteasome inhibitor bortezomib.
Searchable database: http://www.guidetopharmacology.org/index.jsp T1: Proteasome S288
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Nomenclature proteasome subunit beta 5
HGNC, UniProt PSMB5, P28074
EC number 3.4.25.1
Inhibitors bortezomib (pIC50 7.7) [371]
Selective inhibitors ixazomib (pKi 9) [286]
S8: Subtilisin
Enzymes → Peptidases and proteinases → SB: Serine (S) Peptidases → S8: Subtilisin
Overview: One member of this family has garnered intense in-
terest as a clinical drug target. As liver PCSK9 acts to maintain
cholesterol homeostasis, it has become a target of intense in-
terest for clinical drug development. Inhibition of PCSK9 can
lower low-density cholesterol (LDL-C) by clearing LDLR-bound
LDL particles, thereby lowering circulating cholesterol levels. It
is hypothesised that this action may improve outcomes in pa-
tients with atherosclerotic cardiovascular disease [315, 452, 501].
Therapeutics which inhibit PCSK9 are viewed as potentially lu-
crative replacements for statins, upon statin patent expiry. Sev-
eral monoclonal antibodies including alirocumab, evolocumab,
bococizumab, RG-7652 and LY3015014 are under development.
One RNAi therapeutic, code named ALN-PCS02, is also in devel-
opment [106, 147, 155].
Information on members of this family may be found in the online database.
S9: Prolyl oligopeptidase
Enzymes → Peptidases and proteinases → SC: Serine (S) Peptidases → S9: Prolyl oligopeptidase
Nomenclature dipeptidyl peptidase 4
HGNC, UniProt DPP4, P27487
EC number 3.4.14.5
Endogenous substrates glucagon-like peptide 1 (GCG, P01275)
Inhibitors saxagliptin (pKi 9.2) [196], linagliptin (pKi 9) [130], sitagliptin (pIC50 8.1) [111], vildagliptin (pKi 7.8) [196]
Searchable database: http://www.guidetopharmacology.org/index.jsp S9: Prolyl oligopeptidase S289
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Acetylcholine turnover
Enzymes → Acetylcholine turnover
Overview: Acetylcholine is familiar as a neurotransmitter in
the central nervous system and in the periphery. In the somatic
nervous system, it activates nicotinic acetylcholine receptors at
the skeletal neuromuscular junction. It is also employed in the
autonomic nervous system, in both parasympathetic and sympa-
thetic branches; in the former, at the smooth muscle neuromus-
cular junction, activating muscarinic acetylcholine receptors. In
the latter, acetylcholine is involved as a neurotransmitter at the
ganglion, activating nicotinic acetylcholine receptors. Acetyl-
choline is synthesised in neurones through the action of choline
O-acetyltransferase and metabolised after release through the
extracellular action of acetylcholinesterase and cholinesterase.
Choline is accumulated from the extracellular medium by se-
lective transporters (see SLC5A7 and the SLC44 family). Acetyl-
choline is accumulated in synaptic vesicles through the action of
the vesicular acetylcholine transporter SLC18A3.
Nomenclature choline O-acetyltransferase acetylcholinesterase (Cartwright blood group) butyrylcholinesterase
HGNC, UniProt CHAT, P28329 ACHE, P22303 BCHE, P06276
EC number 2.3.1.6: acetyl CoA + choline = acetylcholine +
coenzyme A
3.1.1.7: acetylcholine + H2O = acetic acid +
choline + H+
3.1.1.7: acetylcholine + H2O =
acetic acid + choline + H+
Common abreviation ChAT AChE BChE
Inhibitors compound 2 (pIC50 6.5) [190] – Mouse tacrine (pKi 7.5) [58], galantamine (pIC50 6.3)
[94], rivastigmine (pIC50 5.4) [325]
rivastigmine (pIC50 7.4) [325],
tacrine (pKi 7.2) [58]
Sub/family-selective
inhibitors
– physostigmine (pIC50 7.6–7.8) [325] physostigmine (pIC50 7.6–7.8) [325]
Selective inhibitors – donepezil (pIC50 7.7–8.3) [68, 170, 325],
BW284C51 (pIC50 7.7) [182]
bambuterol (pIC50 8.5) [182]
Comments Splice variants of choline O-acetyltransferase are
suggested to be differentially distributed in the
periphery and CNS (see [30]).
– –
Comments: A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos-oxon, and nerve agents such as tabun,
soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule [570].
Further reading on Acetylcholine turnover
Li Q et al. (2017) Recent progress in the identiﬁcation of selective butyrylcholinesterase inhibitors
for Alzheimer’s disease. Eur J Med Chem 132: 294-309 [PMID:28371641]
Lockridge O. (2015) Review of human butyrylcholinesterase structure, function, genetic vari-
ants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 148: 34-46
[PMID:25448037]
Masson P et al. (2016) Slow-binding inhibition of cholinesterases, pharmacological and toxicolog-
ical relevance. Arch Biochem Biophys 593: 60-8 [PMID:26874196]
Rotundo RL. (2017) Biogenesis, assembly and trafﬁcking of acetylcholinesterase. J Neurochem
[PMID:28326552]
Silman I et al. (2017) Recent developments in structural studies on acetylcholinesterase. J Neu-
rochem [PMID:28503857]
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Adenosine turnover
Enzymes → Adenosine turnover
Overview: A multifunctional, ubiquitous molecule, adenosine
acts at cell-surface G protein-coupled receptors, as well as numer-
ous enzymes, including protein kinases and adenylyl cyclase. Ex-
tracellular adenosine is thought to be produced either by export
or by metabolism, predominantly through ecto-5’-nucleotidase
activity (also producing inorganic phosphate). It is inactivated
either by extracellular metabolism via adenosine deaminase (also
producing ammonia) or, following uptake by nucleoside trans-
porters, via adenosine deaminase or adenosine kinase (requiring
ATP as co-substrate). Intracellular adenosine may be produced by
cytosolic 5’-nucleotidases or through S-adenosylhomocysteine
hydrolase (also producing L-homocysteine).
Nomenclature Adenosine deaminase Adenosine kinase Ecto-5’-Nucleotidase S-Adenosylhomocysteine
hydrolase
Systematic
nomenclature
– – CD73 –
HGNC, UniProt ADA, P00813 ADK, P55263 NT5E, P21589 AHCY, P23526
EC number 3.5.4.4: adenosine +
H2O = inosine + NH3
2.7.1.20 3.1.3.5 3.3.1.1
Common abreviation ADA ADK NT5E SAHH
Rank order of afﬁnity 2’-deoxyadenosine >
adenosine
adenosine adenosine 5’-monophosphate,
5’-GMP, 5’-inosine monophosphate,
5’-UMP > 5’-dAMP, 5’-dGMP
–
Endogenous
substrates
– – – S-adenosylhomocysteine
Products 2’-deoxyinosine,
inosine
adenosine 5’-monophosphate uridine, inosine, guanine, adenosine adenosine
Inhibitors – – – DZNep (pKi 12.3) [184]
– Hamster
Selective inhibitors pentostatin (pIC50
10.8) [4], EHNA (pKi
8.8) [4]
A134974 (pIC50 10.2) [348], ABT702 (pIC50 8.8)
[248]
αβ-methyleneADP (pIC50 8.7) [56] 3-deazaadenosine (pIC50
8.5) [197]
Comments – The enzyme exists in two isoforms derived from
alternative splicing of a single gene product: a short
isoform, ADK-S, located in the cytoplasm is
responsible for the regulation of intra- and
extracellular levels of adenosine and hence
adenosine receptor activation; a long isoform,
ADK-L, located in the nucleus contributes to the
regulation of DNA methylation [48, 569].
Pharmacological inhibition of CD73
is being investigated as a novel
cancer immunotherapy strategy
[552].
–
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Comments: An extracellular adenosine deaminase activity,
termed ADA2 or adenosine deaminase growth factor (ADGF,
CECR1, Q9NZK5) has been identiﬁed [101, 331], which is in-
sensitive to EHNA [595]. Other forms of adenosine deaminase
act on ribonucleic acids and may be divided into two families:
ADAT1 (Q9BUB4) deaminates transfer RNA; ADAR (EC 3.5.4.37,
also known as 136 kDa double-stranded RNA-binding protein,
P136, K88DSRBP, Interferon-inducible protein 4); ADARB1 (EC
3.5.-.-, , also known as dsRNA adenosine deaminase) andADARB2
(EC 3.5.-.-, also known as dsRNA adenosine deaminase B2, RNA-
dependent adenosine deaminase 3) act on double-stranded RNA.
Particular polymorphisms of the ADA gene result in loss-of-
function and severe combined immunodeﬁciency syndrome.
Adenosine deaminase is able to complex with dipeptidyl pepti-
dase IV (EC 3.4.14.5, DPP4, also known as T-cell activation anti-
gen CD26, TP103, adenosine deaminase complexing protein 2)
to form a cell-surface activity [259].
Further reading on Adenosine turnover
Boison D. (2013) Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev. 65: 906-43
[PMID:23592612]
Cortés A et al. (2015) Moonlighting adenosine deaminase: a target protein for drug development.
Med Res Rev 35: 85-125 [PMID:24933472]
Nishikura K (2016) A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol
17: 83-96 [PMID:26648264]
Sawynok J (2016) Adenosine receptor targets for pain. Neuroscience 338: 1-18 [PMID:26500181]
Xiao Y et al. (2015) Role of S-adenosylhomocysteine in cardiovascular disease and its potential
epigenetic mechanism. Int J Biochem Cell Biol 67: 158-66 [PMID:26117455]
Amino acid hydroxylases
Enzymes → Amino acid hydroxylases
Overview: The amino acid hydroxylases (monooxygenases), EC.1.14.16.-, are iron-containing enzymes which utilise molecular oxygen and sapropterin as co-substrate and co-factor, respectively. In
humans, as well as in other mammals, there are two distinct L-Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous
enzymes, TPH1 and TPH2.
Nomenclature L-Phenylalanine hydroxylase L-Tyrosine hydroxylase L-Tryptophan hydroxylase 1 L-Tryptophan hydroxylase 2
HGNC, UniProt PAH, P00439 TH, P07101 TPH1, P17752 TPH2, Q8IWU9
EC number 1.14.16.1: L-phenylalanine + O2 ->
L-tyrosine
1.14.16.2: L-tyrosine + O2 -> levodopa 1.14.16.4 1.14.16.4
Endogenous substrates L-phenylalanine L-tyrosine L-tryptophan L-tryptophan
Products L-tyrosine levodopa 5-hydroxy-L-tryptophan 5-hydroxy-L-tryptophan
Cofactors sapropterin sapropterin, Fe2+ – –
Endogenous activators Protein kinase A-mediated
phosphorylation (Rat) [2]
Protein kinase A-mediated
phosphorylation [251]
Protein kinase A-mediated
phosphorylation [252]
Protein kinase A-mediated
phosphorylation [252]
Inhibitors – methyltyrosine telotristat ethyl [267] –
Selective inhibitors α-methylphenylalanine [191] – Rat,
fenclonine
α-propyldopacetamide,
3-chlorotyrosine, 3-iodotyrosine,
alpha-methyltyrosine
α-propyldopacetamide,
6-ﬂuorotryptophan [377],
fenclonine, fenﬂuramine
α-propyldopacetamide,
6-ﬂuorotryptophan [377],
fenclonine, fenﬂuramine
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(continued)
Nomenclature L-Phenylalanine hydroxylase L-Tyrosine hydroxylase L-Tryptophan hydroxylase 1 L-Tryptophan hydroxylase 2
Comments PAH is an iron bound homodimer or
-tetramer from the same structural
family as tyrosine 3-monooxygenase
and the tryptophan hydroxylases.
Deﬁciency or loss-of-function of PAH is
associated with phenylketonuria
TH is a homotetramer, which is
inhibited by dopamine and other
catecholamines in a physiological
negative feedback pathway [109].
– –
Further reading on Amino acid hydroxylases
Bauer IE et al. (2015) Serotonergic gene variation in substance use pharmacotherapy: a systematic
review. Pharmacogenomics 16: 1307-14 [PMID:26265436]
Daubner SC et al. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch.
Biochem. Biophys. 508: 1-12 [PMID:21176768]
Flydal MI et al. (2013) Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life
65: 341-9 [PMID:23457044]
Roberts KM et al. (2013) Mechanisms of tryptophan and tyrosine hydroxylase. IUBMB Life 65:
350-7 [PMID:23441081]
Tekin I et al. (2014) Complex molecular regulation of tyrosine hydroxylase. J Neural Transm 121:
1451-81 [PMID:24866693]
Waloen K et al. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human
disease. Expert Opin Ther Targets 21: 167-180 [PMID:27973928]
L-Arginine turnover
Enzymes → L-Arginine turnover
Overview: L-arginine is a basic amino acid with a guanidino
sidechain. As an amino acid, metabolism of L-arginine to form
L-ornithine, catalysed by arginase, forms the last step of the
urea production cycle. L-Ornithine may be utilised as a pre-
cursor of polyamines (see Carboxylases and Decarboxylases) or
recycled via L-argininosuccinic acid to L-arginine. L-Arginine
may itself be decarboxylated to form agmatine, although the
prominence of this pathway in human tissues is uncertain.
L-Arginine may be used as a precursor for guanidoacetic acid
formation in the creatine synthesis pathway under the inﬂu-
ence of arginine:glycine amidinotransferase with L-ornithine as
a byproduct. Nitric oxide synthase uses L-arginine to generate
nitric oxide, with L-citrulline also as a byproduct.
L-Arginine in proteins may be subject to post-translational mod-
iﬁcation through methylation, catalysed by protein arginine
methyltransferases. Subsequent proteolysis can liberate asym-
metric NG,NG-dimethyl-L-arginine (ADMA), which is an endoge-
nous inhibitor of nitric oxide synthase activities. ADMA is
hydrolysed by dimethylarginine dimethylhydrolase activities to
generate L-citrulline and dimethylamine.
Further reading on L-Arginine turnover
Lai L et al. (2016) Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers.
J Diabetes Res 2016: 1982096 [PMID:26770984]
Pekarova M et al. (2015) The crucial role of l-arginine in macrophage activation: What you need
to know about it. Life Sci 137: 44-8 [PMID:26188591]
Pudlo M et al. (2017) Arginase Inhibitors: A Rational Approach Over One Century. Med Res Rev 37:
475-513 [PMID:27862081]
Sudar-Milovanovic E et al. (2016) Beneﬁts of L-Arginine on Cardiovascular. System Mini Rev Med
Chem 16: 94-103 [PMID:26471966]
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2.1.1.- Protein arginine N-methyltransferases
Enzymes → L-Arginine turnover → 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT, EC 2.1.1.-) encompass histone arginine N-methyltransferases (PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein N-methyltransferases
(PRMT7, EC 2.1.1.126). They are dimeric or tetrameric enzymes which use S-adenosyl methionine as a methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and di-methylated products; these may be symmetric (SDMA) or asymmetric (NG,NG-dimethyl-L-arginine) versions, where both guanidine nitro-
gens are monomethylated or one of the two is dimethylated, respectively.
Information on members of this family may be found in the online database.
Arginase
Enzymes → L-Arginine turnover → Arginase
Overview: Arginase (EC 3.5.3.1) are manganese-containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is
associated more with the kidney.
Information on members of this family may be found in the online database.
Comments: Nω-hydroxyarginine, an intermediate in NOS metabolism of L-arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform-selective
inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are Nω-hydroxy-nor-L-arginine [525], S-(2-boronoethyl)-L-cysteine [97, 268] and
2(S)-amino-6-boronohexanoic acid [24, 97].
Arginine:glycine amidinotransferase
Enzymes → L-Arginine turnover → Arginine:glycine amidinotransferase
Nomenclature Arginine:glycine amidinotransferase
HGNC, UniProt GATM, P50440
EC number 2.1.4.1
Common abreviation AGAT
Searchable database: http://www.guidetopharmacology.org/index.jsp Arginine:glycine amidinotransferase S294
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Dimethylarginine dimethylaminohydrolases
Enzymes → L-Arginine turnover → Dimethylarginine dimethylaminohydrolases
Overview: Dimethylarginine dimethylaminohydrolases (DDAH, EC 3.5.3.18) are cytoplasmic enzymes which hydrolyse NG,NG-dimethyl-L-arginine to form dimethylamine and L-citrulline.
Nomenclature NG,NG-Dimethylarginine dimethylaminohydrolase 1 NG,NG-Dimethylarginine dimethylaminohydrolase 2
HGNC, UniProt DDAH1, O94760 DDAH2, O95865
EC number 3.5.3.18 3.5.3.18
Common abreviation DDAH1 DDAH2
Cofactors Zn2+ –
Inhibitors compound 2e (pKi 5.7) [279] –
Nitric oxide synthases
Enzymes → L-Arginine turnover → Nitric oxide synthases
Overview: Nitric oxide synthases (NOS, E.C. 1.14.13.39) are a
family of oxidoreductases that synthesize nitric oxide (NO.) via
the NADPH and oxygen-dependent consumption of L-arginine
with the resultant by-product, L-citrulline. There are 3 NOS
isoforms and they are related by their capacity to produce NO,
highly conserved organization of functional domains and signif-
icant homology at the amino acid level. NOS isoforms are func-
tionally distinguished by the cell type where they are expressed,
intracellular targeting and transcriptional and post-translation
mechanisms regulating enzyme activity. The nomenclature sug-
gested by NC-IUPHAR of NOS I, II and III [363] has not gained
wide acceptance, and the 3 isoforms are more commonly referred
to as neuronal NOS (nNOS), inducible NOS (iNOS) and endothe-
lial NOS (eNOS) which reﬂect the location of expression (nNOS
and eNOS) and inducible expression (iNOS). All are dimeric en-
zymes that shuttle electrons from NADPH, which binds to a C-
terminal reductase domain, through the ﬂavins FAD and FMN to
the oxygenase domain of the other monomer to enable the BH4-
dependent reduction of heme bound oxygen for insertion into
the substrate, L-arginine. Electron ﬂow from reductase to oxy-
genase domain is controlled by calmodulin binding to canon-
ical calmodulin binding motif located between these domains.
eNOS and nNOS isoforms are activated at concentrations of
calcium greater than 100 nM, while iNOS shows higher afﬁn-
ity for Ca2+/calmodulin (CALM1 CALM2 CALM3, P62158) with
great avidity and is essentially calcium-independent and consti-
tutively active. Efﬁcient stimulus-dependent coupling of nNOS
and eNOS is achieved via subcellular targeting through respective
N-terminal PDZ and fatty acid acylation domains whereas iNOS
is largely cytosolic and function is independent of intracellular
location. nNOS is primarily expressed in the brain and neuronal
tissue, iNOS in immune cells such as macrophages and eNOS in
the endothelial layer of the vasculature although exceptions in
other cells have been documented. L-NAME and related modi-
ﬁed arginine analogues are inhibitors of all three isoforms, with
IC50 values in the micromolar range.
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Nomenclature Endothelial NOS Inducible NOS Neuronal NOS
HGNC, UniProt NOS3, P29474 NOS2, P35228 NOS1, P29475
EC number 1.14.13.39 1.14.13.39 1.14.13.39
Common abreviation eNOS iNOS nNOS
Endogenous Substrate L-arginine L-arginine L-arginine
Products NO, L-citrulline NO, L-citrulline L-citrulline, NO
Cofactors oxygen, BH4, Zn2+, ﬂavin mononucleotide,
NADPH, heme, ﬂavin adenine dinucleotide
heme, ﬂavin mononucleotide,
ﬂavin adenine dinucleotide, oxygen, NADPH,
Zn2+, BH4
ﬂavin adenine dinucleotide, heme, oxygen,
BH4, ﬂavin mononucleotide, NADPH, Zn2+
Selective inhibitors – 1400W (pIC50 8.2) [178],
2-amino-4-methylpyridine (pIC50 7.4) [139], PIBTU
(pIC50 7.3) [179], NIL (pIC50 5.5) [364],
aminoguanidine [99]
3-bromo-7NI (pIC50 6.1–6.5) [43], 7NI
(pIC50 5.3) [20]
Comments: The reductase domain of NOS catalyses the reduction of cytochrome c and other redox-active dyes [345]. NADPH:O2 oxidoreductase catalyses the formation of superoxide anion/H2O2 in
the absence of L-arginine and sapropterin.
Further reading on Nitric oxide synthases
Bogdan, C. (2015) Nitric oxide synthase in innate and adaptive immunity: An update. Trends
Immunol 36: 161-78 [PMID:25687683]
Lundberg JO et al. (2015) Strategies to increase nitric oxide signalling in cardiovascular disease. Nat
Rev Drug Discov 14: 623-41 [PMID:26265312]
Oliveira-Paula GH et al. (2016) Endothelial nitric oxide synthase: From biochemistry and gene
structure to clinical implications of NOS3 polymorphisms. Gene 575: 584-99 [PMID:26428312]
Shu X et al. (2015) Endothelial nitric oxide synthase in the microcirculation. Cell Mol Life Sci 72:
4561-75 [PMID:26390975]
Zhao Y et al. (2015) Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci 129: 83-94
[PMID:26499181]
Carboxylases and decarboxylases
Enzymes → Carboxylases and decarboxylases
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Carboxylases
Enzymes → Carboxylases and decarboxylases → Carboxylases
Overview: The carboxylases allow the production of new carbon-carbon bonds by introducing HCO3- or CO2 into target molecules. Two groups of carboxylase activities, some of which are bidirectional,
can be deﬁned on the basis of the cofactor requirement, making use of biotin (EC 6.4.1.-) or vitamin K hydroquinone (EC 4.1.1.-).
Nomenclature Pyruvate carboxylase Acetyl-CoA carboxylase 1 Acetyl-CoA carboxylase 2 Propionyl-CoA carboxylase γ-Glutamyl carboxylase
HGNC, UniProt PC, P11498 ACACA, Q13085 ACACB, O00763 – GGCX, P38435
Subunits – – – Propionyl-CoA carboxylaseβ subunit,
Propionyl-CoA carboxylase α subunit
–
EC number 6.4.1.1 6.4.1.2 6.4.1.2 6.4.1.3 4.1.1.90
Common
abreviation
PC ACC1 ACC2 PCCA,PCCB GGCX
Endogenous
substrates
ATP, pyruvic acid ATP, acetyl CoA acetyl CoA, ATP propionyl-CoA, ATP glutamyl peptides
Products Pi, ADP,
oxalacetic acid
Pi, ADP, malonyl-CoA Pi, ADP, malonyl-CoA ADP, methylmalonyl-CoA, Pi carboxyglutamyl
peptides
Cofactors biotin biotin biotin biotin vitamin K hydroquinone,
NADPH
Inhibitors – – – – anisindione
Selective
inhibitors
– TOFA (pIC50 4.9) [599] TOFA (pIC50 4.9) [599] – –
Comments – Citrate and other dicarboxylic acids are allosteric activators
of acetyl-CoA carboxylase.
Propionyl-CoA carboxylase is able to
function in both forward and reverse ac-
tivity modes, as a ligase (carboxylase) or
lyase (decarboxylase), respectively.
Loss-of-function muta-
tions in γ-glutamyl car-
boxylase are associated
with clotting disorders.
Comments: Dicarboxylic acids including citric acid are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase
(decarboxylase) activity, respectively. Loss-of-function mutations in GGCX are associated with clotting disorders.
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Decarboxylases
Enzymes → Carboxylases and decarboxylases → Decarboxylases
Overview: The decarboxylases generate CO2 and the indicated products from acidic substrates, requiring pyridoxal phosphate or pyruvic acid as a co-factor.
Nomenclature Glutamic acid decarboxylase 1 Glutamic acid decarboxylase 2 Histidine decarboxylase
HGNC, UniProt GAD1, Q99259 GAD2, Q05329 HDC, P19113
EC number 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.22
Common abreviation GAD1 GAD2 HDC
Endogenous substrates L-glutamic acid, L-aspartic acid L-glutamic acid, L-aspartic acid L-histidine
Products GABA GABA histamine
Cofactors pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate
Selective inhibitors s-allylglycine s-allylglycine AMA, FMH [174]
Comments L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-
alanine [577]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological
disorders (see Further reading).
–
Nomenclature L-Arginine
decarboxylase
L-Aromatic amino-acid
decarboxylase
Malonyl-CoA
decarboxylase
Ornithine
decarboxylase
Phosphatidylserine
decarboxylase
S-Adenosylmethionine
decarboxylase
HGNC,
UniProt
AZIN2,
Q96A70
DDC, P20711 MLYCD, O95822 ODC1, P11926 PISD, Q9UG56 AMD1, P17707
EC number 4.1.1.19 4.1.1.28: levodopa ->
dopamine + CO2
5-hydroxy-L-tryptophan
-> 5-hydroxytryptamine
+ CO2
This enzyme also catalyses
the following reaction::
L-tryptophan ->
tryptamine + CO2
4.1.1.9 4.1.1.17 4.1.1.65 4.1.1.50
Common
abreviation
ADC AADC MLYCD ODC PSDC SAMDC
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(continued)
Nomenclature L-Arginine
decarboxylase
L-Aromatic amino-acid
decarboxylase
Malonyl-CoA
decarboxylase
Ornithine
decarboxylase
Phosphatidylserine
decarboxylase
S-Adenosylmethionine
decarboxylase
Endogenous
substrates
L-arginine levodopa,
5-hydroxy-L-tryptophan,
L-tryptophan
malonyl-CoA L-ornithine phosphatidylserine S-adenosyl methionine
Products agmatine
[601]
5-hydroxytryptamine,
dopamine
acetyl CoA putrescine phosphatidylethanolamine S-adenosyl-L-
methioninamine
Cofactors pyridoxal
phosphate
pyridoxal phosphate pyridoxal
phosphate
pyridoxal
phosphate
pyruvic acid pyruvic acid
Selective
inhibitors
– 3-hydroxybenzylhydrazine,
L-α-methyldopa,
benserazide [108],
carbidopa
– APA (pIC50 7.5)
[494], eﬂornithine
(pKd 4.9) [422]
– sardomozide (pIC50 8)
[493]
Comments The presence
of a functional
ADC activity in
human tissues
has been
questioned
[96].
AADC is a homodimer. Inhibited by
AMP-activated
protein
kinase-evoked
phosphorylation
[451]
The activity of
ODC is regulated
by the presence of
an antizyme
(ENSG00000104904)
and an ODC
antizyme inhibitor
(ENSG00000155096).
S-allylglycine is also an
inhibitor of SAMDC
[393].
s-allylglycine is also an
inhibitor of SAMDC
[393].
Further reading on Carboxylases and decarboxylases
Bale S et al. (2010) Structural biology of S-adenosylmethionine decarboxylase. Amino Acids 38:
451-60 [PMID:19997761]
Jitrapakdee S et al. (2008) Structure, mechanism and regulation of pyruvate carboxylase. Biochem.
J. 413: 369-87 [PMID:18613815]
Lietzan AD et al. (2014) Functionally diverse biotin-dependent enzymes with oxaloacetate decar-
boxylase activity. Arch. Biochem. Biophys. 544: 75-86 [PMID:24184447]
Moya-García AA et al. (2009) Structural features of mammalian histidine decarboxylase reveal the
basis for speciﬁc inhibition. Br. J. Pharmacol. 157: 4-13 [PMID:19413567]
Tong L. (2013) Structure and function of biotin-dependent carboxylases. Cell. Mol. Life Sci. 70:
863-91 [PMID:22869039]
Vance JE et al. (2013) Formation and function of phosphatidylserine and phos-
phatidylethanolamine in mammalian cells. Biochim. Biophys. Acta 1831: 543-54
[PMID:22960354]
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Catecholamine turnover
Enzymes → Catecholamine turnover
Overview: Catecholamines are deﬁned by the presence of
two adjacent hydroxyls on a benzene ring with a sidechain
containing an amine. The predominant catacholamines
in mammalian biology are the neurotransmitter/hormones
dopamine, (-)-noradrenaline (norepinephrine) and (-)-adrenaline
(epinephrine). These hormone/transmitters are synthe-
sized by sequential metabolism from L-phenylalanine via
L-tyrosine. Hydroxylation of L-tyrosine generates levodopa,
which is decarboxylated to form dopamine. Hydroxylation
of the ethylamine sidechain generates (-)-noradrenaline (nore-
pinephrine), which can be methylated to form (-)-adrenaline
(epinephrine). In particular neuronal and adrenal chromaf-
ﬁn cells, the catecholamines dopamine, (-)-noradrenaline and
(-)-adrenaline are accumulated into vesicles under the inﬂuence
of the vesicular monoamine transporters (VMAT1/SLC18A1 and
VMAT2/SLC18A2). After release into the synapse or the blood-
stream, catecholamines are accumulated through the action
cell-surface transporters, primarily the dopamine (DAT/SLC6A3)
and norepinephrine transporter (NET/SLC6A2). The primary
routes of metabolism of these catecholamines are oxidation
via monoamine oxidase activities of methylation via catechol
O-methyltransferase.
Nomenclature L-Phenylalanine
hydroxylase
Tyrosine
aminotransferase
L-Tyrosine hydroxylase Dopamine
beta-hydroxylase
(dopamine
beta-monooxygenase)
L-Aromatic amino-acid
decarboxylase
HGNC, UniProt PAH, P00439 TAT, P17735 TH, P07101 DBH, P09172 DDC, P20711
EC number 1.14.16.1:
L-phenylalanine + O2 ->
L-tyrosine
2.6.1.5: L-tyrosine +
α-ketoglutaric acid ->
4-hydroxyphenylpyruvic acid
+ L-glutamic acid
1.14.16.2: L-tyrosine +
O2 -> levodopa
1.14.17.1: dopamine +
O2 = (-)-noradrenaline +
H2O
4.1.1.28: levodopa ->
dopamine + CO2
5-hydroxy-L-tryptophan ->
5-hydroxytryptamine + CO2
This enzyme also catalyses
the following reaction::
L-tryptophan -> tryptamine
+ CO2
Common
abreviation
– TAT – DBH AADC
Endogenous
substrates
L-phenylalanine – L-tyrosine – levodopa,
5-hydroxy-L-tryptophan,
L-tryptophan
Products L-tyrosine – levodopa – 5-hydroxytryptamine,
dopamine
Cofactors sapropterin pyridoxal phosphate sapropterin, Fe2+ Cu2+, L-ascorbic acid pyridoxal phosphate
Endogenous
activators
Protein kinase
A-mediated
phosphorylation (Rat) [2]
– Protein kinase
A-mediated
phosphorylation [251]
– –
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(continued)
Nomenclature L-Phenylalanine
hydroxylase
Tyrosine
aminotransferase
L-Tyrosine hydroxylase Dopamine
beta-hydroxylase
(dopamine
beta-monooxygenase)
L-Aromatic amino-acid
decarboxylase
Selective inhibitors α-methylphenylalanine
[191] – Rat, fenclonine
– α-propyldopacetamide,
3-chlorotyrosine,
3-iodotyrosine,
alpha-methyltyrosine
nepicastat (pIC50 8)
[496]
3-hydroxybenzylhydrazine,
L-α-methyldopa, benserazide
[108], carbidopa
Comments PAH is an iron bound
homodimer or -tetramer
from the same structural
family as tyrosine
3-monooxygenase and
the tryptophan
hydroxylases. Deﬁciency
or loss-of-function of
PAH is associated with
phenylketonuria
Tyrosine may also be
metabolized in the liver
by tyrosine transaminase
to generate
4-hydroxyphenylpyruvic acid,
which can be further
metabolized to
homogentisic acid.
TAT is a homodimer,
where loss-of-function
mutations are associated
with type II tyrosinemia.
TH is a homotetramer,
which is inhibited by
dopamine and other
catecholamines in a
physiological negative
feedback pathway [109].
DBH is a homotetramer.
A protein
structurally-related to
DBH (MOXD1, Q6UVY6)
has been described and
for which a function has
yet to be identiﬁed [76].
AADC is a homodimer.
Nomenclature Phenylethanolamine
N-methyltransferase
Monoamine oxidase A Monoamine oxidase B Catechol-O-methyltransferase
HGNC, UniProt PNMT, P11086 MAOA, P21397 MAOB, P27338 COMT, P21964
EC number 2.1.1.28:
(-)-noradrenaline ->
(-)-adrenaline
1.4.3.4 (-)-adrenaline ->
3,4-dihydroxymandelic acid + NH3
(-)-noradrenaline ->
3,4-dihydroxymandelic acid + NH3tyramine
-> 4-hydroxyphenyl acetaldehyde + NH3
dopamine ->
3,4-dihydroxyphenylacetaldehyde + NH3
5-hydroxytryptamine ->
5-hydroxyindole acetaldehyde + NH3
1.4.3.4 2.1.1.6: S-adenosyl-L-methionine + a
catechol = S-adenosyl-L-homocysteine +
a guaiacol (-)-noradrenaline ->
normetanephrine dopamine ->
3-methoxytyramine
3,4-dihydroxymandelic acid ->
vanillylmandelic acid (-)-adrenaline ->
metanephrine
Common abreviation PNMT MAO-A MAO-B COMT
Cofactors S-adenosyl methionine ﬂavin adenine dinucleotide ﬂavin adenine dinucleotide S-adenosyl methionine
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(continued)
Nomenclature Phenylethanolamine
N-methyltransferase
Monoamine oxidase A Monoamine oxidase B Catechol-O-methyltransferase
Inhibitors LY134046 (pKi 7.6)
[163]
moclobemide (pKi 8.3) [247], phenelzine
(Irreversible inhibition) (pKi 7.3) [39],
tranylcypromine (pIC50 4.7) [587],
selegiline (pKi 4.2) [357], beﬂoxatone
[107], clorgiline, pirlindole [350]
rasagiline (pIC50 7.8) [591],
phenelzine (Irreversible
inhibition) (pKi 7.8) [39],
lazabemide (pKi 7.1) [200,
532], selegiline (pKi 5.7–6)
[121, 357], tranylcypromine
(pIC50 4.7) [587]
tolcapone (soluble enzyme) (pKi 9.6)
[317], tolcapone (membrane-bound
enzyme) (pKi 9.5) [317], entacapone
(soluble enzyme) (pKi 9.5) [317],
entacapone (membrane-bound
enzyme) (pKi 8.7) [317]
Selective inhibitors – – saﬁnamide (pKi 6.3) [38] –
Comments – – – COMT appears to exist in both
membrane-bound and soluble forms.
COMT has also been described to
methylate steroids, particularly
hydroxyestradiols
Further reading on Catecholamine turnover
Dauvilliers Y et al. (2015) Catechol-O-methyltransferase, dopamine, and sleep-wake regulation.
Sleep Med Rev 22: 47-53 [PMID:25466290]
Deshwal S et al. (2017) Emerging role of monoamine oxidase as a therapeutic target for cardiovas-
cular disease. Curr Opin Pharmacol 33: 64-69 [PMID:28528298]
Fisar Z. (2016) Drugs related to monoamine oxidase activity. Prog Neuropsychopharmacol Biol Psy-
chiatry 69: 112-24 [PMID:26944656]
Ramsay RR. (2016). Molecular aspects of monoamine oxidase B. Prog Neuropsychopharmacol Biol
Psychiatry 69: 81-9 [PMID:26891670]
Waloen K et al. (2017). Tyrosine and tryptophan hydroxylases as therapeutic targets in human
disease. Expert Opin Ther Targets 21: 167-180 [PMID:27973928]
Ceramide turnover
Enzymes → Ceramide turnover
Overview: Ceramides are a family of sphingophospholipids
synthesized in the endoplasmic reticulum, which mediate cell
stress responses, including apoptosis, autophagy and senescence,
Serine palmitoyltransferase generates 3-ketosphinganine, which
is reduced to sphinganine (dihydrosphingosine). N-Acylation al-
lows the formation of dihydroceramides, which are subsequently
reduced to form ceramides. Once synthesized, ceramides are traf-
ﬁcked from the ER to the Golgi bound to the ceramide transfer
protein, CERT (COL4A3BP, Q9Y5P4). Ceramide can be metabo-
lized via multiple routes, ensuring tight regulation of its cellu-
lar levels. Addition of phosphocholine generates sphingomyelin
while carbohydrate is added to form glucosyl- or galactosylce-
ramides. Ceramidase re-forms sphingosine or sphinganine from
ceramide or dihydroceramide. Phosphorylation of ceramide gen-
erates ceramide phosphate. The determination of accurate ki-
netic parameters for many of the enzymes in the sphingolipid
metabolic pathway is complicated by the lipophilic nature of the
substrates.
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Serine palmitoyltransferase
Enzymes → Ceramide turnover → Serine palmitoyltransferase
Overview: The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic
activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb weremost active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA [202]. Complexes
involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with
C16, C18 and C20 acylCoAs [202].
Nomenclature serine palmitoyltransferase
long chain base subunit 1
serine palmitoyltransferase
long chain base subunit 2
serine palmitoyltransferase
long chain base subunit 3
serine palmitoyltransferase
small subunit A
serine palmitoyltransferase
small subunit B
HGNC, UniProt SPTLC1, O15269 SPTLC2, O15270 SPTLC3, Q9NUV7 SPTSSA, Q969W0 SPTSSB, Q8NFR3
EC number 2.3.1.50: L-serine +
palmitoyl-CoA ->
3-ketosphinganine +
coenzyme A + CO2
2.3.1.50: L-serine +
palmitoyl-CoA ->
3-ketosphinganine +
coenzyme A + CO2
2.3.1.50: L-serine +
palmitoyl-CoA ->
3-ketosphinganine +
coenzyme A + CO2
– –
Common
abreviation
SPT1 SPT2 SPT3 SPTSSA SPTSSB
Cofactors pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate – –
Selective
inhibitors
myriocin (pKi 9.6) [358] –
Mouse
myriocin [358] myriocin [358] – –
Ceramide synthase
Enzymes → Ceramide turnover → Ceramide synthase
Overview: This family of enzymes, also known as sphingosine N-acyltransferase, is located in the ER facing the cytosol with an as-yet undeﬁned topology and stoichiometry. Ceramide synthase in vitro
is sensitive to inhibition by the fungal derived toxin, fumonisin B1.
Nomenclature ceramide synthase 1 ceramide synthase 2 ceramide synthase 3 ceramide synthase 4 ceramide synthase 5 ceramide synthase 6
HGNC, UniProt CERS1, P27544 CERS2, Q96G23 CERS3, Q8IU89 CERS4, Q9HA82 CERS5, Q8N5B7 CERS6, Q6ZMG9
EC number 2.3.1.24: acylCoA + sphinganine -> dihydroceramide + coenzyme A sphingosine + acylCoA -> ceramide + coenzyme A
Common
abreviation
CERS1 CERS2 CERS3 CERS4 CERS5 CERS6
Substrates C18-CoA [543] C24- and C26-CoA
[292]
C26-CoA and
longer [361, 424]
C18-, C20- and
C22-CoA [438]
C16-CoA [288, 438] C14- and C16-CoA
[360]
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Sphingolipid 4-desaturase
Enzymes → Ceramide turnover → Sphingolipid 4-desaturase
Overview: DEGS1 and DEGS2 are 4TM proteins.
Nomenclature delta 4-desaturase, sphingolipid 1 delta 4-desaturase, sphingolipid 2
HGNC, UniProt DEGS1, O15121 DEGS2, Q6QHC5
EC number 1.14.-.- 1.14.-.-
Cofactors NAD NAD
Inhibitors RBM2-1B (pIC50 4.7) [63] –
Comments Myristoylation of DEGS1 enhances its activity and targets it to the mitochondria [28]. –
Comments: DEGS1 activity is inhibited by a number of natural products, including curcumin and 9-tetrahydrocannabinol [138].
Sphingomyelin synthase
Enzymes → Ceramide turnover → Sphingomyelin synthase
Overview: Following translocation from the ER to the Golgi under the inﬂuence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of
phosphocholine from the phospholipid phosphatidylcholine.
Sphingomyelin synthase-related protein 1 is structurally related but lacks sphingomyelin synthase activity.
Nomenclature sphingomyelin synthase 1 sphingomyelin synthase 2 sterile alpha motif domain containing 8
HGNC, UniProt SGMS1, Q86VZ5 SGMS2, Q8NHU3 SAMD8, Q96LT4
EC number 2.7.8.27: ceramide + phosphatidylcholine ->
sphingomyelin + diacylglycerol
2.7.8.27: ceramide + phosphatidylcholine ->
sphingomyelin + diacylglycerol
2.7.8.-: ceramide + phosphatidylethanolamine
-> ceramide phosphoethanolamine
Inhibitors compound 1j (pIC50 5.7) [301] compound D24 (pIC50 4.9) [116] –
Comments – Palmitoylation of sphingomyelin synthase 2 may
allow targeting to the plasma membrane [517].
–
Searchable database: http://www.guidetopharmacology.org/index.jsp Sphingomyelin synthase S304
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13877/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology (2017) 174, S272–S359
Sphingomyelin phosphodiesterase
Enzymes → Ceramide turnover → Sphingomyelin phosphodiesterase
Overview: Also known as sphingomyelinase.
Nomenclature sphingomyelin
phosphodiesterase 1
sphingomyelin
phosphodiesterase 2
sphingomyelin
phosphodiesterase 3
sphingomyelin
phosphodiesterase 4
sphingomyelin
phosphodiesterase
acid-like 3A
sphingomyelin
phosphodiesterase
acid-like 3B
HGNC, UniProt SMPD1, P17405 SMPD2, O60906 SMPD3, Q9NY59 SMPD4, Q9NXE4 SMPDL3A, Q92484 SMPDL3B, Q92485
EC number 3.1.4.12: sphingomyelin -> ceramide + phosphocholine 3.1.4.-: sphingomyelin -> ceramide + phosphocholine
Inhibitors – inhibitor A (pKi 5.8)
[586] – Bovine
– – – –
Neutral sphingomyelinase coupling factors
Enzymes → Ceramide turnover → Neutral sphingomyelinase coupling factors
Overview: Protein FAN [3] and polycomb protein EED [410] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.
Nomenclature embryonic ectoderm development neutral sphingomyelinase activation associated factor
HGNC, UniProt EED, O75530 NSMAF, Q92636
Selective inhibitors A-395 (Binding) (pKi 9.4) [217] –
Searchable database: http://www.guidetopharmacology.org/index.jsp Neutral sphingomyelinase coupling factors S305
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13877/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology (2017) 174, S272–S359
Ceramide glucosyltransferase
Enzymes → Ceramide turnover → Ceramide glucosyltransferase
Nomenclature UDP-glucose ceramide glucosyltransferase
HGNC, UniProt UGCG, Q16739
EC number 2.4.1.80: UDP-glucose + ceramide = uridine diphosphate + glucosylceramide
Inhibitors miglustat (pKi 5.1) [63]
Comments Glycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.
Acid ceramidase
Enzymes → Ceramide turnover → Acid ceramidase
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase 1
HGNC, UniProt ASAH1, Q13510
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid
Comments This lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product [274].
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Neutral ceramidases
Enzymes → Ceramide turnover → Neutral ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature N-acylsphingosine amidohydrolase 2 N-acylsphingosine amidohydrolase 2B
HGNC, UniProt ASAH2, Q9NR71 ASAH2B, P0C7U1
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid –
Comments The enzyme is associated with the plasma membrane [516]. –
Comments: ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.
Alkaline ceramidases
Enzymes → Ceramide turnover → Alkaline ceramidases
Overview: The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.
Nomenclature alkaline ceramidase 1 alkaline ceramidase 2 alkaline ceramidase 3
HGNC, UniProt ACER1, Q8TDN7 ACER2, Q5QJU3 ACER3, Q9NUN7
EC number 3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.23: ceramide -> sphingosine + a fatty acid 3.5.1.-
Comments ACER1 is associated with the ER [505]. ACER2 is associated with the Golgi apparatus [582]. ACER3 is associated with the ER and Golgi
apparatus [336].
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Ceramide kinase
Enzymes → Ceramide turnover → Ceramide kinase
Nomenclature ceramide kinase
HGNC, UniProt CERK, Q8TCT0
EC number 2.7.1.138: ceramide + ATP -> ceramide 1-phosphate + ADP
Inhibitors NVP 231 (pIC50 7.9) [188]
Comments: A ceramide kinase-like protein has been identiﬁed in the human genome (CERKL, Q49MI3).
Further reading on Ceramide turnover
Aburasayn H et al. (2016) Targeting ceramide metabolism in obesity. Am J Physiol Endocrinol Metab
311: E423-35 [PMID:27382035]
Adada M et al. (2016) Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphin-
gomyelinases. Chem Phys Lipids 197: 45-59 [PMID:26200918]
Casals N et al. (2016) Carnitine palmitoyltransferase 1C: From cognition to cancer. Prog Lipid Res
61: 134-48 [PMID:26708865]
Casasampere M et al. (2016) Inhibitors of dihydroceramide desaturase 1: Therapeutic agents and
pharmacological tools to decipher the role of dihydroceramides in cell biology. Chem Phys
Lipids 197: 33-44 [PMID:26248324]
Fucho R et al. (2017) Ceramides and mitochondrial fatty acid oxidation in obesity. FASEB J 31:
1263-1272 [PMID:28003342]
Hernandez-Corbacho MJ et al. (2017) Sphingolipids in mitochondria. Biochim Biophys Acta 1862:
56-68 [PMID:27697478]
Ilan Y. (2016) Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as sec-
ondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin
resistance. Am J Physiol Gastrointest Liver Physiol 310: G1102-17 [PMID:27173510]
Iqbal J et al. (2017) Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends
Endocrinol Metab 28: 506-518 [PMID:28462811]
Kihara A. (2016) Synthesis and degradation pathways, functions, and pathology of ceramides and
epidermal acylceramides. Prog Lipid Res 63: 50-69 [PMID:27107674]
Petrache I et al. (2016) Ceramide Signaling and Metabolism in Pathophysiological States of the
Lung. Annu Rev Physiol 78: 463-80 [PMID:26667073]
Rodriguez-Cuenca S et al. (2017) Sphingolipids and glycerophospholipids - The “ying and yang”
of lipotoxicity in metabolic diseases. Prog Lipid Res 66: 14-29 [PMID:28104532]
Sasset L et al. (2016) Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeosta-
sis. Trends Endocrinol Metab 27: 807-819 [PMID:27562337]
Vogt D et al. (2017) Therapeutic Strategies and Pharmacological Tools Inﬂuencing S1P Signaling
and Metabolism. Med Res Rev 37: 3-51 [PMID:27480072]
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Chromatin modifying enzymes
Enzymes → Chromatin modifying enzymes
Overview: Chromatin modifying enzymes, and other
chromatin-modifying proteins, fall into three broad categories:
writers, readers and erasers. The function of these pro-
teins is to dynamically maintain cell identity and regulate pro-
cesses such as differentiation, development, proliferation and
genome integrity via recognition of speciﬁc ’marks’ (covalent
post-translational modiﬁcations) on histone proteins and DNA
[280]. In normal cells, tissues and organs, precise co-ordination
of these proteins ensures expression of only those genes required
to specify phenotype or which are required at speciﬁc times,
for speciﬁc functions. Chromatin modiﬁcations allow DNA
modiﬁcations not coded by the DNA sequence to be passed on
through the genome and underlies heritable phenomena such as
X chromosome inactivation, aging, heterochromatin formation,
reprogramming, and gene silencing (epigenetic control).
To date at least eight distinct types of modiﬁcations are found
on histones. These include small covalent modiﬁcations such as
acetylation, methylation, and phosphorylation, the attachment
of larger modiﬁers such as ubiquitination or sumoylation, and
ADP ribosylation, proline isomerization and deimination. Chro-
matin modiﬁcations and the functions they regulate in cells are
reviewed by Kouzarides (2007) [280].
Writer proteins include the histone methyltransferases, histone
acetyltransferases, some kinases and ubiquitin ligases.
Readers include proteins which contain methyl-lysine-
recognition motifs such as bromodomains, chromodomains,
tudor domains, PHD zinc ﬁngers, PWWP domains and MBT
domains.
Erasers include the histone demethylases and histone deacety-
lases (HDACs and sirtuins).
Dysregulated epigenetic control can be associated with human
diseases such as cancer [137], where a wide variety of cellular and
protein abberations are known to perturb chromatin structure,
gene transcription and ultimately cellular pathways [27, 477].
Due to the reversible nature of epigenetic modiﬁcations, chro-
matin regulators are very tractable targets for drug discovery and
the development of novel therapeutics. Indeed, small molecule
inhibitors of writers (e.g. azacitidine and decitabine target the
DNA methyltransferases DNMT1 and DNMT3 for the treatment
of myelodysplastic syndromes [175, 565]) and erasers (e.g. the
HDAC inhibitors vorinostat, romidepsin and belinostat for the
treatment of T-cell lymphomas [153, 265]) are already being used
in the clinic. The search for the next generation of compounds
with improved speciﬁcity against chromatin-associated proteins
is an area of intense basic and clinical research [61]. Current
progress in this ﬁeld is reviewed by Simó-Riudalbas and Esteller
(2015) [478].
2.1.1.- Protein arginine N-methyltransferases
Enzymes → Chromatin modifying enzymes → 2.1.1.- Protein arginine N-methyltransferases
Overview: Protein arginine N-methyltransferases (PRMT,
EC 2.1.1.-) encompass histone arginine N-methyltransferases
(PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein N-
methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric
or tetrameric enzymes which use S-adenosyl methionine as
a methyl donor, generating S-adenosylhomocysteine as a
by-product. They generate both mono-methylated and di-
methylated products; these may be symmetric (SDMA) or asym-
metric (NG,NG-dimethyl-L-arginine) versions, where both guani-
dine nitrogens aremonomethylated or one of the two is dimethy-
lated, respectively.
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp 2.1.1.- Protein arginine N-methyltransferases S309
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3.5.1.- Histone deacetylases (HDACs)
Enzymes → Chromatin modifying enzymes → 3.5.1.- Histone deacetylases (HDACs)
Overview: Histone deacetylases act as erasers of epigenetic
acetylation marks on lysine residues in histones. Removal of
the acetyl groups facilitates tighter packing of chromatin (het-
erochromatin formation) leading to transcriptional repression.
The histone deacetylase family has been classiﬁed in to ﬁve sub-
families based on phylogenetic comparison with yeast homo-
logues:
Class I contains HDACs 1, 2, 3 and 8
Class IIa contains HDACs 4, 5, 7 and 9
Class IIb contains HDACs 6 and 10
Class III contains the sirtuins (SIRT1-7)
Class IV contains only HDAC11.
Classes I, II and IV use Zn+ as a co-factor, whereas catalysis by
Class III enzymes requires NAD+ as a co-factor, and members of
this subfamily have ADP-ribosylase activity in addition to protein
deacetylase function [456].
HDACs havemore general protein deacetylase activity, being able
to deacetylate lysine residues in non-histone proteins [90] such as
microtubules [233], the hsp90 chaperone [281] and the tumour
suppressor p53 [322].
Dysregulated HDAC activity has been identiﬁed in cancer cells
and tumour tissues [305, 444], making HDACs attractive molec-
ular targets in the search for novel mechanisms to treat can-
cer [567]. Several small molecule HDAC inhibitors are already
approved for clinical use: romidepsin, belinostat, vorinostat,
panobinostat, belinostat, valproic acid and tucidinostat. HDACs
and HDAC inhibitors currently in development as potential anti-
cancer therapeutics are reviewed by Simó-Riudalbas and Esteller
(2015) [478].
Information on members of this family may be found in the online database.
Cyclic nucleotide turnover/signalling
Enzymes → Cyclic nucleotide turnover/signalling
Overview: Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides
are mediated through activation of protein kinases (cAMP- and cGMP-dependent protein kinases), ion channels (cyclic nucleotide-gated, CNG, and hyperpolarization and cyclic nucleotide-gated, HCN)
and guanine nucleotide exchange factors (GEFs, Epac).
Adenylyl cyclases (ACs)
Enzymes → Cyclic nucleotide turnover/signalling → Adenylyl cyclases (ACs)
Overview: Adenylyl cyclase, E.C. 4.6.1.1, converts ATP to
cyclic AMP and pyrophosphate. Mammalian membrane-bound
adenylyl cyclases are typically made up of two clusters of six
TM domains separating two intracellular, overlapping catalytic
domains that are the target for the nonselective activators
forskolin, NKH477 (except AC9, [419]) and Gαs (the stimula-
tory G protein α subunit). Adenosine and its derivatives (e.g.
2’,5’-dideoxyadenosine), acting through the P-site, appear to be
physiological inhibitors of adenylyl cyclase activity [527]. Three
families of adenylyl cyclase are distinguishable: calmodulin
(CALM1 CALM2 CALM3, P62158)-stimulated (AC1, AC3 and
AC8), Ca2+-inhibitable (AC5, AC6 and AC9) and Ca2+-insensitive
(AC2, AC4 and AC7) forms.
Searchable database: http://www.guidetopharmacology.org/index.jsp Adenylyl cyclases (ACs) S310
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Nomenclature adenylyl cyclase 1 adenylyl cyclase 2 (brain) adenylyl cyclase 3 adenylyl cyclase 4
HGNC, UniProt ADCY1, Q08828 ADCY2, Q08462 ADCY3, O60266 ADCY4, Q8NFM4
Common abreviation AC1 AC2 AC3 AC4
Endogenous activators calmodulin (CALM1 CALM2
CALM3, P62158), PKC-evoked
phosphorylation [246, 515]
Gβγ, PKC-evoked phosphorylation
[80, 326, 520]
calmodulin (CALM1 CALM2
CALM3, P62158), PKC-evoked
phosphorylation [89, 246]
Gβγ [173]
Endogenous inhibitors Gαi, Gαo, Gβγ [520, 521] – Gαi, RGS2, CaM kinase II-evoked
phosphorylation [479, 521, 562]
PKC-evoked phophorylation
[603]
Nomenclature adenylyl cyclase 5 adenylyl cyclase 6 adenylyl cyclase 7 adenylyl cyclase 8 adenylyl cyclase 9
HGNC, UniProt ADCY5, O95622 ADCY6, O43306 ADCY7, P51828 ADCY8, P40145 ADCY9, O60503
Common abreviation AC5 AC6 AC7 AC8 AC9
Endogenous activators PKC-evoked phophorylation
[262]
– PKC-evoked
phosphorylation
[561]
Ca2+ [62] –
Endogenous inhibitors Gαi, Ca2+, PKA-evoked
phosphorylation [240, 243,
521]
Gαi, Ca2+, PKA-evoked
phosphorylation, PKC-evoked
phosphorylation [83, 289,
521, 590]
– – Ca2+/calcineurin
[402]
Inhibitors NKY80 (pIC50 5.2) [52, 390] NKY80 (pIC50 4.8) [52] – – –
Comments: Nitric oxide has been proposed to inhibit AC5 and AC6 selectively [223], although it is unclear whether this phenomenon is of physiological signiﬁcance. A soluble adenylyl cyclase has
been described (ADCY10, Q96PN6 [54]), unaffected by either Gα or Gβγ subunits, which has been suggested to be a cytoplasmic bicarbonate (pH-insensitive) sensor [82]. It can be inhibited selectively by
KH7 (pIC50 5.0-5.5) [221].
Further reading on Adenylyl cyclases
Dessauer CW et al. (2017) International Union of Basic and Clinical Pharmacology. CI. Structures
and Small Molecule Modulators of Mammalian Adenylyl Cyclases. Pharmacol Rev 69: 93-139
[PMID:28255005]
Halls ML et al. (2017) Adenylyl cyclase signalling complexes - Pharmacological challenges and
opportunities. Pharmacol Ther 172: 171-180 [PMID:28132906]
Wu L et al. (2016) Adenylate cyclase 3: a new target for anti-obesity drug development. Obes Rev
17: 907-14 [PMID:27256589]
Searchable database: http://www.guidetopharmacology.org/index.jsp Adenylyl cyclases (ACs) S311
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Exchange protein activated by cyclic AMP (EPACs)
Enzymes → Cyclic nucleotide turnover/signalling → Exchange protein activated by cyclic AMP (EPACs)
Overview: Epacs are members of a family of guanine nu-
cleotide exchange factors (ENSFM00250000000899), which also
includes RapGEF5 (GFR, KIAA0277, MR-GEF, Q92565) and
RapGEFL1 (Link-GEFII, Q9UHV5). They are activated endoge-
nously by cyclic AMP and with some pharmacological selectiv-
ity by 8-pCPT-2’-O-Me-cAMP [134]. Once activated, Epacs in-
duce an enhanced activity of the monomeric G proteins, Rap1
and Rap2 by facilitating binding of guanosine-5’-triphosphate
in place of guanosine 5’-diphosphate, leading to activation of
phospholipase C [459].
Nomenclature Rap guanine nucleotide exchange factor 3 Rap guanine nucleotide exchange factor 4
HGNC, UniProt RAPGEF3, O95398 RAPGEF4, Q8WZA2
Common abreviation Epac1 Epac2
Inhibitors ESI-09 (pIC50 5.5) [12] HJC 0350 (pIC50 6.5) [78], ESI-09 (pIC50 4.4–5.2) [12, 79]
Further reading on Exchange protein activated by cyclic AMP (EPAC)
Fujita T et al. (2017) The role of Epac in the heart. Cell Mol Life Sci 74: 591-606 [PMID:27549789]
Parnell E et al. (2015) The future of EPAC-targeted therapies: agonism versus antagonism. Trends
Pharmacol Sci 36: 203-14 [PMID:25744542]
Wang P et al. (2017) Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic
targets. Bioorg Med Chem Lett 27: 1633-1639 [PMID:28283242]
Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
Enzymes → Cyclic nucleotide turnover/signalling → Guanylyl cyclases (GCs) → Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
Overview: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase (GTP diphosphate-lyase (cyclising)), E.C. 4.6.1.2, is a heterodimer comprising a β1 subunit and one of two alpha subunits (α1, α2) giving
rise to two functionally indistinguishable isoforms, GC-1 (α1β1) and GC-2 (α2β1) [449, 593]. A haem group is associated with the β subunit and is the target for the endogenous ligand NO, and, potentially,
carbon monoxide [159]. The enzyme converts guanosine-5’-triphosphate to the intracellular second messenger cyclic guanosine-3’,5’-monophosphate (cyclic GMP).
Searchable database: http://www.guidetopharmacology.org/index.jsp Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase S312
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Nomenclature Guanylyl cyclase, α1β1 Guanylyl cyclase, α2β1
Subunits Guanylyl cyclase β1 subunit, Guanylyl cyclase α1 subunit Guanylyl cyclase β1 subunit, Guanylyl cyclase α2 subunit
Common abreviation GC-1 GC-2
Endogenous ligands NO, CO NO, CO
Selective activators YC-1 [159, 272, 449], cinaciguat [apo-GC-1] [500], riociguat [498, 499] YC-1 [272, 449], cinaciguat [apo-GC-2] [500], riociguat [500, 499]
Selective inhibitors NS 2028 (pIC50 8.1) [389] – Bovine, ODQ (pIC50 7.5) [177] ODQ
Subunits
Nomenclature Guanylyl cyclase α1 subunit Guanylyl cyclase α2 subunit Guanylyl cyclase β1 subunit Guanylyl cyclase β2 subunit
HGNC, UniProt GUCY1A3, Q02108 GUCY1A2, P33402 GUCY1B3, Q02153 GUCY1B2, O75343
Comments: ODQ also shows activity at other haem-containing proteins [142], while YC-1 may also inhibit cGMP-hydrolysing phosphodiesterases [158, 169].
Further reading on Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
Papapetropoulos A et al. (2015) Extending the translational potential of targeting NO/cGMP-
regulated pathways in the CVS. Br J Pharmacol 172: 1397-414 [PMID:25302549]
Pechanova O et al. (2015) Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol 172:
1415-33 [PMID:25297560]
Vanhoutte PM et al. (2016) Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of
the Endothelium-Derived Vasodilator Mediator. Circ Res 119: 375-96 [PMID:27390338]
Yetik-Anacak G et al. (2015) Gas what: NO is not the only answer to sexual function. Br J Pharmacol
172: 1434-54 [PMID:24661203]
Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Enzymes → Cyclic nucleotide turnover/signalling → Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Overview: 3’,5’-Cyclic nucleotide phosphodiesterases (PDEs, 3’,5’-cyclic-nucleotide 5’-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3’,5’-cyclic nucleotide (usually cyclic AMP or
cyclic GMP). Isobutylmethylxanthine is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2’,3’-cyclic nucleotide 3’-phosphodiesterase
(E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.
Searchable database: http://www.guidetopharmacology.org/index.jsp Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs) S313
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Nomenclature phosphodiesterase 1A phosphodiesterase 1B phosphodiesterase 1C
HGNC, UniProt PDE1A, P54750 PDE1B, Q01064 PDE1C, Q14123
Common abreviation PDE1A PDE1B PDE1C
Rank order of afﬁnity cyclic GMP > cyclic AMP cyclic GMP > cyclic AMP cyclic GMP = cyclic AMP
Endogenous activators calmodulin (CALM1 CALM2 CALM3, P62158) calmodulin (CALM1 CALM2 CALM3, P62158) calmodulin (CALM1 CALM2 CALM3, P62158)
Inhibitors crisaborole (pIC50 5.2) [8] – –
Selective inhibitors SCH51866 (pIC50 7.2) [542], vinpocetine
(pIC50 5.1) [319]
SCH51866 (pIC50 7.2) [542] SCH51866 (pIC50 7.2) [542], vinpocetine
(pIC50 4.3) [319]
Nomenclature phosphodiesterase 2A phosphodiesterase 3A phosphodiesterase 3B
HGNC, UniProt PDE2A, O00408 PDE3A, Q14432 PDE3B, Q13370
Common abreviation PDE2A PDE3A PDE3B
Rank order of afﬁnity cyclic AMP  cyclic GMP – –
Endogenous activators cyclic GMP – –
Endogenous inhibitors – cyclic GMP cyclic GMP
Inhibitors milrinone (pIC50 <6.5) [504] cilostazol (pIC50 6.7) [504], inamrinone
(pIC50 4.8) [480]
–
Selective inhibitors BAY607550 (pIC50 8.3–8.8) [47], EHNA
(pIC50 5.3) [355]
cilostamide (pIC50 7.5) [504], anagrelide
(pIC50 7.1–7.3) [257, 341, 349], milrinone
(pIC50 6.3–6.4) [131, 504]
cilostamide (pIC50 7.3) [504], cilostazol
(pIC50 6.4) [504], milrinone (pIC50 6) [504],
inamrinone (pIC50 4.5) [504]
Comments EHNA is also an inhibitor of
adenosine deaminase (E.C. 3.5.4.4).
– –
Searchable database: http://www.guidetopharmacology.org/index.jsp Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs) S314
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Nomenclature phosphodiesterase 4A phosphodiesterase 4B phosphodiesterase 4C phosphodiesterase 4D phosphodiesterase 5A
HGNC, UniProt PDE4A, P27815 PDE4B, Q07343 PDE4C, Q08493 PDE4D, Q08499 PDE5A, O76074
Common
abreviation
PDE4A PDE4B PDE4C PDE4D PDE5A
Rank order of
afﬁnity
cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic AMP  cyclic GMP cyclic AMP 
cyclic GMP
cyclic GMP > cyclic AMP
Endogenous
activators
– – – PKA-mediated
phosphorylation [229]
Protein kinase A, protein kinase
G [100]
Inhibitors ibudilast (pIC50 7.3) [275],
RS-25344 (pIC50 7.2) [453]
roﬂumilast (pIC50 9.4)
[321], ibudilast (pIC50
7.2) [275], RS-25344
(pIC50 6.5) [453]
RS-25344 (pIC50 8.1)
[453], ibudilast (pIC50
6.6) [275]
RS-25344 (pIC50 8.4)
[453]
gisadenaﬁl (pIC50 8.9) [433],
milrinone (pIC50 7.3)
Sub/family-
selective
inhibitors
rolipram (pIC50 9) [553],
CDP840 (pKi 8) [406],
Ro20-1724 (pIC50 6.5)
[553]
rolipram (pIC50 9) [553],
Ro20-1724 (pIC50 6.4)
[553]
CDP840 (pKi 7.7) [406],
rolipram (pIC50 6.5)
[553], Ro20-1724 (pIC50
5.4) [553]
CDP840 (pKi 8.1)
[406], rolipram (pIC50
7.2) [553], Ro20-1724
(pIC50 6.2) [553]
–
Selective
inhibitors
YM976 (pIC50 8.3) [14],
apremilast (pIC50 7.8)
[457]
– apremilast (pIC50 6.9)
[457]
apremilast (pIC50 7.5)
[457]
vardenaﬁl (pIC50 9.7) [51],
T0156 (pIC50 9.5) [362],
sildenaﬁl (pIC50 8.4–9) [538,
551], tadalaﬁl (pIC50 8.5) [379],
SCH51866 (pIC50 7.2) [542],
zaprinast (pIC50 6.8) [538]
Nomenclature phosphodiesterase
6A
phosphodiesterase
6B
phosphodiesterase 6C phosphodiesterase
6D
phosphodiesterase
6G
phosphodiesterase
6H
HGNC, UniProt PDE6A, P16499 PDE6B, P35913 PDE6C, P51160 PDE6D, O43924 PDE6G, P18545 PDE6H, Q13956
Common abreviation PDE6A PDE6B PDE6C PDE6D PDE6G PDE6H
Inhibitors – – sildenaﬁl (pIC50 7.4) [551] – – –
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Nomenclature phosphodiesterase 7A phosphodiesterase 7B phosphodiesterase 8A phosphodiesterase 8B
HGNC, UniProt PDE7A, Q13946 PDE7B, Q9NP56 PDE8A, O60658 PDE8B, O95263
Common abreviation PDE7A PDE7B PDE8A PDE8B
Rank order of afﬁnity cyclic AMP  cyclic GMP [353] cyclic AMP  cyclic GMP [176] cyclic AMP  cyclic GMP [146] cyclic AMP  cyclic GMP [214]
Inhibitors crisaborole (pIC50 6.1) [8] BRL50481 (pIC50 4.9) [9] – –
Selective inhibitors BRL50481 (pIC50 6.7–6.8) [9, 486] dipyridamole (pIC50 5.7–6) [179,
455], SCH51866 (pIC50 5.8) [455]
dipyridamole (pIC50 5.1) [146] dipyridamole (pIC50 4.3) [214]
Comments PDE7A appears to be
membrane-bound or soluble for
PDE7A1 and 7A2 splice variants,
respectively
– – –
Nomenclature phosphodiesterase 9A phosphodiesterase 10A phosphodiesterase 11A
HGNC, UniProt PDE9A, O76083 PDE10A, Q9Y233 PDE11A, Q9HCR9
Common abreviation PDE9A PDE10A PDE11A
Rank order of afﬁnity cyclic GMP  cyclic AMP [145] cyclic AMP, cyclic GMP [161] cyclic AMP, cyclic GMP [141]
Inhibitors SCH51866 (pIC50 5.8) [145], zaprinast (pIC50 4.5) [145] – tadalaﬁl (pIC50 6.5) [379], BC11-38 (pIC50 6.5) [79]
Comments: PDE1A, 1B and 1C appear to act as soluble homod-
imers, while PDE2A is a membrane-bound homodimer. PDE3A
and PDE3B are membrane-bound.
PDE4 isoforms are essentially cyclic AMP speciﬁc. The potency
of YM976 at other members of the PDE4 family has not been
reported. PDE4B–D long forms are inhibited by extracellular
signal-regulated kinase (ERK)-mediated phosphorylation [224,
225]. PDE4A–D splice variants can be membrane-bound or cy-
tosolic [229]. PDE4 isoforms may be labelled with [3H]rolipram.
PDE6 is a membrane-bound tetramer composed of two cat-
alytic chains (PDE6A or PDE6C and PDE6B), an inhibitory chain
(PDE6G or PDE6H) and the PDE6D chain. The enzyme is es-
sentially cyclic GMP speciﬁc and is activated by the α-subunit
of transducin (Gαt) and inhibited by sildenaﬁl, zaprinast and
dipyridamole with potencies lower than those observed for
PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and
congenital stationary night blindness.
Further reading on Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
Das A et al. (2015) PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol
Ther 147: 12-21 [PMID:25444755]
Jorgensen C et al. (2015) Phosphodiesterase4D (PDE4D)–A risk factor for atrial ﬁbrillation and
stroke? J Neurol Sci 359: 266-74 [PMID:26671126]
Klussmann E. (2016) Protein-protein interactions of PDE4 familymembers - Functions, interactions
and therapeutic value. Cell Signal 28: 713-8 [PMID:26498857]
Korkmaz-Icoz S et al. (2017) Targeting phosphodiesterase 5 as a therapeutic option against
myocardial ischaemia/reperfusion injury and for treating heart failure. Br J Pharmacol
[PMID:28213937]
Leal LF et al. (2015) Phosphodiesterase 8B and cyclic AMP signaling in the adrenal cortex. Endocrine
50: 27-31 [PMID:25971952]
Movsesian M. (2016) Novel approaches to targeting PDE3 in cardiovascular disease. Pharmacol Ther
163: 74-81 [PMID:27108947]
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Ricciarelli R et al. (2015) Phosphodiesterase 4D: an enzyme to remember. Br J Pharmacol 172:
4785-9 [PMID:26211680]
Wu C et al. (2016) Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Obes Rev 17: 429-41 [PMID:26997580]
Cytochrome P450
Enzymes → Cytochrome P450
Overview: The cytochrome P450 enzyme family (CYP450), E.C.
1.14.-.-, were originally deﬁned by their strong absorbance at 450
nm due to the reduced carbon monoxide-complexed haem com-
ponent of the cytochromes. They are an extensive family of
haem-containingmonooxygenases with a huge range of both en-
dogenous and exogenous substrates. Listed below are the
human enzymes; their relationship with rodent CYP450 enzyme
activities is obscure in that the species orthologue may not medi-
ate metabolism of the same substrates. Although the majority of
CYP450 enzyme activities are concentrated in the liver, the extra-
hepatic enzyme activities also contribute to patho/physiological
processes. Genetic variation of CYP450 isoforms is widespread
and likely underlies a signiﬁcant proportion of the individual
variation to drug administration.
CYP1 family
Enzymes → Cytochrome P450 → CYP1 family
Nomenclature CYP1A1 CYP1A2 CYP1B1
HGNC, UniProt CYP1A1, P04798 CYP1A2, P05177 CYP1B1, Q16678
EC number 1.14.1.1 1.14.1.1 1.14.1.1
Comments – – Mutations have been associated with primary congenitial glucoma [503]
Searchable database: http://www.guidetopharmacology.org/index.jsp CYP1 family S317
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CYP2 family
Enzymes → Cytochrome P450 → CYP2 family
Nomenclature CYP2A6 CYP2A7 CYP2C8 CYP2J2 CYP2R1
HGNC, UniProt CYP2A6, P11509 CYP2A7, P20853 CYP2C8, P10632 CYP2J2, P51589 CYP2R1, Q6VVX0
EC number 1.14.14.1 1.14.14.1 1.14.14.1 1.14.14.1 1.14.13.15
Inhibitors – – phenelzine (pKi 5.1) [150] terfenadine (pIC50 5.1)
[287]
–
Comments Metabolises nicotine. CYP2A7 does not
incorporate haem and is
functionally inactive [162]
Converts arachidonic acid to
11(R)-12(S)-epoxyeicosatrienoic
acid or
14(R)-15(S)-epoxyeicosatrienoic
acid [596].
Converts arachidonic acid
to 14(R)-15(S)-
epoxyeicosatrienoic acid
[579].
Converts vitamin D3
to calcifediol [85].
CYP3 family
Enzymes → Cytochrome P450 → CYP3 family
Nomenclature CYP3A4
HGNC, UniProt CYP3A4, P08684
EC number 1.14.13.32: Albendazole + NADPH + O2 = albendazole S-oxide + NADP+ + H2
1.14.13.157: 1,8-cineole + NADPH + O2 = 2-exo-hydroxy-1,8-cineole + NADP+ + H2O
1.14.13.97: Taurochenodeoxycholate + NADPH + O2 = taurohyocholate + NADP+ + H2O
Lithocholate + NADPH + O2 = hyodeoxycholate + NADP+ + H2O 1.14.13.67: quinine + NADPH + O2 = 3-hydroxyquinine + NADP+ + H2O2
Substrates atorvastatin [155], codeine [155], diazepam [155], tamoxifen [155], erlotinib [155]
Products 4-hydroxy-tamoxifen quinone methide [469], 4-hydroxy-tamoxifen [469]
Inhibitors ritonavir (pKi >7) [266]
Comments Metabolises a vast range of xenobiotics, including antidepressants, benzodiazepines, calcium channel blockers, and chemotherapeutic agents. CYP3A4
catalyses the 25-hydroxylation of trihydroxycholestane in liver microsomes [166].
Searchable database: http://www.guidetopharmacology.org/index.jsp CYP3 family S318
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CYP4 family
Enzymes → Cytochrome P450 → CYP4 family
Nomenclature CYP4A11 CYP4F2 CYP4F3 CYP4F8
HGNC, UniProt CYP4A11, Q02928 CYP4F2, P78329 CYP4F3, Q08477 CYP4F8, P98187
EC number 1.14.15.3 1.14.13.30 1.14.13.30 1.14.14.1
Inhibitors – 17-octadecynoic acid (pKi 5.9) [470] – –
Comments Converts lauric acid to
12-hydroxylauric acid.
Responsible for ω-hydroxylation of
LTB4, LXB4 [359], and tocopherols,
including vitamin E [491]
Responsible for ω-hydroxylation of
LTB4, LXB4 [359], and
polyunsaturated fatty acids [143, 207]
Converts PGH2 to 19-hydroxyPGH2
[60] and 8,9-EET or 11,12-EET to
18-hydroxy-8,9-EET or
18-hydroxy-11,12-EET [378].
Nomenclature CYP4F12 CYP4F22 CYP4V2 CYP4X1 CYP4Z1
HGNC, UniProt CYP4F12, Q9HCS2 CYP4F22, Q6NT55 CYP4V2, Q6ZWL3 CYP4X1, Q8N118 CYP4Z1, Q86W10
EC number 1.14.14.1 1.14.14.- 1.14.-.- 1.14.14.1 1.14.14.1
Comments AC004597.1
(ENSG00000225607) is
described as being highly
similar to CYP4F12
Converts arachidonic acid
to 16-HETE and 18-HETE
[378].
Converts myristic acid to
14-hydroxymyristic acid
[372].
Converts anandamide to
14,15-epoxyeicosatrienoic
ethanolamide [497].
Converts lauric acid to
12-hydroxylauric acid.
Comments: Converts lauric acid to 12-hydroxylauric acid.
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CYP5, CYP7 and CYP8 families
Enzymes → Cytochrome P450 → CYP5, CYP7 and CYP8 families
Nomenclature CYP5A1 CYP7A1 CYP7B1 CYP8A1 CYP8B1
HGNC, UniProt TBXAS1, P24557 CYP7A1, P22680 CYP7B1, O75881 PTGIS, Q16647 CYP8B1, Q9UNU6
EC number 5.3.99.5: PGH2 =
thromboxane A2
1.14.13.17 1.14.13.100 5.3.99.4 1.14.13.95
Common name Thromboxane synthase – – Prostacyclin synthase –
Comments Inhibited by dazoxiben
[427] and camonagrel
[194].
Converts cholesterol to
7α-hydroxycholesterol
[379].
Converts
dehydroepiandrosterone
to 7α-DHEA [445].
Converts PGH2 to PGI2
[209]. Inhibited by
tranylcypromine [193]
Converts
7α-hydroxycholest-4-en-3-one
to 7-alpha,12α-
dihydroxycholest-4-en-3-one
(in rabbit) [239] in the
biosynthesis of bile acids.
CYP11, CYP17, CYP19, CYP20 and CYP21 families
Enzymes → Cytochrome P450 → CYP11, CYP17, CYP19, CYP20 and CYP21 families
Nomenclature CYP11A1 CYP11B1 CYP11B2
HGNC, UniProt CYP11A1, P05108 CYP11B1, P15538 CYP11B2, P19099
EC number 1.14.15.6 1.14.15.4 1.14.15.4
1.14.15.5
Common name – – Aldosterone synthase
Inhibitors mitotane [297, 303] metyrapone (pIC50 7.8) [602], mitotane osilodrostat (pIC50 9.7) [585]
Comments Converts cholesterol to pregnenolone
plus 4-methylpentanal.
Converts deoxycortisone and 11-deoxycortisol to cortisone and
cortisol, respectively. Loss-of-function mutations are associated with
familial adrenal hyperplasia and hypertension. Inhibited by
metyrapone [558]
Converts corticosterone to aldosterone
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Nomenclature CYP17A1 CYP19A1 CYP20A1 CYP21A2
HGNC, UniProt CYP17A1, P05093 CYP19A1, P11511 CYP20A1, Q6UW02 CYP21A2, P08686
EC number 1.14.99.9 1.14.14.1 1.14.-.- 1.14.99.10
Common name – Aromatase – –
Inhibitors abiraterone (pIC50 7.1–8.4) [413, 417] anastrozole (pIC50 7.8) [367],
aminoglutethimide [405]
– (2S,4S)-ketoconazole
(pIC50 5.3) [447] – Rat
Selective inhibitors galeterone (pIC50 6.5) [204] letrozole (pKi 10.7) [346], exemestane
(pIC50 7.3) [92], testolactone (pKi 4.5)
[102]
– –
Comments Converts pregnenolone and progesterone to
17α-hydroxypregnenolone and
17α-hydroxyprogesterone, respectively. Converts
17α-hydroxypregnenolone and
17α-hydroxyprogesterone to
dehydroepiandrosterone and androstenedione,
respectively. Converts corticosterone to cortisol.
Converts androstenedione and
testosterone to estrone and
17β-estradiol, respectively. Inhibited by
anastrozole [415], and letrozole [35]
– Converts progesterone and
17α-hydroxyprogesterone
to deoxycortisone and
11-deoxycortisol,
respectively
CYP24, CYP26 and CYP27 families
Enzymes → Cytochrome P450 → CYP24, CYP26 and CYP27 families
Nomenclature CYP24A1 CYP26A1 CYP26B1 CYP27A1 CYP27B1
HGNC, UniProt CYP24A1, Q07973 CYP26A1, O43174 CYP26B1, Q9NR63 CYP27A1, Q02318 CYP27B1, O15528
EC number 1.14.13.126 1.14.-.- 1.14.-.- 1.14.13.15 1.14.13.13
Common name – – – Sterol 27-hydroxylase –
Comments Converts
1,25-dihydroxyvitamin D3
(calcitriol) to
1α,24R,25-trihydroxyvitamin D3.
Converts retinoic acid to
4-hydroxyretinoic acid.
Inhibited by liarozole
Converts retinoic acid to
4-hydroxyretinoic acid.
Converts cholesterol to
27-hydroxycholesterol.
Converts
25-hydroxyvitamin D3 to
1,25-dihydroxyvitamin D3
(calcitriol)
Searchable database: http://www.guidetopharmacology.org/index.jsp CYP24, CYP26 and CYP27 families S321
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13877/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology (2017) 174, S272–S359
CYP39, CYP46 and CYP51 families
Enzymes → Cytochrome P450 → CYP39, CYP46 and CYP51 families
Nomenclature CYP39A1 CYP46A1 CYP51A1
HGNC, UniProt CYP39A1, Q9NYL5 CYP46A1, Q9Y6A2 CYP51A1, Q16850
EC number 1.14.13.99 1.14.13.98 –
Common name – Cholesterol 24-hydroxylase Lanosterol 14-α-demethylase
Inhibitors – – azalanstat (pKi 9.1) [549]
Comments Converts 24-hydroxycholesterol to
7α,24-dihydroxycholesterol [302].
Converts cholesterol to 24(S)-hydroxycholesterol. Converts lanosterol to
4,4-dimethylcholesta-8.14.24-trienol.
Further reading on Cytochrome P450
Backman JT et al. (2016) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Pharmacol Rev 68: 168-241 [PMID:26721703]
Davis CM et al. (2017) Cytochrome P450 eicosanoids in cerebrovascular function and disease.
Pharmacol Ther [PMID:28527918]
Ghosh D et al. (2016) Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase
from the Structure-Function Perspective. J Med Chem 59: 5131-48 [PMID:26689671]
Go RE et al. (2015) Cytochrome P450 1 family and cancers. J Steroid Biochem Mol Biol 147: 24-30
[PMID:25448748]
Guengerich FP et al. (2016) Recent Structural Insights into Cytochrome P450 Function. Trends
Pharmacol Sci 37: 625-40 [PMID:27267697]
Isvoran A et al. (2017) Pharmacogenomics of the cytochrome P450 2C family: impacts of amino
acid variations on drug metabolism. Drug Discov Today 22: 366-376 [PMID:27693711]
Jamieson KL et al. (2017) Cytochrome P450-derived eicosanoids and heart function. Pharmacol
Ther [PMID:28551025]
Mak PJ et al. (2017) Spectroscopic studies of the cytochrome P450 reaction mechanisms. Biochim
Biophys Acta [PMID:28668640]
Moutinho M et al. (2016) Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Biochim Biophys Acta 1861 1911-1920 [PMID:27663182]
Shalan H et al. (2017) Keeping the spotlight on cytochrome P450. Biochim Biophys Acta
[PMID:28599858]
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Endocannabinoid turnover
Enzymes → Endocannabinoid turnover
Overview: The principle endocannabinoids are 2-
acylglycerol esters, such as 2-arachidonoylglycerol (2AG),
and N-acylethanolamines, such as anandamide (N-
arachidonoylethanolamine, AEA). The glycerol esters and
ethanolamides are synthesised and hydrolysed by parallel, in-
dependent pathways. Mechanisms for release and re-uptake of
endocannabinoids (and related entities) are unclear, although
candidates for intracellular transport have been suggested. For
the generation of 2-arachidonoylglycerol, the key enzyme in-
volved is diacylglycerol lipase (DGL), whilst several routes for
anandamide synthesis have been described, the best charac-
terized of which involves N-acylphosphatidylethanolamine-
phospholipase D (NAPE-PLD, [476]). A transacylation enzyme
which forms N-acylphosphatidylethanolamines has recently
been identiﬁed as a cytosolic enzyme, PLA2G4E (Q3MJ16) [383].
In vitro experiments indicate that the endocannabinoids are
also substrates for oxidative metabolism via cyclooxygenase,
lipoxygenase and cytochrome P450 enzyme activities [11, 154,
488].
N-Acylethanolamine turnover
Enzymes → Endocannabinoid turnover → N-Acylethanolamine turnover
Nomenclature N-Acylphosphatidylethanolamine-
phospholipase D
Fatty acid amide hydrolase Fatty acid amide hydrolase-2 N-Acylethanolamine acid amidase
HGNC, UniProt NAPEPLD, Q6IQ20 FAAH, O00519 FAAH2, Q6GMR7 NAAA, Q02083
EC number – 3.5.1.99: anandamide + H2O <=>
arachidonic acid + ethanolamine
oleamide + H2O <=> oleic acid +
NH3 The enzyme is responsible for
the catabolism of neuromodulatory
fatty acid amides, including
anandamide and oleamide:
anandamide + H2O <=>
arachidonic acid + ethanolamine
oleamide + H2O <=> oleic acid +
NH3
3.5.1.99: anandamide + H2O
<=> arachidonic acid +
ethanolamine
oleamide + H2O <=> oleic acid +
NH3 The enzyme is responsible
for the catabolism of
neuromodulatory fatty acid
amides, including anandamide
and oleamide: anandamide +
H2O <=> arachidonic acid +
ethanolamine
oleamide + H2O <=> oleic acid +
NH3
3.5.1.-
Common abreviation NAPE-PLD FAAH FAAH2 NAAA
Rank order of afﬁnity – anandamide > oleamide >
N-oleoylethanolamide >
N-palmitoylethanolamine [563]
oleamide >
N-oleoylethanolamide >
anandamide >
N-palmitoylethanolamine [563]
N-palmitoylethanolamine > MEA
> SEA ≥ N-oleoylethanolamide
> anandamide [539]
Selective inhibitors – JNJ1661010 (pIC50 7.8) [264],
PF750 (pIC50 6.3–7.8) [5], OL135
(pIC50 7.4) [563], URB597 (pIC50
6.3–7) [563], PF3845 (pIC50 6.6) [6]
OL135 (pIC50 7.9–8.4) [261,
563], URB597 (pIC50 7.5–8.3)
[261, 563]
S-OOPP (pIC50 6.4) [489] – Rat,
CCP (pIC50 5.3) [535]
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(continued)
Nomenclature N-Acylphosphatidylethanolamine-
phospholipase D
Fatty acid amide hydrolase Fatty acid amide hydrolase-2 N-Acylethanolamine acid amidase
Comments NAPE-PLD activity appears to be
enhanced by polyamines in the
physiological range [311], but
fails to transphosphatidylate with
alcohols [408] unlike
phosphatidylcholine-speciﬁc
phospholipase D.
– The FAAH2 gene is found in many
primate genomes, marsupials, and
other distantly related vertebrates,
but not a variety of lower
placental mammals, including
mouse and rat [563].
–
Comments: Routes for N-acylethanolamine biosynthesis other than through NAPE-PLD activity have been identiﬁed [536].
2-Acylglycerol ester turnover
Enzymes → Endocannabinoid turnover → 2-Acylglycerol ester turnover
Nomenclature Diacylglycerol lipase α Diacylglycerol lipase β Monoacylglycerol lipase αβ-Hydrolase 6
HGNC, UniProt DAGLA, Q9Y4D2 DAGLB, Q8NCG7 MGLL, Q99685 ABHD6, Q9BV23
EC number 3.1.1.- 3.1.1.- 3.1.1.23 3.1.1.23
Common abreviation DAGLα DAGLβ MAGL ABHD6
Endogenous
substrates
diacylglycerol diacylglycerol 2-oleoyl glycerol =
2-arachidonoylglycerol 
anandamide [181]
1-arachidonoylglycerol >
2-arachidonoylglycerol >
1-oleoylglycerol >
2-oleoyl glycerol [375]
Selective inhibitors orlistat (pIC50 7.2) [40],
RHC80267 (pIC50 4.2) [255]
orlistat (pIC50 7) [40], RHC80267 JJKK 048 (pIC50 9.3) [1], KML29
(pIC50 8.5) [77], JZL184 (pIC50
8.1) [314]
WWL70 (pIC50 7.2) [299],
WWL123 (pIC50 6.4) [21]
Comments – – – WWL70 has also been suggested
to have activity at oxidative
metabolic pathways independent
of ABHD6 [513].
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Comments on Endocannabinoid turnover: Many of the
compounds described as inhibitors are irreversible and so po-
tency estimates will vary with incubation time. FAAH2 is not
found in rodents [563] and a few of the inhibitors described have
been assessed at this enzyme activity. 2-arachidonoylglycerol
has been reported to be hydrolysed by multiple enzyme activi-
ties from neural preparations, including ABHD2 (P08910) [356],
ABHD12 (Q8N2K0) [44], neuropathy target esterase (PNPLA6,
Q8IY17 [338]) and carboxylesterase 1 (CES1, P23141 [581]).
ABHD2 (P08910) has also been described as a triacylglycerol
lipase and ester hydrolase [329], while ABHD12 (Q8N2K0) is
also able to hydrolyse lysophosphatidylserine [531]. ABHD12
(Q8N2K0) has been described to be inhibited selectively by triter-
penoids, such as betulinic acid [401].
Further reading on Endocannabinoid turnover
Blankman JL et al. (2013) Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65:
849-71 [PMID:23512546]
Janssen FJ et al. (2016) Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic
disorders. Bioorg. Med. Chem. Lett. 26: 3831-7 [PMID:27394666]
Ueda N et al. (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical
and alternative pathways. FEBS J. 280: 1874-94 [PMID:23425575]
Wellner N et al. (2013) N-acylation of phosphatidylethanolamine and its biological functions in
mammals. Biochim. Biophys. Acta 1831: 652-62 [PMID:23000428]
Eicosanoid turnover
Enzymes → Eicosanoid turnover
Overview: Eicosanoids are 20-carbon fatty acids, where the
usual focus is the polyunsaturated analogue arachidonic acid and
its metabolites. Arachidonic acid is thought primarily to de-
rive from phospholipase A2 action on membrane phosphatidyl-
choline, and may be re-cycled to form phospholipid through
conjugation with coenzyme A and subsequently glycerol deriva-
tives. Oxidative metabolism of arachidonic acid is conducted
through three major enzymatic routes: cyclooxygenases; lipoxy-
genases and cytochrome P450-like epoxygenases, particularly
CYP2J2. Isoprostanes are structural analogues of the prostanoids
(hence the nomenclature D-, E-, F-isoprostanes and isothrombox-
anes), which are produced in the presence of elevated free radi-
cals in a non-enzymatic manner, leading to suggestions for their
use as biomarkers of oxidative stress. Molecular targets for their
action have yet to be deﬁned.
Cyclooxygenase
Enzymes → Eicosanoid turnover → Cyclooxygenase
Overview: Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor : oxygen oxidoreductase) activity, catal-
yses the formation of PGG2 from arachidonic acid. Hydroperoxidase activity inherent in the enzyme catalyses the formation of PGH2 from PGG2. COX-1 and -2 can be nonselectively inhibited by
ibuprofen, ketoprofen, naproxen, indomethacin and paracetamol (acetaminophen). PGH2 may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an
apparently tissue-dependent manner.
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Nomenclature COX-1 COX-2
HGNC, UniProt PTGS1, P23219 PTGS2, P35354
EC number 1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen acceptor +
H2O + PGH2 arachidonic acid => PGG2 => PGH2 This enzyme is also
associated with the following reaction:: docosahexaenoic acid => PGH3
1.14.99.1: Hydrogen donor + arachidonic acid + 2O2 = hydrogen acceptor +
H2O + PGH2 arachidonic acid => PGG2 => PGH2 This enzyme is also
associated with the following reaction:: docosahexaenoic acid => PGH3
Selective inhibitors ketorolac (pIC50 9.7) [557], FR122047 (pIC50 7.5) [382] celecoxib (pIC50 8.7) [41], valdecoxib (pIC50 8.3) [512], diclofenac (pIC50 7.7)
[45], rofecoxib (pIC50 6.1–6.5) [557], lumiracoxib (pKi 6.5) [46], meloxicam
(pIC50 6.3) [294], etoricoxib (pIC50 6) [439]
Prostaglandin synthases
Enzymes → Eicosanoid turnover → Prostaglandin synthases
Overview: Subsequent to the formation of PGH2, the
cytochrome P450 activities thromboxane synthase (CYP5A1,
TBXAS1, P24557 , EC 5.3.99.5) and prostacyclin syn-
thase (CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate
thromboxane A2 and prostacyclin (PGI2), respectively (see
Cytochrome P450s). Additionally, multiple enzyme activities
are able to generate prostaglandin E2 (PGE2), prostaglandin
D2 (PGD2) and prostaglandin F2α (PGF2α). PGD2 can be
metabolised to 9α,11β-prostacyclin F2α through the multifunc-
tional enzyme activity of AKR1C3. PGE2 can be metabolised to
9α,11β-prostaglandin F2α through the 9-ketoreductase activity
of CBR1. Conversion of the 15-hydroxyecosanoids, including
prostaglandins, lipoxins and leukotrienes to their keto deriva-
tives by the NAD-dependent enzyme HPGD leads to a reduction
in their biological activity.
Nomenclature mPGES1 mPGES2 cPGES L-PGDS
HGNC, UniProt PTGES, O14684 PTGES2, Q9H7Z7 PTGES3, Q15185 PTGDS, P41222
EC number 5.3.99.3: PGH2 = PGE2 5.3.99.3: PGH2 = PGE2 5.3.99.3: PGH2 = PGE2 5.3.99.2: PGH2 = PGD2
Cofactors glutathione dihydrolipoic acid – –
Comments – – Phosphorylated and activated by casein kinase 2 (CK2)
[370]. Appears to regulate steroid hormone function by
interaction with dimeric hsp90 [74, 253].
–
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Nomenclature H-PGDS AKR1C3 CBR1 HPGD
HGNC, UniProt HPGDS, O60760 AKR1C3, P42330 CBR1, P16152 HPGD, P15428
EC number 5.3.99.2: PGH2 = PGD2 1.3.1.20
1.1.1.188: PGD2 + NADP+ = PGF2α +
NADPH + H+
1.1.1.64
1.1.1.239
1.1.1.213
1.1.1.184
1.1.1.189: PGE2 + NADP+ = PGF2α +
NADPH + H+
1.1.1.197
1.1.1.141 15-hydroxyprostaglandins
=> 15-ketoprostaglandins LXA4 =>
15-keto-lipoxin A4
Cofactors – NADP+ NADP+ –
Inhibitors HQL-79 (pIC50 5.3–5.5)
[16]
tolfenamic acid (pKi 8.1) [421]
ﬂufenamic acid, indomethacin,
ﬂavonoids [344, 484]
wedelolactone (pIC50 5.4) [604]
Comments – Also acts as a hydroxysteroid
dehydrogenase activity.
– –
Comments: YS121 has been reported to inhibit mPGES1 and 5-LOX with a pIC50 value of 5.5 [276].
Lipoxygenases
Enzymes → Eicosanoid turnover → Lipoxygenases
Overview: The lipoxygenases (LOXs) are a structurally related family of non-heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For
arachidonic acid as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are ﬁve lipoxygenases, the 5S-(arachidonate : oxygen 5-oxidoreductase), 12R-(arachidonate
12-lipoxygenase, 12R-type), 12S-(arachidonate : oxygen 12-oxidoreductase), and two distinct 15S-(arachidonate : oxygen 15-oxidoreductase) LOXs that oxygenate arachidonic acid in different positions
along the carbon chain and form the corresponding 5S-, 12S-, 12R-, or 15S-hydroperoxides, respectively.
Nomenclature 5-LOX 12R-LOX 12S-LOX 15-LOX-1 15-LOX-2 E-LOX
HGNC, UniProt ALOX5, P09917 ALOX12B, O75342 ALOX12,
P18054
ALOX15,
P16050
ALOX15B,
O15296
ALOXE3, Q9BYJ1
EC number 1.13.11.34: arachidonic acid
+ O2 = LTA4 + H2O
1.13.11.31
arachidonic acid +
O2 => 12R-HPETE
1.13.11.31
arachidonic acid
+ O2 =>
12S-HPETE
1.13.11.33:
arachidonic acid
+ O2 =
15S-HPETE
linoleic acid +
O2 =>
13S-HPODE
1.13.11.33:
arachidonic acid
+ O2 =
15S-HPETE
1.13.11.-
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Nomenclature 5-LOX 12R-LOX 12S-LOX 15-LOX-1 15-LOX-2 E-LOX
Endogenous
substrates
arachidonic acid – – – – 12R-HPETE
Endogenous
activators
5-LOX activating protein
(ALOX5AP, P20292)
– – – – –
Endogenous
inhibitors
Protein kinase A-mediated
phosphorylation [324]
– – – – –
Selective
inhibitors
CJ13610 (pIC50 7.2) [144],
PF-04191834 (pIC50 6.6)
[342], zileuton
– – compound 34
(pKi >8) [425]
– –
Comments FLAP activity can be
inhibited by MK-886 [124]
and BAY-X1005 [210]
leading to a selective
inhibition of 5-LOX activity
– – – – E-LOX metabolises the
product from the
12R-lipoxygenase
(12R-HPETE) to a speciﬁc
epoxyalcohol compound
[592].
Comments: An 8-LOX (EC 1.13.11.40, arachidonate:oxygen 8-oxidoreductase) may be the mouse orthologue of 15-LOX-2 [167]. Some general LOX inhibitors are nordihydroguiaretic acid and esculetin.
Zileuton and caffeic acid are used as 5-lipoxygenase inhibitors, while baicalein and CDC are 12-lipoxygenase inhibitors. The speciﬁcity of these inhibitors has not been rigorously assessed with all LOX
forms: baicalein, along with other ﬂavonoids, such as ﬁsetin and luteolin, also inhibits 15-LOX-1 [450].
Leukotriene and lipoxin metabolism
Enzymes → Eicosanoid turnover → Leukotriene and lipoxin metabolism
Overview: Leukotriene A4 (LTA4), produced by 5-LOX activ-
ity, and lipoxins may be subject to further oxidative metabolism;
ω-hydroxylation is mediated by CYP4F2 and CYP4F3, while β-
oxidation in mitochondria and peroxisomes proceeds in a man-
ner dependent on coenzyme A conjugation. Conjugation of LTA4
at the 6 position with reduced glutathione to generate LTC4 oc-
curs under the inﬂuence of leukotriene C4 synthase, with the
subsequent formation of LTD4 and LTE4, all three of which are
agonists at CysLT receptors. LTD4 formation is catalysed by γ-
glutamyltransferase, and subsequently dipeptidase 2 removes the
terminal glycine from LTD4 to generate LTE4. Leukotriene A4
hydrolase converts the 5,6-epoxide LTA4 to the 5-hydroxylated
LTB4, an agonist for BLT receptors. LTA4 is also acted upon by
12S-LOX to produce the trihydroxyeicosatetraenoic acids lipox-
ins LXA4 and LXB4. Treatment with a LTA4 hydrolase inhibitor in
a murine model of allergic airway inﬂammation increased LXA4
levels, in addition to reducing LTB4, in lung lavage ﬂuid [429].
LTA4 hydrolase is also involved in biosynthesis of resolvin Es.
Aspirin has been reported to increase endogenous forma-
tion of 18S-hydroxyeicosapentaenoate (18S-HEPE) compared
with 18R-HEPE, a resolvin precursor. Both enantiomers may
be metabolised by human recombinant 5-LOX; recombinant
LTA4 hydrolase converted chiral 5S(6)-epoxide-containing inter-
mediates to resolvin E1 and 18S-resolvin E1 [384].
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Nomenclature Leukotriene C4 synthase γ-Glutamyltransferase Dipeptidase 1 Dipeptidase 2
HGNC, UniProt LTC4S, Q16873 GGCT, O75223 DPEP1, P16444 DPEP2, Q9H4A9
EC number 4.4.1.20: LTC4 = glutathione +
LTA4
2.3.2.2: (5-L-glutamyl)-peptide +
an amino acid = a peptide + a
5-L-glutamyl amino acid
LTC4 + H2O => LTD4 +
L-glutamate
3.4.13.19: LTD4 + H2O = LTE4 +
glycine
3.4.13.19: LTD4 + H2O = LTE4 +
glycine
Inhibitors – – cilastatin (pKi 6) [189] –
Comments: LTA4H is a member of a family of arginyl aminopeptidases (ENSFM00250000001675), which also includes aminopeptidase B (RNPEP, 9H4A4) and aminopeptidase B-like 1 (RNPEPL1,
Q9HAU8). Dipeptidase 1 and 2 are members of a family of membrane dipeptidases, which also includes (DPEP3, Q9H4B8) for which LTD4 appears not to be a substrate.
Further reading on Eicosanoid turnover
Ackermann JA et al. (2017) The double-edged role of 12/15-lipoxygenase during inﬂammation and
immunity Biochim Biophys Acta 1862: 371-381 [PMID:27480217]
Grosser T et al. (2017) The Cardiovascular Pharmacology of Nonsteroidal Anti-Inﬂammatory Drugs.
Trends Pharmacol Sci [PMID:28651847]
Horn T et al. (2015) Evolutionary aspects of lipoxygenases and genetic diversity of human
leukotriene signaling. Prog Lipid Res 57: 13-39 [PMID:25435097]
Joshi YB et al. (2015) The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s
disease. Trends Pharmacol Sci 36: 181-6 [PMID:25708815]
Koeberle A et al. (2015) Perspective of microsomal prostaglandin E2 synthase-1 as drug target in
inﬂammation-related disorders. Biochem Pharmacol 98: 1-15 [PMID:26123522]
Kuhn H et al. (2015) Mammalian lipoxygenases and their biological relevance. Biochim Biophys
Acta 1851: 308-30 [PMID:25316652]
Patrignani P et al. (2015) Cyclooxygenase inhibitors: From pharmacology to clinical read-outs.
Biochim Biophys Acta 1851: 422-32 [PMID:25263946]
Radmark O et al. (2015) 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and
disease. Biochim Biophys Acta 1851: 331-9 [PMID:25152163]
Sasaki Y et al. (2017) Role of prostacyclin synthase in carcinogenesis. Prostaglandins Other Lipid
Mediat [PMID:28506876]
Seo MJ et al. (2017) Prostaglandin synthases: Molecular characterization and involvement in
prostaglandin biosynthesis. Prog Lipid Res 66: 50-68 [PMID:28392405]
Vitale P et al. (2016) COX-1 Inhibitors: Beyond Structure Toward Therapy. Med Res Rev 36: 641-71
[PMID:27111555]
GABA turnover
Enzymes → GABA turnover
Overview: The inhibitory neurotransmitter γ-aminobutyrate
(GABA, 4-aminobutyrate) is generated in neurones by glutamic
acid decarboxylase. GAD1 and GAD2 are differentially expressed
during development, where GAD2 is thought to subserve a
trophic role in early life and is distributed throughout the cyto-
plasm. GAD1 is expressed in later life and is more associated with
nerve terminals [136] where GABA is principally accumulated
in vesicles through the action of the vesicular inhibitory amino
acid transporter SLC32A1. The role of γ-aminobutyraldehyde de-
hydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is
less clear. Following release from neurons, GABA may interact
with either GABAA or GABAB receptors and may be accumu-
lated in neurones and glia through the action of members of
the SLC6 family of transporters. Successive metabolism through
GABA transaminase and succinate semialdehyde dehydrogenase
generates succinic acid, which may be further metabolized in the
mitochondria in the tricarboxylic acid cycle.
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Nomenclature Glutamic acid decarboxylase 1 Glutamic acid decarboxylase 2
HGNC, UniProt GAD1, Q99259 GAD2, Q05329
EC number 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2 4.1.1.15: L-glutamic acid + H+ -> GABA + CO2
Common abreviation GAD1 GAD2
Endogenous substrates L-glutamic acid, L-aspartic acid L-glutamic acid, L-aspartic acid
Products GABA GABA
Cofactors pyridoxal phosphate pyridoxal phosphate
Selective inhibitors s-allylglycine s-allylglycine
Comments
L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-alanine [577]. Autoantibodies
against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).
Nomenclature aldehyde dehydrogenase 9 family member A1 4-aminobutyrate aminotransferase aldehyde dehydrogenase 5 family member A1
HGNC, UniProt ALDH9A1, P49189 ABAT, P80404 ALDH5A1, P51649
EC number 1.2.1.19: 4-aminobutanal + NAD + H2O = GABA
+ NADH + H+ 1.2.1.47:
4-trimethylammoniobutanal + NAD + H2O =
4-trimethylammoniobutanoate + NADPH + 2H+
1.2.1.3: an aldehyde + H2O + NAD = a
carboxylate + 2H+ + NADH
2.6.1.19: GABA + α-ketoglutaric acid =
L-glutamic acid + 4-oxobutanoate 2.6.1.22:
(S)-3-amino-2-methylpropanoate +
α-ketoglutaric acid =
2-methyl-3-oxopropanoate + L-glutamic acid
1.2.1.24: 4-oxobutanoate + NAD + H2O =
succinic acid + NADH + 2H+
4-hydroxy-trans-2-nonenal + NAD + H2O =
4-hydroxy-trans-2-nonenoate + NADH + 2H+
Common abreviation – GABA-T SSADH
Cofactors NAD pyridoxal phosphate NAD [469]
Inhibitors – vigabatrin (Irreversible inhibition) (pKi 3.1)
[306, 475]
4-acryloylphenol (pIC50 6.5) [519]
Further reading on GABA turnover
Koenig MK et al. (2017) Phenotype of GABA-transaminase deﬁciency. Neurology 88: 1919-1924
[PMID:28411234]
Lee H et al. (2015) Ornithine aminotransferase versus GABA aminotransferase: implications for the
design of new anticancer drugs. Med Res Rev 35: 286-305 [PMID:25145640]
McQuail JA et al. (2015) Molecular aspects of age-related cognitive decline: the role of GABA sig-
naling. Trends Mol Med 21: 450-60 [PMID:26070271]
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Glycerophospholipid turnover
Enzymes → Glycerophospholipid turnover
Overview: Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).
Phosphoinositide-speciﬁc phospholipase C
Enzymes → Glycerophospholipid turnover → Phosphoinositide-speciﬁc phospholipase C
Overview: Phosphoinositide-speciﬁc phospholipase C (PLC,
EC 3.1.4.11), catalyses the hydrolysis of PIP2 to IP3 and 1,2-
diacylglycerol, each of which havemajor secondmessenger func-
tions. Two domains, X and Y, essential for catalytic activity,
are conserved in the different forms of PLC. Isoforms of PLC-β
are activated primarily by G protein-coupled receptors through
members of the Gq/11 family of G proteins. The receptor-
mediated activation of PLC-γ involves their phosphorylation by
receptor tyrosine kinases (RTK) in response to activation of a va-
riety of growth factor receptors and immune system receptors.
PLC-1 may represent a point of convergence of signalling via
both G protein-coupled and catalytic receptors. Ca2+ ions are
required for catalytic activity of PLC isoforms and have been sug-
gested to be the major physiological form of regulation of PLC-δ
activity. PLC has been suggested to be activated non-selectively
by the small molecule m3M3FBS [23], although this mechanism
of action has been questioned [284]. The aminosteroid U73122
has been described as an inhibitor of phosphoinositide-speciﬁc
PLC [485], although its selectivity among the isoforms is untested
and it has been reported to occupy the H1 histamine receptor
[235].
Nomenclature PLCβ1 PLCβ2 PLCβ3 PLCβ4 PLCγ1 PLCγ2
HGNC, UniProt PLCB1, Q9NQ66 PLCB2, Q00722 PLCB3,
Q01970
PLCB4,
Q15147
PLCG1,
P19174
PLCG2, P16885
Endogenous
activators
Gαq, Gα11, Gβγ
[220, 399, 487]
Gα16, Gβγ, Rac2 (RAC2,
P15153) [65, 236, 237,
297, 399]
Gαq, Gβγ [71,
295, 399]
Gαq [196] PIP3 [22] PIP3, Rac1 (RAC1, P63000),
Rac2 (RAC2, P15153), Rac3
(RAC3, P60763) [22, 411,
550]
Inhibitors – – – – – CCT129957 (pIC50 5.5) [436]
Nomenclature PLCδ1 PLCδ3 PLCδ4 PLC1 PLCζ1 PLCη1 PLCη2
HGNC, UniProt PLCD1, P51178 PLCD3,
Q8N3E9
PLCD4,
Q9BRC7
PLCE1, Q9P212 PLCZ1,
Q86YW0
PLCH1,
Q4KWH8
PLCH2, O75038
Endogenous
activators
Transglutaminase II,
p122-RhoGAP {Rat}, spermine,
Gβγ [199, 226, 368, 399]
– – Ras, rho [490, 571] – – Gβγ [600]
Endogenous
inhibitors
Sphingomyelin [404] – – – – – –
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Comments: A series of PLC-like proteins (PLCL1, Q15111; PLCL2, Q9UPR0 and PLCH1, Q4KWH8) form a family with PLCδ and PLCζ1 isoforms, but appear to lack catalytic activity.
PLC-δ2 has been cloned from bovine sources [351].
Further reading on Phosphoinositide-speciﬁc phospholipase C
Cocco L et al. (2015) Phosphoinositide-speciﬁc phospholipase C in health and disease. J Lipid Res
56: 1853-60 [PMID:25821234]
Cockcroft S et al. (2016) Topological organisation of the phosphatidylinositol 4,5-bisphosphate-
phospholipase C resynthesis cycle: PITPs bridge the ER-PM gap. Biochem J 473: 4289-4310
[PMID:27888240]
Litosch I. (2015) Regulating G protein activity by lipase-independent functions of phospholipase
C. Life Sci 137: 116-24 [PMID:26239437]
Nakamura Y et al. (2017) Regulation and physiological functions of mammalian phospholipase C.
J Biochem 161: 315-321 [PMID:28130414]
Swann K et al. (2016) The sperm phospholipase C-zeta and Ca2+ signalling at fertilization in mam-
mals. Biochem Soc Trans 44: 267-72 [PMID:26862214]
Phospholipase A2
Enzymes → Glycerophospholipid turnover → Phospholipase A2
Overview: Phospholipase A2 (PLA2, EC 3.1.1.4) cleaves
the sn-2 fatty acid of phospholipids, primarily phos-
phatidylcholine, to generate lysophosphatidylcholine and
arachidonic acid. Most commonly-used inhibitors (e.g.
bromoenol lactone, arachidonyl triﬂuoromethyl ketone or
methyl arachidonyl ﬂuorophosphonate) are either non-selective
within the family of phospholipase A2 enzymes or have activity
against other eicosanoid-metabolising enzymes.
Secreted or extracellular forms: sPLA2-1B, sPLA2-2A,
sPLA2-2D, sPLA2-2E, sPLA2-2F, sPLA2-3, sPLA2-10 and sPLA2-12A
Cytosolic, calcium-dependent forms: cPLA2-4A, cPLA2-4B,
cPLA2-4C, cPLA2-4D, cPLA2-4E and cPLA2-4F
Other forms: PLA2-G5, iPLA2-G6, PLA2-G7 and PAFAH2
(platelet-activating factor acetylhydrolase 2)
Further reading on Phospholipase A2
Leslie CC. (2015) Cytosolic phospholipase A(2): physiological function and role in disease. J Lipid
Res 56: 1386-402 [PMID:25838312]
Ong WY et al. (2015) Synthetic and natural inhibitors of phospholipases A2: their importance
for understanding and treatment of neurological disorders. ACS Chem Neurosci 6: 814-31
[PMID:25891385]
Ramanadham S et al. (2015) Calcium-independent phospholipases A2 and their roles in biological
processes and diseases. J Lipid Res 56: 1643-68 [PMID:26023050]
Nomenclature sPLA2-1B sPLA2-2A sPLA2-2D sPLA2-2E sPLA2-2F sPLA2-3
HGNC, UniProt PLA2G1B, P04054 PLA2G2A, P14555 PLA2G2D, Q9UNK4 PLA2G2E, Q9NZK7 PLA2G2F, Q9BZM2 PLA2G3, Q9NZ20
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Nomenclature cPLA2-4A cPLA2-4B cPLA2-4C cPLA2-4D cPLA2-4E cPLA2-4F
HGNC, UniProt PLA2G4A, P47712 PLA2G4B,
P0C869
PLA2G4C,
Q9UP65
PLA2G4D,
Q86XP0
PLA2G4E,
Q3MJ16
PLA2G4F,
Q68DD2
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4
Inhibitors compound 57 (pIC50 8.4) [320] – – – – –
Comments cPLA2-4A also expresses
lysophospholipase (EC 3.1.1.5)
activity [473].
– – – – –
Nomenclature PLA2-G5 iPLA2-G6 PLA2-G7 sPLA2-10 sPLA2-12A platelet activating factor
acetylhydrolase 2
HGNC, UniProt PLA2G5,
P39877
PLA2G6,
O60733
PLA2G7, Q13093 PLA2G10,
O15496
PLA2G12A,
Q9BZM1
PAFAH2, Q99487
EC number 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.4 3.1.1.47
Inhibitors – darapladib (pIC50 10) [42] – – –
Selective inhibitors rilapladib (Competitive) (pIC50 9.6) [568]
Comments: The sequence of PLA2-2C suggests a lack of catalytic
activity, while PLA2-12B (GXIIB, GXIII sPLA2-like) appears to be
catalytically inactive [448]. A further fragment has been identi-
ﬁed with sequence similarities to Group II PLA2 members. Oto-
conin 90 (OC90) shows sequence homology to PLA2-G10.
A binding protein for secretory phospholipase A2 has been identi-
ﬁed which shows modest selectivity for sPLA2-1B over sPLA2-2A,
and also binds snake toxin phospholipase A2 [13]. The bind-
ing protein appears to have clearance function for circulating se-
cretory phospholipase A2, as well as signalling functions, and is
a candidate antigen for idiopathic membraneous nephropathy
[29].
PLA2-G7 and PAFAH2 also express platelet-activating factor
acetylhydrolase activity (EC 3.1.1.47).
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Phosphatidylcholine-speciﬁc phospholipase D
Enzymes → Glycerophospholipid turnover → Phosphatidylcholine-speciﬁc phospholipase D
Overview: Phosphatidylcholine-speciﬁc phospholipase D (PLD, EC 3.1.4.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols,
such as butanol in a transphosphatidylation reaction [428].
Nomenclature PLD1 PLD2
HGNC, UniProt PLD1, Q13393 PLD2, O14939
EC number 3.1.4.4 3.1.4.4
A phosphatidylcholine + H2O <=> choline + a phosphatidate
Endogenous activators ADP-ribosylation factor 1 (ARF1, P84077), PIP2, RhoA, PKC evoked
phosphorylation, RalA [201, 323]
ADP-ribosylation factor 1 (ARF1, P84077), PIP2 [316], oleic acid [454]
Endogenous inhibitors Gβγ [418] Gβγ [418]
Inhibitors FIPI (pIC50 8) [463] FIPI (pIC50 7.8) [484]
Selective inhibitors compound 69 (pIC50 7.3) [463] VU0364739 (pIC50 7.7) [293]
Comments: A lysophospholipase D activity (ENPP2,
Q13822, also known as ectonucleotide pyrophos-
phatase/phosphodiesterase 2, phosphodiesterase I, nucleotide
pyrophosphatase 2, autotaxin) has been described, which not
only catalyses the production of lysophosphatidic acid (LPA)
from lysophosphatidylcholine, but also cleaves ATP (see God-
ing et al., 2003 [185]). Additionally, an N-acylethanolamine-
speciﬁc phospholipase D (NAPEPLD, Q6IQ20) has been
characterized, which appears to have a role in the generation of
endocannabinoids/endovanilloids, including anandamide [388].
This enzyme activity appears to be enhanced by polyamines in
the physiological range [311] and fails to transphosphatidylate
with alcohols [408].
Three further, less well-characterised isoforms are PLD3 (PLD3,
Q8IV08, other names Choline phosphatase 3, HindIII K4L ho-
molog, Hu-K4), PLD4 (PLD4, Q96BZ4, other names Choline
phosphatase 4, Phosphatidylcholine-hydrolyzing phospholi-
pase, D4C14orf175 UNQ2488/PRO5775) and PLD5 (PLD5,
Q8N7P1). PLD3 has been reported to be involved in myogen-
esis [391]. PLD4 is described not to have phospholipase D cat-
alytic activity [588], but has been associated with inﬂammatory
disorders [386, 507, 526]. Sequence analysis suggests that PLD5
is catalytically inactive.
Further reading on Phospholipase D
Brown HA et al. (2017) Targeting phospholipase D in cancer, infection and neurodegenerative
disorders. Nat Rev Drug Discov 16: 351-367 [PMID:28209987]
Frohman MA. (2015) The phospholipase D superfamily as therapeutic targets. Trends Pharmacol Sci
36: 137-44 [PMID:25661257]
Nelson RK et al. (2015) Physiological and pathophysiological roles for phospholipase D. J Lipid Res
56: 2229-37 [PMID:25926691]
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Lipid phosphate phosphatases
Enzymes → Glycerophospholipid turnover → Lipid phosphate phosphatases
Overview: Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to
generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase which acts
as a tumour suppressor by reducing cellular levels of PI 3,4,5-P, thereby toning down activity of PDK1 and PKB. Loss-of-function mutations are frequently identiﬁed as somatic mutations in cancers.
Nomenclature Lipin1 Lipin2 Lipin3 PPA2A PPA2B PPA3A phosphatase and tensin
homolog
HGNC, UniProt LPIN1,
Q14693
LPIN2, Q92539 LPIN3,
Q9BQK8
PLPP1,
O14494
PLPP3, O14495 PLPP2,
O43688
PTEN, P60484
EC number 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.4 3.1.3.67
3.1.3.48
3.1.3.16
Substrates – phosphatidic acid – – phosphatidic acid – phosphatidylinositol
(3,4,5)-trisphosphate
Phosphatidylinositol kinases
Enzymes → Glycerophospholipid turnover → Phosphatidylinositol kinases
Overview:
Phosphatidylinositol may be phosphorylated at either 3- or 4-
positions on the inositol ring by PI 3-kinases or PI 4-kinases, re-
spectively.
Phosphatidylinositol 3-kinases
Phosphatidylinositol 3-kinases (PI3K, provisional nomenclature)
catalyse the introduction of a phosphate into the 3-position
of phosphatidylinositol (PI), phosphatidylinositol 4-phosphate
(PIP) or phosphatidylinositol 4,5-bisphosphate (PIP2). There
is evidence that PI3K can also phosphorylate serine/threonine
residues on proteins. In addition to the classes described be-
low, further serine/threonine protein kinases, including ATM
(Q13315) and mTOR (P42345), have been described to phos-
phorylate phosphatidylinositol and have been termed PI3K-
related kinases. Structurally, PI3Ks have common motifs of
at least one C2, calcium-binding domain and helical domains,
alongside structurally-conserved catalytic domains. Wortmannin
and LY 294002 are widely-used inhibitors of PI3K activities.
Wortmannin is irreversible and showsmodest selectivity between
Class I and Class II PI3K, while LY294002 is reversible and selec-
tive for Class I compared to Class II PI3K.
Class I PI3Ks (EC 2.7.1.153) phosphorylate phosphatidylinos-
itol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-
trisphosphate and are heterodimeric, matching catalytic and
regulatory subunits. Class IA PI3Ks include p110α, p110β and
p110δ catalytic subunits, with predominantly p85 and p55 regu-
latory subunits. The single catalytic subunit that forms Class IB
PI3K is p110γ. Class IA PI3Ks are more associated with receptor
tyrosine kinase pathways, while the Class IB PI3K is linked more
with GPCR signalling.
Class II PI3Ks (EC 2.7.1.154) phosphorylate phosphatidylinos-
itol to generate phosphatidylinositol 3-phosphate (and possibly
phosphatidylinositol 4-phosphate to generate phosphatidylinos-
itol 3,4-bisphosphate). Three monomeric members exist, PI3K-
C2α, β and β, and include Ras-binding, Phox homology and two
C2domains.
The only class III PI3K isoform (EC 2.7.1.137) is a heterodimer
formed of a catalytic subunit (VPS34) and regulatory subunit
(VPS15).
Phosphatidylinositol 4-kinases
Phosphatidylinositol 4-kinases (EC 2.7.1.67) generate phos-
phatidylinositol 4-phosphate and may be divided into higher
molecular weight type III and lower molecular weight type II
forms.
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1-phosphatidylinositol 4-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → 1-phosphatidylinositol 4-kinase family
Nomenclature phosphatidylinositol 4-kinase alpha phosphatidylinositol 4-kinase beta
HGNC, UniProt PI4KA, P42356 PI4KB, Q9UBF8
EC number 2.7.1.67 2.7.1.67
Common abreviation PI4KIIIα/PIK4CA PI4KIIIβ/PIK4CB
Endogenous activation – PKD-mediated phosphorylation [212]
Sub/family-selective inhibitors wortmannin (pIC50 6.7–6.8) [180, 352] wortmannin (pIC50 6.7–6.8) [180, 352]
Selective inhibitors – PIK-93 (pIC50 7.7) [26, 271]
Phosphatidylinositol-4-phosphate 3-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Phosphatidylinositol-4-phosphate 3-kinase family
Nomenclature phosphatidylinositol-4-phosphate 3-kinase
catalytic subunit type 2 alpha
phosphatidylinositol-4-phosphate 3-kinase
catalytic subunit type 2 beta
phosphatidylinositol-4-phosphate 3-kinase
catalytic subunit type 2 gamma
HGNC, UniProt PIK3C2A, O00443 PIK3C2B, O00750 PIK3C2G, O75747
EC number 2.7.1.154 2.7.1.154 2.7.1.154
Common abreviation C2α/PIK3C2A C2β/PIK3C2B C2γ/PIK3C2G
Inhibitors torin 2 (pIC50 7.6) [312] PI-103 (pIC50 8) [213] –
Enzymes → Glycerophospholipid turnover → Phosphatidylinositol phosphate kinases
Overview: PIP2 is generated by phosphorylation of PI 4-phosphate or PI 5-phosphate by type I PI 4-phosphate 5-kinases or type II PI 5-phosphate 4-kinases.
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Phosphatidylinositol 3-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Phosphatidylinositol 3-kinase family
Nomenclature phosphatidylinositol 3-kinase catalytic subunit type 3
HGNC, UniProt PIK3C3, Q8NEB9
EC number 2.7.1.137
Common abreviation VPS34
Phosphatidylinositol-4,5-bisphosphate 3-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Phosphatidylinositol-4,5-bisphosphate 3-kinase family
Nomenclature phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
HGNC, UniProt PIK3CA, P42336 PIK3CB, P42338
EC number 2.7.1.153
2.7.11.1
2.7.1.153
Common abreviation PI3Kα PI3Kβ
Inhibitors PIK-75 (pIC50 9.5) [213], gedatolisib (pIC50 9.4) [544], PF-04691502 (pKi
9.2) [309], PI-103 (pIC50 8.7) [435], BGT-226 (pIC50 8.4) [337],
KU-0060648 (pIC50 8.4) [66], dactolisib (pIC50 8.4) [332], apitolisib (pIC50
8.3) [506]
KU-0060648 (pIC50 9.3) [66], PI-103 (pIC50 8.5) [435], AZD6482 (pIC50 8)
[380], ZSTK474 (pIC50 7.4–7.8) [578, 583], apitolisib (pIC50 7.6) [506],
BGT-226 (pIC50 7.2) [337]
Sub/family-selective inhibitors pictilisib (pIC50 8.5) [149] pictilisib (pIC50 7.5) [149]
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Nomenclature phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
HGNC, UniProt PIK3CG, P48736 PIK3CD, O00329
EC number 2.7.1.153 2.7.1.153
Common abreviation PI3Kγ PI3Kδ
Inhibitors dactolisib (pIC50 8.3) [332], apitolisib (pIC50 7.8) [506], PI-103 (pIC50
7.8) [435], BGT-226 (pIC50 7.4) [337], ZSTK474 (pIC50 7.3–7.3) [578,
583], TG-100-115 (pIC50 7.1) [394], alpelisib (pIC50 6.6) [164],
KU-0060648 (pIC50 6.2) [66]
KU-0060648 (pIC50 >10) [66], idelalisib (in vitro activity against
recombinant enzyme) (pIC50 8.6) [290], PI-103 (pIC50 8.5) [435],
ZSTK474 (pIC50 8.2–8.3) [578, 583], apitolisib (pIC50 8.2) [506],
dactolisib (pIC50 8.1) [332], alpelisib (pIC50 6.5) [164]
Sub/family-selective inhibitors pictilisib (pIC50 7.1) [149] pictilisib (pIC50 8.5) [149]
Selective inhibitors CZC 24832 (pKd 7.7) [32] –
1-phosphatidylinositol-3-phosphate 5-kinase family
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → 1-phosphatidylinositol-3-phosphate 5-kinase family
Nomenclature phosphoinositide kinase, FYVE-type zinc ﬁnger containing
HGNC, UniProt PIKFYVE, Q9Y2I7
EC number 2.7.1.150: ATP + 1-phosphatidyl-1D-myo-inositol 3-phosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate
Type I PIP kinases (1-phosphatidylinositol-4-phosphate 5-kinase family)
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Type I PIP kinases (1-phosphatidylinositol-4-phosphate 5-kinase family)
Overview: Type I PIP kinases are required for the production of the second messenger phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(4)P [426]. This enzyme family is
also known as type I PIP(5)Ks.
Nomenclature phosphatidylinositol-4-phosphate 5-kinase type 1 alpha phosphatidylinositol-4-phosphate 5-kinase type 1 gamma
HGNC, UniProt PIP5K1A, Q99755 PIP5K1C, O60331
EC number 2.7.1.68 2.7.1.68
Common abreviation PIP5K1A PIP5K1C
Inhibitors ISA-2011B [465] –
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Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family)
Enzymes → Kinases (EC 2.7.x.x) → Lipid modifying kinases → Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family)
Overview: Type II PIP kinases are essential for the production of the second messenger phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(5)P [426]. This enzyme family
is also known as type II PIP(5)Ks.
Nomenclature phosphatidylinositol-5-phosphate 4-kinase type 2 alpha phosphatidylinositol-5-phosphate
4-kinase type 2 beta
phosphatidylinositol-5-phosphate
4-kinase type 2 gamma
HGNC, UniProt PIP4K2A, P48426 PIP4K2B, P78356 PIP4K2C, Q8TBX8
EC number 2.7.1.149
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate <=> ADP +
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
2.7.1.149 2.7.1.149
Common abreviation PIP4K2A PIP4K2B PIP4K2C
Further reading on Phosphatidylinositol kinases
Bauer TM et al. (2015) Targeting PI3 kinase in cancer. Pharmacol Ther 146: 53-60 [PMID:25240910]
Mayer IA et al. (2016) The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med 67:
11-28 [PMID:26473415]
Singh P et al. (2016) p110alpha and p110beta isoforms of PI3K signaling: are they two sides of the
same coin? FEBS Lett 590: 3071-82 [PMID:27552098]
Zhu J et al. (2015) Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hemato-
logical malignancies. Drug Discov Today 20: 988-94 [PMID:25857437]
Further reading on Glycerophospholipid turnover
Cauvin C et al. (2015) Phosphoinositides: Lipids with informative heads andmastermind functions
in cell division. Biochim Biophys Acta 1851: 832-43 [PMID:25449648]
Irvine RF. (2016) A short history of inositol lipids. J Lipid Res 57: 1987-1994 [PMID:27623846]
Poli A et al. (2016) Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phos-
phate Kinases and Phospholipases C. J Cell Physiol 231: 1645-55 [PMID:26626942]
Haem oxygenase
Enzymes → Haem oxygenase
Overview: Haem oxygenase (heme,hydrogen-donor:oxygen oxidoreductase (α-methene-oxidizing, hydroxylating)), E.C. 1.14.99.3, converts heme into biliverdin and carbonmonoxide, utilizing NADPH
as cofactor.
Searchable database: http://www.guidetopharmacology.org/index.jsp Haem oxygenase S339
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13877/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology (2017) 174, S272–S359
Nomenclature Haem oxygenase 1 Haem oxygenase 2
HGNC, UniProt HMOX1, P09601 HMOX2, P30519
EC number 1.14.14.18
Protoheme + 3 [reduced NADPH-hemoprotein reductase] + 3 O(2) <=>
biliverdin + Fe(2+) + CO + 3 [oxidized NADPH-hemoprotein reductase] + 3
H(2)O
1.14.14.18
Protoheme + 3 [reduced NADPH–hemoprotein reductase] + 3 O(2) <=>
biliverdin + Fe(2+) + CO + 3 [oxidized NADPH–hemoprotein reductase] + 3
H(2)O
Common abreviation HO1 HO2
Comments: The existence of a third non-catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene [215]. The chemical tin protoporphyrin IX
acts as a haem oxygenase inhibitor in rat liver with an IC50 value of 11 nM [128].
Further reading on Haem oxygenase
Abraham NG et al. (2016) Translational Signiﬁcance of Heme Oxygenase in Obesity and Metabolic
Syndrome. Trends Pharmacol Sci 37: 17-36 [PMID:26515032]
Naito Y et al. (2014) Heme oxygenase-1 and anti-inﬂammatory M2 macrophages. Arch Biochem
Biophys 564: 83-8 [PMID:25241054]
Otterbein LE et al. (2016) Heme Oxygenase-1 and Carbon Monoxide in the Heart: The Balancing
Act Between Danger Signaling and Pro-Survival. Circ Res 118: 1940-59 [PMID:27283533]
Poulos TL. (2014) Heme enzyme structure and function. Chem. Rev. 114: 3919-62
[PMID:24400737]
Hydrogen sulphide synthesis
Enzymes → Hydrogen sulphide synthesis
Overview: Hydrogen sulﬁde is a gasotransmitter, with similar-
ities to nitric oxide and carbon monoxide. Although the en-
zymes indicated below have multiple enzymatic activities, the
focus here is the generation of hydrogen sulphide (H2S) and the
enzymatic characteristics are described accordingly. Cystathio-
nine β-synthase (CBS) and cystathionine γ-lyase (CSE) are pyri-
doxal phosphate (PLP)-dependent enzymes. 3-mercaptopyruvate
sulfurtransferase (3-MPST) functions to generate H2S; only CAT
is PLP-dependent, while 3-MPST is not. Thus, this third pathway
is sometimes referred to as PLP-independent. CBS and CSE are
predominantly cytosolic enzymes, while 3-MPST is found both
in the cytosol and the mitochondria.
Nomenclature Cystathionine β-synthase Cystathionine γ-lyase L-Cysteine:2-oxoglutarate
aminotransferase
3-Mercaptopyruvate
sulfurtransferase
HGNC, UniProt CBS, P35520 CTH, P32929 KYAT1, Q16773 MPST, P25325
EC number 4.2.1.22 4.4.1.1 4.4.1.13 2.8.1.2
Common abreviation CBS CSE CAT MPST
Endogenous substrates L-cysteine (Km 6×10−3M) [81],
L-homocysteine
L-cysteine L-cysteine 3-mercaptopyruvic acid (Km
1.2×10−3M) [369]
Products cystathionine NH3, pyruvic acid NH3, pyruvic acid pyruvic acid
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Nomenclature Cystathionine β-synthase Cystathionine γ-lyase L-Cysteine:2-oxoglutarate
aminotransferase
3-Mercaptopyruvate
sulfurtransferase
Cofactors pyridoxal phosphate pyridoxal phosphate pyridoxal phosphate Zn2+
Inhibitors aminooxyacetic acid (pIC50 5.1) [17] aminoethoxyvinylglycine (pIC50 6) [17],
aminooxyacetic acid (pIC50 6) [17],
β-Cyano-L-alanine (pIC50 5.8) [17],
propargylglycine (pIC50 4.4) [17]
– –
Further reading on Hydrogen sulphide synthesis
Asimakopoulou A et al. (2013) Selectivity of commonly used pharmacological inhibitors for cys-
tathionine á synthase (CBS) and cystathionine g lyase (CSE). British Journal of Pharmacology
169: 922-932 [PM:23488457]
Kanagy NL et al. (2017) Vascular biology of hydrogen sulﬁde. Am J Physiol Cell Physiol 312: C537-
C549 [PMID:28148499]
Meng G et al. (2017) Protein S-sulfhydration by hydrogen sulﬁde in cardiovascular system. Br J
Pharmacol [PMID:28148499]
Wallace JL et al. (2015) Hydrogen sulﬁde-based therapeutics: exploiting a unique but ubiquitous
gasotransmitter. Nat Rev Drug Discov 14: 329-45 [PMID:28148499]
Hydrolases
Enzymes → Hydrolases
Overview: Listed in this section are hydrolases not accumulated
in other parts of the Concise Guide, such as monoacylglycerol
lipase and acetylcholinesterase. Pancreatic lipase is the predom-
inant mechanism of fat digestion in the alimentary system; its
inhibition is associated with decreased fat absorption. CES1 is
present at lower levels in the gut than CES2 (P23141), but pre-
dominates in the liver, where it is responsible for the hydrolysis of
many aliphatic, aromatic and steroid esters. Hormone-sensitive
lipase is also a relatively non-selective esterase associated with
steroid ester hydrolysis and triglyceride metabolism, particularly
in adipose tissue. Endothelial lipase is secreted from endothelial
cells and regulates circulating cholesterol in high density lipopro-
teins.
Nomenclature pancreatic lipase lipase G, endothelial type carboxylesterase 1 lipase E, hormone sensitive type
HGNC, UniProt PNLIP, P16233 LIPG, Q9Y5X9 CES1, P23141 LIPE, Q05469
EC number 3.1.1.3 3.1.1.3 3.1.1.1 3.1.1.79
Common abreviation PNLIP LIPG CES1 LIPE
Inhibitors orlistat (pIC50 8.9) [61] – – –
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Nomenclature ectonucleoside triphosphate diphosphohydrolase 1 ectonucleoside triphosphate diphosphohydrolase 2
Systematic nomenclature CD39 CD39L1
HGNC, UniProt ENTPD1, P49961 ENTPD2, Q9Y5L3
EC number 3.6.1.5
Hydrolyzes NTPs to nucleotide monophosphates (NMPs): A nucleoside
5’-triphosphate + 2 H2O <=> a nucleoside 5’-phosphate + 2 phosphate
3.6.1.-
Hydrolyzes extracellular nucleotide 5’-triphosphates: NTP>NMP +
2 phosphate
Common abreviation NTPDase-1 NTPDase-2
Selective inhibitors – PSB-6426 (pKi 5.1) [53]
Comments ENTPD1 sequentially converts extracellular purine nucleotides (ATP and ADP) to the
monophosphate form. Adenosine is then generated by the action of
Ecto-5’-Nucleotidase (CD73). ENTPD1 is the rate-limiting step. Extracellular ATP acts
as a damage-associated molecular pattern (DAMP) that activates innate immune
cells through adenosine-induced activation of P2X and P2Y purinogenic receptors.
–
Further reading on Hydrolases
Markey GM. (2011) Carboxylesterase 1 (Ces1): from monocyte marker to major player. J. Clin.
Pathol. 64: 107-9 [PMID:21177752]
Takenaka MC et al. (2016) Regulation of the T Cell Response by CD39. Trends Immunol 37: 427-39
[PMID:27236363]
Inositol phosphate turnover
Enzymes → Inositol phosphate turnover
Overview: The sugar alcohol D-myo-inositol is a component
of the phosphatidylinositol signalling cycle, where the princi-
pal second messenger is inositol 1,4,5-trisphosphate, IP3, which
acts at intracellular ligand-gated ion channels, IP3 receptors to
elevate intracellular calcium. IP3 is recycled to inositol by
phosphatases or phosphorylated to form other active inositol
polyphosphates. Inositol produced from dephosphorylation of
IP3 is recycled into membrane phospholipid under the inﬂuence
of phosphatidyinositol synthase activity (CDP-diacylglycerol-
inositol 3-phosphatidyltransferase [EC 2.7.8.11]).
Inositol 1,4,5-trisphosphate 3-kinases
Enzymes → Inositol phosphate turnover → Inositol 1,4,5-trisphosphate 3-kinases
Overview: Inositol 1,4,5-trisphosphate 3-kinases (E.C. 2.7.1.127, ENSFM00250000001260) catalyse the generation of inositol 1,3,4,5-tetrakisphosphate (IP4) from IP3. IP3 kinase activity is enhanced in
the presence of calcium/calmodulin (CALM1 CALM2 CALM3, P62158) [98].
Information on members of this family may be found in the online database.
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Inositol polyphosphate phosphatases
Enzymes → Inositol phosphate turnover → Inositol polyphosphate phosphatases
Overview: Members of this family exhibit phosphatase activity towards IP3, as well as towards other inositol derivatives, including the phospholipids PIP2 and PIP3. With IP3 as substrate, 1-phosphatase
(EC 3.1.3.57) generates 4,5,-IP2, 4-phosphatases (EC 3.1.3.66, ENSFM00250000001432) generate 1,5,-IP2 and 5-phosphatases (E.C. 3.1.3.36 or 3.1.3.56) generate 1,4,-IP2.
Information on members of this family may be found in the online database.
Comments: In vitro analysis suggested IP3 and IP4 were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that PIP2 and PIP3 were more efﬁciently hydrolysed [458].
Inositol monophosphatase
Enzymes → Inositol phosphate turnover → Inositol monophosphatase
Overview: Inositol monophosphatase (E.C. 3.1.3.25, IMPase, myo-inositol-1(or 4)-phosphate phosphohydrolase) is a magnesium-dependent homodimer which hydrolyses myo-inositol monophosphate
to generate myo-inositol and phosphate. Glycerol may be a physiological phosphate acceptor. Li+ is a nonselective un-competitive inhibitor more potent at IMPase 1 (pKi ca. 3.5, [347]; pIC50 3.2, [385])
than IMPase 2 (pIC50 1.8-2.1, [385]). IMPase activity may be inhibited competitively by L690330 (pKi 5.5, [347]), although the enzyme selectivity is not yet established.
Nomenclature IMPase 1 IMPase 2
HGNC, UniProt IMPA1, P29218 IMPA2, O14732
EC number 3.1.3.25 3.1.3.25
Rank order of afﬁnity inositol 4-phosphate > inositol 3-phosphate > inositol 1-phosphate [347] –
Inhibitors Li+ (pKi 3.5) [347] –
Comments: Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder [481, 482, 589]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears
to mimic the effects of Li+ in mice [104, 105].
Further reading on Inositol phosphate turnover
Irvine R. (2016) A tale of two inositol trisphosphates. Biochem Soc Trans 44: 202-11
[PMID:26862207]
Livermore TM et al. (2016) Phosphate, inositol and polyphosphates. Biochem Soc Trans 44: 253-9
[PMID:26862212]
Miyamoto A et al. (2017) Probes for manipulating and monitoring IP3. Cell Calcium 64: 57-64
[PMID:27887748]
Windhorst S et al. (2017) Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-
expressed and functions as an oncogene in several tumor types. Biochem Pharmacol 137: 1-9
[PMID:28377279]
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Lanosterol biosynthesis pathway
Enzymes → Lanosterol biosynthesis pathway
Overview: Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG-CoA reductase pathway. The ﬁrst two steps
(formation of acetoacetyl CoA and the mitochondrial generation of (S)-3-hydroxy-3-methylglutaryl-CoA) are also associated with oxidation of fatty acids.
Nomenclature acetyl-CoA acetyltransferase 1 acetyl-CoA acetyltransferase 2 hydroxymethylglutaryl-CoA synthase 1 hydroxymethylglutaryl-CoA synthase 2
HGNC, UniProt ACAT1, P24752 ACAT2, Q9BWD1 HMGCS1, Q01581 HMGCS2, P54868
EC number 2.3.1.9: 2acetyl CoA =
acetoacetyl CoA + coenzyme A
2.3.1.9: 2acetyl CoA =
acetoacetyl CoA + coenzyme A
2.3.3.10: acetyl CoA + H2O +
acetoacetyl CoA ->
(S)-3-hydroxy-3-methylglutaryl-CoA
+ coenzyme A
2.3.3.10: acetyl CoA + H2O +
acetoacetyl CoA ->
(S)-3-hydroxy-3-methylglutaryl-CoA
+ coenzyme A
Comments – – HMGCoA synthase is found in cytosolic
(HMGCoA synthase 1) and mitochondrial
(HMGCoA synthase 2) versions; the
former associated with (R)-mevalonate
synthesis and the latter with ketogenesis.
HMGCoA synthase is found in cytosolic
(HMGCoA synthase 1) and mitochondrial
(HMGCoA synthase 2) versions; the
former associated with (R)-mevalonate
synthesis and the latter with ketogenesis.
Nomenclature hydroxymethylglutaryl-CoA reductase mevalonate kinase phosphomevalonate kinase diphosphomevalonate
decarboxylase
HGNC, UniProt HMGCR, P04035 MVK, Q03426 PMVK, Q15126 MVD, P53602
EC number 1.1.1.34: (S)-3-hydroxy-3-methylglutaryl-CoA +
NADPH -> (R)-mevalonate + coenzyme A + NADP+
Reaction mechanism:: First step:
(S)-3-hydroxy-3-methylglutaryl-CoA + NADPH ->
mevaldyl-CoA + NADP+ Second step:
mevaldyl-CoA + H2O -> (R)-mevalonate + NADP+
2.7.1.36: ATP + (R)-mevalonate
-> ADP +
(R)-5-phosphomevalonate
2.7.4.2: ATP +
(R)-5-phosphomevalonate
= ADP +
(R)-5-diphosphomevalonate
4.1.1.33: ATP +
(R)-5-diphosphomevalonate ->
ADP + isopentenyl diphosphate
+ CO2 + PO34-
Inhibitors lovastatin (Competitive) (pKi 9.2) [10],
rosuvastatin (Competitive) (pIC50 8.3) [241],
cerivastatin (Competitive) (pKi 8.2) [67],
atorvastatin (Competitive) (pIC50 8.1) [241],
cerivastatin (Competitive) (pIC50 8) [528],
simvastatin (Competitive) (pIC50 8) [241],
ﬂuvastatin (Competitive) (pIC50 7.6) [241]
– – –
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Nomenclature hydroxymethylglutaryl-CoA reductase mevalonate kinase phosphomevalonate kinase diphosphomevalonate
decarboxylase
Comments HMGCoA reductase is associated with intracellular
membranes; enzymatic activity is inhibited by
phosphorylation by AMP-activated kinase. The
enzymatic reaction is a three-step reaction
involving the intermediate generation of
mevaldehyde-CoA and mevaldehyde.
Mevalonate kinase activity is
regulated by the downstream
products farnesyl diphosphate
and geranyl diphosphate as an
example of feedback inhibition.
– –
Nomenclature isopentenyl-diphosphate -isomerase 1 isopentenyl-diphosphate -isomerase 2 geranylgeranyl diphosphate synthase
HGNC, UniProt IDI1, Q13907 IDI2, Q9BXS1 GGPS1, O95749
EC number 5.3.3.2: isopentenyl diphosphate =
dimethylallyl diphosphate
5.3.3.2: isopentenyl diphosphate =
dimethylallyl diphosphate
2.5.1.29: trans,trans-farnesyl diphosphate + isopentenyl diphosphate
-> geranylgeranyl diphosphate + diphosphate
2.5.1.10: geranyl diphosphate + isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate + diphosphate
2.5.1.1: dimethylallyl diphosphate + isopentenyl diphosphate =
geranyl diphosphate + diphosphate
Nomenclature farnesyl diphosphate synthase squalene synthase squalene monooxygenase lanosterol synthase
HGNC, UniProt FDPS, P14324 FDFT1, P37268 SQLE, Q14534 LSS, P48449
EC number 2.5.1.10: geranyl diphosphate +
isopentenyl diphosphate ->
trans,trans-farnesyl diphosphate +
diphosphate
2.5.1.1: dimethylallyl diphosphate +
isopentenyl diphosphate =
geranyl diphosphate + diphosphate
2.5.1.21:
2trans,trans-farnesyl diphosphate ->
presqualene diphosphate +
diphosphate
presqualene diphosphate + NAD(P)H +
H+ -> squalene + diphosphate +
NAD(P)+
1.14.13.132: H+ + NADPH + O2
+ squalene = H2O + NADP+ +
(S)-2,3-epoxysqualene
5.4.99.7:
(S)-2,3-epoxysqualene =
lanosterol
Cofactors – NADPH – –
Inhibitors risedronate (pIC50 8.4) [33],
zoledronic acid (pKi 7.1) [129],
alendronate (pIC50 6.3) [33]
zaragozic acid A (pKi 10.1) [34] – Rat,
zaragozic acid A (pIC50 9.2) [530]
–
Selective
inhibitors
ibandronic acid (pKi 6.7) [129],
pamidronic acid (pIC50 6.7) [129]
– – –
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Further reading on Lanosterol biosynthesis pathway
Moutinho M et al. (2017) The mevalonate pathway in neurons: It’s not just about cholesterol. Exp
Cell Res [PMID:28232115]
Mullen PJ et al. (2016) The interplay between cell signalling and themevalonate pathway in cancer.
Nat Rev Cancer 16: 718-731 [PMID:27562463]
Ness GC. (2015) Physiological feedback regulation of cholesterol biosynthesis: Role of translational
control of hepatic HMG-CoA reductase and possible involvement of oxylanosterols. Biochim
Biophys Acta 1851: 667-73 [PMID:25701719]
Porter TD. (2015) Electron Transfer Pathways in Cholesterol Synthesis. Lipids 50: 927-36
[PMID:26344922]
Samaras K et al. (2016) Does statin use cause memory decline in the elderly? Trends Cardiovasc Med
26: 550-65 [PMID:27177529]
Nucleoside synthesis and metabolism
Enzymes → Nucleoside synthesis and metabolism
Overview: The de novo synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahy-
drofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate
dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.
Nomenclature dihydrofolate reductase dihydroorotate
dehydrogenase (quinone)
inosine monophosphate
dehydrogenase 1
inosine monophosphate
dehydrogenase 2
xanthine dehydrogenase
HGNC, UniProt DHFR, P00374 DHODH, Q02127 IMPDH1, P20839 IMPDH2, P12268 XDH, P47989
EC number 1.5.1.3 1.3.5.2 1.1.1.205 1.1.1.205 1.17.1.4
Inhibitors pemetrexed (pKi 8.1) [171,
474], pralatrexate (pKi 7.3)
[244]
teriﬂunomide (pKi 7.5)
[214], leﬂunomide (pKi
4.9) [397]
mycophenolic acid
(pIC50 7.7) [376],
ribavirin (pIC50 5.6–6)
[572], thioguanine [132,
546]
mycophenolic acid (pIC50
7.7) [376], ribavirin
(pIC50 5.6–6) [572],
thioguanine [132, 546]
febuxostat (pKi 9.9)
[387] – Bovine,
allopurinol (pKi 5.2) [36]
Selective
inhibitors
methotrexate (pKi 8.9) [446] – – – –
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Nomenclature ribonucleotide
reductase catalytic
subunit M1
ribonucleotide
reductase regulatory
subunit M2
ribonucleotide
reductase
regulatory TP53
inducible
subunit M2B
thymidylate
synthetase
phosphoribosylglycinamide
formyltransferase,
phosphoribosylglyci-
namide synthetase,
phosphoribosy-
laminoimidazole
synthetase
purine nucleoside
phosphorylase
HGNC, UniProt RRM1, P23921 RRM2, P31350 RRM2B, Q7LG56 TYMS, P04818 GART, P22102 PNP, P00491
EC number 1.17.14.1 1.17.4.1 1.17.1.4 2.1.1.45 2.1.2.2 6.3.3.1
6.3.4.13
–
Common
abreviation
– – – – GART –
Inhibitors clofarabine (pIC50 8.3) [400], ﬂudarabine (pIC50 6)
[534], hydroxyurea (pIC50 3.8) [471], gemcitabine
[219]
– pemetrexed (pKi 7)
[474], capecitabine
[69, 398]
pemetrexed (pKi 5)
[474] – Mouse
–
Selective inhibitors – – – raltitrexed (pIC50
6.5) [172]
– –
Comments: Thymidylate synthetase allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. Purine nucleoside phosphorylase allows separation of a nucleoside
into the nucleobase and ribose phosphate for nucleotide salvage. Xanthine dehydrogenase generates urate in the purine degradation pathway. Post-translational modiﬁcations of xanthine dehydrogenase
convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species. Ribonucleotide
reductases allow the production of deoxyribonucleotides from ribonucleotides.
Further reading on Nucleoside synthesis and metabolism
Day RO et al. (2016) Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci (Lond)
130: 2167-2180 [PMID:27798228]
Okafor ON et al. (2017) Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol
Ther 172: 139-150 [PMID:27916655]
Sramek M et al. (2017) Much more than you expected: The non-DHFR-mediated effects of
methotrexate. Biochim Biophys Acta 1861: 499-503 [PMID:27993660]
Sphingosine 1-phosphate turnover
Enzymes → Sphingosine 1-phosphate turnover
Overview: S1P (sphingosine 1-phosphate) is a pro-survival
signal, in contrast to ceramide. It is formed by the sphingo-
sine kinase-catalysed phosphorylation of sphingosine. S1P can
be released from cells to act as an agonist at a family of ﬁve
G protein-coupled receptors (S1P1-5) but also has intracellular
targets. S1P can be dephosphorylated back to sphingosine or
hydrolysed to form hexadecanal and phosphoethanolamine.
Sphingosine choline phosphotransferase (EC 2.7.8.10) gen-
erates sphingosylphosphocholine from sphingosine and
CDP-choline. Sphingosine β-galactosyltransferase (EC 2.4.1.23)
generates psychosine from sphingosine in the presence of UDP-
α-D-galactose. The molecular identities of these enzymes have
not been conﬁrmed.
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Sphingosine kinase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine kinase
Nomenclature sphingosine kinase 1 sphingosine kinase 2
HGNC, UniProt SPHK1, Q9NYA1 SPHK2, Q9NRA0
EC number 2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
ATP + sphinganine = sphinganine 1-phosphate + ADP
2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP
ATP + sphinganine = sphinganine 1-phosphate + ADP
Common abreviation SPHK1 SPHK2
Cofactors Mg2+ [469] Mg2+
Sub/family-selective inhibitors SKI-II (pIC50 6.3) [156] –
Selective inhibitors PF-543 (pIC8.7) [556], ABC294640 (pKi 5) [157], ROMe (pIC50 4.6) [304]
Further reading on Sphingosine kinases
Adams DR et al. (2016) Sphingosine Kinases: Emerging Structure-Function Insights. Trends Biochem
Sci 41: 395-409 [PMID:27021309]
Marfe G et al. (2015) Sphingosine kinases signalling in carcinogenesis. Mini Rev Med Chem 15:
300-14 [PMID:25723458]
Pyne NJ et al. (2017) Sphingosine Kinase 2 in Autoimmune/Inﬂammatory Disease and the Develop-
ment of Sphingosine Kinase 2 Inhibitors. Trends Pharmacol Sci 38: 581-591 [PMID:28606480]
Pyne S et al. (2016) Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent
advances. Prog Lipid Res 62: 93-106 [PMID:26970273]
SantosWL et al. (2015) Drugging sphingosine kinases. ACS Chem Biol 10: 225-33 [PMID:25384187]
Sphingosine 1-phosphate phosphatase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine 1-phosphate phosphatase
Nomenclature sphingosine-1-phosphate phosphatase 1 sphingosine-1-phosphate phosphatase 2
HGNC, UniProt SGPP1, Q9BX95 SGPP2, Q8IWX5
EC number 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic phosphate 3.1.3.-: sphingosine 1-phosphate -> sphingosine + inorganic
phosphate
Common abreviation SGPP1 SGPP2
Comments Depletion of S1P phosphohydrolase-1 (SPP1), which degrades intracellular S1P, induces the
unfolded protein response and endoplasmic reticulum stress-induced autophagy [231].
–
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Sphingosine 1-phosphate lyase
Enzymes → Sphingosine 1-phosphate turnover → Sphingosine 1-phosphate lyase
Nomenclature sphingosine-1-phosphate lyase 1
HGNC, UniProt SGPL1, O95470
EC number 4.1.2.27: sphingosine 1-phosphate -> phosphoethanolamine + hexadecanal
Cofactors pyridoxal phosphate
Inhibitors compound 31 (pIC50 6.7) [564]
Comments THI (2-Acetyl-5-tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations [462].
Further reading on Sphingosine 1-phosphate lyase
Ebenezer DL et al. (2016) Targeting sphingosine-1-phosphate signaling in lung diseases. Pharmacol
Ther 168: 143-157 [PMID:27621206]
Sanllehi P et al. (2016) Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases
and sphingosine-1-phosphate lyase). Chem Phys Lipids 197: 69-81 [PMID:26200919]
Thyroid hormone turnover
Enzymes → Thyroid hormone turnover
Overview:
The thyroid hormones triiodothyronine and thyroxine, usually abbreviated as triiodothyronine and T4, respectively, are synthesized in the thyroid gland by sequential metabolism of tyrosine residues in
the glycosylated homodimeric protein thyroglobulin (TG, P01266) under the inﬂuence of the haem-containing protein iodide peroxidase. Iodide peroxidase/TPO is a haem-containing enzyme, from the
same structural family as eosinophil peroxidase (EPX, P11678), lactoperoxidase (LPO, P22079) and myeloperoxidase (MPO, P05164). Circulating thyroid hormone is bound to thyroxine-binding globulin
(SERPINA7, P05543).
Nomenclature thyroid peroxidase
HGNC, UniProt TPO, P07202
EC number 1.11.1.8: [Thyroglobulin]-L-tyrosine + H2O2 + H+ + I- -> [Thyroglobulin]-3,5,3’-triiodo-L-thyronine + [thyroglobulin]-aminoacrylate + H2O
Common abreviation TPO
Cofactors Ca2+
Inhibitors methimazole [373], propylthiouracil [373]
Comments Carbimazole is a pro-drug for methimazole
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Tissue deiodinases
These are 1 TM selenoproteins that remove an iodine from T4 (3,3’,5,5’-tetraiodothyronine) to generate triiodothyronine (3,3’,5-triiodothyronine, a more potent agonist at thyroid hormone receptors) or
rT3 (rT3, 3,3’,5’-triiodothyronine, a relatively inactive analogue). DIO1 is also able to deiodinate RT3 to form 3,3’-diidothyronine (T2). Iodotyrosine deiodinase is a 1TM homodimeric enzyme.
Nomenclature iodothyronine deiodinase 1 iodothyronine deiodinase 2 iodothyronine deiodinase 3 iodotyrosine deiodinase
HGNC, UniProt DIO1, P49895 DIO2, Q92813 DIO3, P55073 IYD, Q6PHW0
EC number 1.97.1.10: T4 ->
triiodothyronine rT3 -> T2
1.97.1.10: T4 ->
triiodothyronine rT3 -> T2
1.97.1.11: T4 ->
triiodothyronine rT3 -> T2
1.22.1.1: 3-iodotyrosine -> L-tyrosine + I-
3,5-diiodo-L-tyrosine -> 3-iodotyrosine + I-
Common abreviation DIO1 DIO2 DIO3 IYD
Cofactors – – – ﬂavin adenine dinucleotide, NADPH
Further reading on Thyroid hormone turnover
Darras VM et al. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear
thyroid hormone receptor-mediated impact on vertebrate development. Biochim. Biophys. Acta
1849: 130-41 [PMID:24844179]
Gereben B et al. (2015) Scope and limitations of iodothyronine deiodinases in hypothyroidism.
Nat Rev Endocrinol 11: 642-52 [PMID:26416219]
Mondal S et al. (2017) Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and
their action. Mol Cell Endocrinol [PMID:28408161]
Schweizer U et al. (2015) New insights into the structure and mechanism of iodothyronine deiod-
inases. J Mol Endocrinol 55: R37-52 [PMID:26390881]
van der Spek AH et al. (2017) Thyroid hormone metabolism in innate immune cells. J Endocrinol
232: R67-R81 [PMID:27852725]
1.14.11.29 2-oxoglutarate oxygenases
Enzymes → 1.14.11.29 2-oxoglutarate oxygenases
Overview: Hypoxia inducible factor (HIF) is a transcriptional
complex that is involved in oxygen homeostasis [466]. At normal
oxygen levels, the alpha subunit of HIF (HIF-1α) is targeted for
degradation by prolyl hydroxylation by the prolyl hydrolxyases
PHD proteins 1-3 (HIF-PHs) whch are 2-oxoglutarate oxygenases
responsible for the post-translational modiﬁcation of a speciﬁc
proline in each of the oxygen-dependent degradation domains
of HIF-1α. Hydroxylated HIFs are then targeted for proteasomal
degradation via the von Hippel-Lindau ubiquitination complex
[245]. Under hypoxic conditions, the hydroxylation reaction is
blunted which results in decreased HIF degradation. The surviv-
ing HIFs are then available to translocate to the nucleus where
they heterodimerize with HIF-1β, effecting increased expression
of hypoxia-inducible genes.
HIF-PH enzymes are being investigated as pharmacological tar-
gets as their inhibition mimics the hypoxic state and switches
on transcription of genes associated with processes such as ery-
thropoiesis and vasculogenesis [151]. Small molecule HIF-PH in-
hibitors are in clinical trial as novel therapies for the amelioration
of anemia associated with chronic kidney disease [50].
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Nomenclature egl-9 family hypoxia inducible factor 2 egl-9 family hypoxia inducible factor 1 egl-9 family hypoxia inducible factor 3
HGNC, UniProt EGLN2, Q96KS0 EGLN1, Q9GZT9 EGLN3, Q9H6Z9
EC number – 1.14.11.29 1.14.11.29
Common abreviation PHD1 PHD2 PHD3
Inhibitors IOX2 (pIC50 7.7) [91]
Further reading on 2-oxoglutarate oxygenases
Ivan M et al. (2017) The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks. Mol Cell
66: 772-779 [PMID:28622522]
Markolovic S et al. (2015) Protein Hydroxylation Catalyzed by 2-Oxoglutarate-dependent Oxyge-
nases. J Biol Chem 290: 20712-22 [PMID:26152730]
Salminen A et al. (2015) 2-Oxoglutarate-dependent dioxygenases are sensors of energymetabolism,
oxygen availability, and iron homeostasis: potential role in the regulation of aging process. Cell
Mol Life Sci 72: 3897-914 [PMID:26118662]
Wu Y et al. (2017) Application of in-vitro screening methods on hypoxia inducible factor prolyl
hydroxylase inhibitors. Bioorg Med Chem 25: 3891-3899 [PMID:28625716]
Zurlo G et al. (2016) New Insights into Protein Hydroxylation and Its Important Role in Human
Diseases. Biochim Biophys Acta 1866: 208-220 [PMID:27663420]
1.14.13.9 kynurenine 3-monooxygenase
Enzymes → 1.14.13.9 kynurenine 3-monooxygenase
Nomenclature Kynurenine 3-monooxygenase
HGNC, UniProt KMO, O15229
EC number 1.14.13.9
L-kynurenine + NADPH + O2 <=> 3-hydroxy-L-kynurenine + NADP(+) + H2O
Comments Kynurenine 3-monooxygenase participates in metabolism of the essential amino acid tryptophan.
Further reading on Kynurenine 3-monooxygenases
Dounay AB et al. (2015) Challenges and Opportunities in the Discovery of New Therapeutics Tar-
geting the Kynurenine Pathway. J Med Chem 58: 8762-82 [PMID:26207924]
Erhardt S et al. (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neurophar-
macology 112: 297-306 [PMID:27245499]
Fujigaki H et al. (2017) L-Tryptophan-kynurenine pathway enzymes are therapeutic target for
neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology 112: 264-274
[PMID:26767951]
Smith JR et al. (2016) Kynurenine-3-monooxygenase: a review of structure, mechanism, and in-
hibitors. Drug Discov Today 21: 315-24 [PMID:26589832]
Song P et al. (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular
diseases. Cell Mol Life Sci 74: 2899-2916 [PMID:28314892]
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2.4.2.30 poly(ADP-ribose)polymerases
Enzymes → 2.4.2.30 poly(ADP-ribose)polymerases
Overview: The Poly ADP-ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in
DNA, allowing the recruitment of repair enzymes by the synthesis of NAD-derived ADP-ribose polymers, which are subsequently degraded by a glycohydrolase (PARG, Q86W56).
Nomenclature poly(ADP-ribose) polymerase 1 poly(ADP-ribose) polymerase 2 poly (ADP-ribose) polymerase 3
HGNC, UniProt PARP1, P09874 PARP2, Q9UGN5 PARP3, Q9Y6F1
EC number 2.4.2.30 2.4.2.30 –
Common abreviation PARP1 PARP2 PARP3
Selective inhibitors AG14361 (pKi 8.2) [483] – –
Further reading on Poly(ADP-ribose)polymerases
Bai P. (2015) Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance. Mol
Cell 58: 947-58 [PMID:26091343]
Bai P et al. (2015) Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends
Endocrinol Metab 26: 75-83 [PMID:25497347]
Bock FJ et al. (2016) New directions in poly(ADP-ribose) polymerase biology. FEBS J 283: 4017-4031
[PMID:27087568]
Bock FJ et al. (2015) RNA Regulation by Poly(ADP-Ribose) Polymerases. Mol Cell 58: 959-69
[PMID:26091344]
Ryu KW et al. (2015) New facets in the regulation of gene expression by ADP-ribosylation and
poly(ADP-ribose) polymerases. Chem Rev 115: 2453-81 [PMID:25575290]
2.5.1.58 Protein farnesyltransferase
Enzymes → 2.5.1.58 Protein farnesyltransferase
Overview: Farnesyltransferase is a member of the prenyl-
transferases family which also includes geranylgeranyltransferase
types I (EC 2.5.1.59) and II (EC 2.5.1.60) [72]. Protein far-
nesyltransferase catalyses the post-translational formation of a
thioether linkage between the C-1 of an isoprenyl group and a
cysteine residue fourth from the C-terminus of a protein (ie to
the CaaX motif, where ’a’ is an aliphatic amino acid and ’X’ is
usually serine, methionine, alanine or glutamine; leucine for EC
2.5.1.59) [165]. Farnesyltransferase is a dimer, composed of an
alpha and beta subunit and requires Mg2+ and Zn2+ ions as co-
factors. The active site is located between the subunits. Prenyla-
tion creates a hydrophobic domain on protein tails which acts as
a membrane anchor.
Substrates of the prenyltransferases include Ras, Rho, Rab, other
Ras-related small GTP-binding proteins, G-protein γ-subunits,
nuclear lamins, centromeric proteins and many proteins in-
volved in visual signal transduction.
In relation to the causative association between oncogenic Ras
proteins and cancer, farnesyltransferase has become an impor-
tant mechanistic drug discovery target.
Information on members of this family may be found in the online database.
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Further reading on Protein farnesyltransferase
Gao S et al. (2016) The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the
Brain. Mol Neurobiol 53: 6925-6937 [PMID:26666664]
Shen M et al. (2015) Farnesyltransferase and geranylgeranyltransferase I: structures,
mechanism, inhibitors and molecular modeling. Drug Discov Today 20: 267-76
https://www.ncbi.nlm.nih.gov/pubmed/25450772[PMID:25450772]
Shen Y et al. (2015) The Recent Development of Farnesyltransferase Inhibitors as Anticancer and
Antimalarial Agents. Mini Rev Med Chem 15: 837-57 [PMID:25963569]
Wang M et al. (2016) Protein prenylation: unique fats make their mark on biology. Nat Rev Mol
Cell Biol 17: 110-22 [PMID:26790532]
3.5.1.- Histone deacetylases (HDACs)
Enzymes → 3.5.1.- Histone deacetylases (HDACs)
Overview: Histone deacetylases act as erasers of epigenetic
acetylation marks on lysine residues in histones. Removal of
the acetyl groups facilitates tighter packing of chromatin (het-
erochromatin formation) leading to transcriptional repression.
The histone deacetylase family has been classiﬁed in to ﬁve sub-
families based on phylogenetic comparison with yeast homo-
logues:
Class I contains HDACs 1, 2, 3 and 8
Class IIa contains HDACs 4, 5, 7 and 9
Class IIb contains HDACs 6 and 10
Class III contains the sirtuins (SIRT1-7)
Class IV contains only HDAC11.
Classes I, II and IV use Zn+ as a co-factor, whereas catalysis by
Class III enzymes requires NAD+ as a co-factor, and members of
this subfamily have ADP-ribosylase activity in addition to protein
deacetylase function [456].
HDACs havemore general protein deacetylase activity, being able
to deacetylate lysine residues in non-histone proteins [91] such as
microtubules [233], the hsp90 chaperone [281] and the tumour
suppressor p53 [322].
Dysregulated HDAC activity has been identiﬁed in cancer cells
and tumour tissues [305, 444], making HDACs attractive molec-
ular targets in the search for novel mechanisms to treat can-
cer [567]. Several small molecule HDAC inhibitors are already
approved for clinical use: romidepsin, belinostat, vorinostat,
panobinostat, belinostat, valproic acid and tucidinostat. HDACs
and HDAC inhibitors currently in development as potential anti-
cancer therapeutics are reviewed by Simó-Riudalbas and Esteller
(2015) [478].
Information on members of this family may be found in the online database.
Further reading on Histone deacetylases
Maolanon AR et al. (2017) Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase
Enzymes. Chembiochem 18: 5-49 [PMID:27748555]
Micelli C et al. (2015) Histone deacetylases: structural determinants of inhibitor selectivity. Drug
Discov Today 20: 718-35 [PMID:25687212]
Millard CJ et al. (2017) Targeting Class I Histone Deacetylases in a “Complex” Environment. Trends
Pharmacol Sci 38: 363-377 [PMID:28139258]
Roche J et al. (2016) Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 121:
451-83 [PMID:27318122]
Zagni C et al. (2017) The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade
After Vorinostat. Med Res Rev [PMID:28181261]
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3.5.3.15 Peptidyl arginine deiminases (PADI)
Enzymes → 3.5.3.15 Peptidyl arginine deiminases (PADI)
Overview: In humans, the peptidyl arginine deiminases (PADIs;
HGNC family link) are a family of ﬁve enzymes, PADI1-4 and
PADI6. PADIs catalyze the deimination of protein L-arginine
residues to L-citrulline and ammonia, generating peptidyl-
citrulline on histones, ﬁbrinogen, and other biologically relevant
proteins. The human isozymes exhibit tissue-speciﬁc expression
patterns [256]. Overexpression and/or increased PADI activity
is observed in several diseases, including rheumatoid arthritis,
Alzheimer’s disease, multiple sclerosis, lupus, Parkinson’s dis-
ease, and cancer [37]. Pharmacological PADI inhibition reverses
protein-hypercitrullination and disease in mouse models of mul-
tiple sclerosis [366].
Information on members of this family may be found in the online database.
Further reading on Peptidyl arginine deiminases
Koushik S et al. (2017) PAD4: pathophysiology, current therapeutics and future perspective in
rheumatoid arthritis. Expert Opin Ther Targets 21: 433-447 [PMID:28281906]
Tu R et al. (2016) Peptidyl Arginine Deiminases and Neurodegenerative Diseases. Curr Med Chem
23: 104-14 [PMID:26577926]
Whiteley CG. (2014) Arginine metabolising enzymes as targets against Alzheimers’ disease. Neu-
rochem Int 67: 23-31 [PMID:24508404]
RAS subfamily
Enzymes → 3.6.5.2 Small monomeric GTPases → RAS subfamily
Overview: The RAS proteins (HRAS, NRAS and KRAS) are small
membrane-localised G protein-like molecules of 21 kd. They act
as an on/off switch linking receptor and non-receptor tyrosine
kinase activation to downstream cytoplasmic or nuclear events.
Binding of GTP activates the switch, and hydrolysis of the GTP
to GDP inactivates the switch.
The RAS proto-oncogenes are the most frequently mutated class
of proteins in human cancers. Common mutations compromise
the GTP-hydrolysing ability of the proteins causing constitutive
activation [495], which leads to increased cell proliferation and
decreased apoptosis [598]. Because of their importance in onco-
genic transformation these proteins have become the targets of
intense drug discovery effort [25].
Information on members of this family may be found in the online database.
Further reading on RAS subfamily
Dorard C et al. (2017) Deciphering the RAS/ERK pathway in vivo Biochem Soc Trans 45: 27-36
[PMID:28202657]
Keeton AB et al. (2017) The RAS-Effector Interaction as a Drug Target. Cancer Res 77: 221-226
[PMID:28062402]
Lu S et al. (2016) Ras Conformational Ensembles, Allostery, and Signaling. Chem Rev 116: 6607-65
[PMID:26815308]
Ostrem JM et al. (2016) Direct small-molecule inhibitors of KRAS: from structural insights to
mechanism-based design. Nat Rev Drug Discov 15: 771-785 [PMID:27469033]
Papke B et al. (2017) Drugging RAS: Know the enemy. Science 355: 1158-1163 [PMID:28302824]
Quah SY et al. (2016) Pharmacological modulation of oncogenic Ras by natural products and their
derivatives: Renewed hope in the discovery of novel anti-Ras drugs. Pharmacol Ther 162: 35-57
[PMID:27016467]
Simanshu DK et al. (2017) RAS Proteins and Their Regulators in Human Disease. Cell 170: 17-33
[PMID:28666118]
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4.2.1.1 Carbonate dehydratases
Enzymes → 4.2.1.1 Carbonate dehydratases
Overview: Carbonic anhydrases facilitate the interconversion of water and carbon dioxide with bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identiﬁed in man. The
enzymes function in acid-base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.
Nomenclature carbonic anhydrase 1 carbonic anhydrase 7 carbonic anhydrase 12
HGNC, UniProt CA1, P00915 CA7, P43166 CA12, O43570
EC number 4.2.1.1 4.2.1.1 4.2.1.1
Inhibitors chlorthalidone (pKi 6.5) methazolamide (pKi 8.7) [467], acetazolamide (pKi 8.6) [19],
brinzolamide (pKi 8.6) [467], chlorthalidone (pKi 8.6) [524]
chlorthalidone (pKi 8.4) [524], diclofenamide (pKi 7.3) [547]
Further reading on 4.2.1.1 Carbonic anhydrases
Frost SC. (2014) Physiological functions of the alpha class of carbonic anhydrases. Subcell Biochem
75: 9-30 [PMID:24146372]
Supuran CT. (2017) Advances in structure-based drug discovery of carbonic anhydrase inhibitors.
Expert Opin Drug Discov 12: 61-88 [PMID:27783541]
Supuran CT. (2016) Structure and function of carbonic anhydrases. Biochem J 473: 2023-32
[PMID:27407171]
5.99.1.2 DNA Topoisomerases
Enzymes → 5.99.1.2 DNA Topoisomerases
Overview: DNA topoisomerases regulate the supercoiling of nuclear DNA to inﬂuence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the
DNA to allow unwinding, followed by re-attachment to reseal the backbone. Members of the family are targetted in anti-cancer chemotherapy.
Nomenclature topoisomerase (DNA) I topoisomerase (DNA) II alpha
HGNC, UniProt TOP1, P11387 TOP2A, P11388
EC number 5.99.1.2 5.99.1.2
Inhibitors irinotecan [125, 518] – Bovine etoposide (pIC50 7.3), teniposide [127] – Mouse
Further reading on DNA topoisomerases
Bansal S et al. (2017) Topoisomerases: Resistance versus Sensitivity, How Far We Can Go? Med Res
Rev 37: 404-438 [PMID:27687257]
Capranico G et al. (2017) Type I DNA Topoisomerases. J Med Chem 60: 2169-2192 [PMID:28072526]
Nagaraja V et al. (2017) DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov
Today 22: 510-518 [PMID:27856347]
Pommier Y et al. (2016) Roles of eukaryotic topoisomerases in transcription, replication and ge-
nomic stability. Nat Rev Mol Cell Biol 17: 703-721 [PMID:27649880]
Seol Y et al. (2016) The dynamic interplay between DNA topoisomerases and DNA topology. Bio-
phys Rev 8: 101-111 [PMID:28510219]
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